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Abstract 
  
 The most prevalent subtype of ovarian cancer – high-grade serous (HGS) carcinoma – 
is also the most lethal, since the majority of cases are characterized by advanced-stage 
(metastatic) presentation. Metastasis of this cancer proceeds by an intra-peritoneal route, 
involving detachment of cells from the primary tumour and dissemination throughout the 
peritoneal cavity as multicellular aggregates, or spheroids. Herein, we demonstrate that HGS 
patient-derived tumour cells cultured to form in vitro spheroids exhibit features of cancer 
dormancy, a cellular state known to promote therapeutic resistance and disease recurrence. 
We discovered that upon spheroid formation, cells became non-proliferative, exhibiting a cell 
cycle profile and protein expression pattern (elevated p27Kip1 and RBL2/p130) that was 
consistent with quiescence. This was accompanied by decreased AKT kinase activity, which 
may be important in mediating cell cycle exit via the SCF ubiquitin-ligase complex member 
p45/SKP2. Moreover, when spheroids were re-attached to an adherent substratum, 
quiescence was rapidly reversed in an AKT-dependent manner. Aside from quiescence, we 
also discovered that the cellular self-digestion mechanism autophagy was upregulated during 
spheroid formation. Induction of this process was also observed in adherent cells (and 
augmented in spheroids) by pharmacologic AKT inhibition. To determine autophagy’s effect 
on cell viability, we attempted to block it using siRNAs targeting critical autophagy-related 
(ATG) genes. Interestingly, depletion of Beclin1/ATG6 had no effect, despite its role as a 
canonical inducer of the process. Conversely, depletion of ATG5 and ATG7 led to efficient 
autophagy blockade, as did treatment with the classical autophagy inhibitor Chloroquine and 
the novel agent Spautin-1. These approaches caused a loss of viability in both adherent and 
spheroid cultures. Moreover, combining autophagy blockade with AKT inhibition 
synergistically reduced viability, thus implying that autophagy upregulation functions as a 
survival mechanism. Taken together, these data reveal that two cellular processes, quiescence 
and autophagy, are readily induced by metastatic ovarian cancer cells as features of a 
dormant phenotype. We therefore propose that therapeutically targeting these dormant cells 
will prove highly effective in combating metastasis, resistance, and recurrence in patients 
with metastatic HGS ovarian cancer.  
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Chapter 1  
 
1 Introduction 
 
1.1 Overview of Chapter 1 
 
 This thesis is focused on understanding the biology of metastatic ovarian cancer 
cells, particularly those in three-dimensional clusters or spheroids. The introductory 
chapter begins (Section 1.2) by illustrating the complexity of ovarian cancer, focusing 
specifically on the origins, pathobiology, and lethality of its most prevalent and 
metastatic sub-type – high-grade serous carcinoma. Not only do tumour cells of this sub-
type comprise our biological model, but our in vitro culture system also seeks to model 
high-grade serous metastasis. In Section 1.3, the oncogenic PI3K/AKT/mTOR signaling 
pathway is introduced, since our work in all data chapters characterizes the effects of its 
endogenous or pharmacologic modulation. One such effect is cellular quiescence, which 
is introduced in Section 1.4 since our findings demonstrate its reversible induction in 
spheroids (Chapter 2). Finally, Section 1.5 discusses the paradoxical cellular mechanism 
of autophagy, since work presented in Chapters 3 and 4 explore its regulation and pro-
survival properties in ovarian cancer cells. The final Section summarizes the rationale for 
our studies and outlines the findings presented in this thesis.    
 
1.2 Ovarian Cancer 
 
1.2.1 Classification of ovarian neoplasms 
 
 The ovary is primarily responsible for gametogenesis (i.e., production of oocytes) 
and steroidogenesis (production of estrogen and progesterone) in mammals. Human 
ovaries are each 3-5cm at their longest dimension and located on either side of the 
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uterus1. The ovaries are not physically attached to the uterus or the Fallopian tubes, but 
rather are affixed to the lateral pelvic walls by the broad ligament. Each ovary lies in 
close proximity to Fallopian tube fimbriae (fringes or finger-like terminations), as their 
brief physical interaction during ovulation allows entry of the oocyte for possible 
fertilization 2.  
 
Tumours of the ovary can be broadly classified as non-epithelial and epithelial, 
based on their cell-type of origin. Although non-epithelial tumours (i.e., germ cell 
tumours or sex cord-stromal tumours) comprise ~40% of all ovarian neoplasms, the 
majority of these are benign. In contrast, epithelial ovarian tumours are most often 
malignant and represent >90% of all ovarian cancers3,4. Epithelial ovarian cancers 
(EOCs) can be sub-classified into eight histologic types, the four most prevalent of which 
are serous (50-70%), endometrioid (7-25%), mucinous (~10%), and clear cell (<3-5%)4,5 
(Fig. 1.1). These distinct histologies each resemble differentiated tissues of the female 
reproductive tract, namely secretory Fallopian tube epithelium (serous), endometrial 
glands (endometrioid), mucin-secreting endocervical glands (mucinous), and glycogen-
filled vaginal “rests” (clear cell)6,7. The extent of differentiation toward these histologies 
is defined as tumour grade, where higher grade implies less differentiation or 
resemblance to the aforementioned tissues (among other criteria). Tumours are further 
classified as benign, borderline, or malignant based on their invasiveness and 
proliferative capacity4. Notably, the most prevalent sub-type of EOC is malignant high-
grade serous carcinoma, accounting for nearly 50% of all ovarian malignancies4,5. Thus, 
epithelial ovarian tumours exhibit great heterogeneity in histologic appearance, degree of 
differentiation, and extent of proliferation/invasion. Importantly, they also exhibit 
differences in the genetic aberrations underlying their pathobiology. 
 
1.2.2 Genetics of Epithelial Ovarian Cancer 
 
In 2004, Shih and Kurman sought to reconcile some of the heterogeneity of EOCs 
by proposing a “two-pathway” model of tumour progression. They developed this  model 
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Figure 1.1: Classification of Ovarian Neoplasms.  
Non-epithelial tumours include those arising from either the granulosa, thecal, ovarian stromal, or 
germ cells (oocytes). Epithelial tumours develop via two divergent sequences: a Type I, Low-
Grade (L.G.) pathway thought to arise primarily from ovarian surface epithelial cells, and a Type 
II, High-Grade (H.G.) pathway arising from secretory epithelial cells in the distal Fallopian tube. 
Type I tumours are malignancies of all histologic sub-types. Type II tumours are predominantly 
serous, but also include endometrioid, undifferentiated carcinomas, and carcino-sarcomas (mixed 
epithelial-stromal tumours). Note: tumours of mixed epithelial histology are also observed. 
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by integrating emerging molecular-genetic data with what has long been known about 
epithelial ovarian cancers: different histologic sub-types can exhibit widely divergent 
natural histories and clinical behaviors. According to this model, EOCs are divided into 
Type I and Type II tumours based on their pathobiology and associated genetic 
aberrations8. Type I tumours include low-grade serous, endometrioid, mucinous, and 
clear cell histotypes that develop as a result of a stepwise progression from precursor 
lesions (e.g., endometriosis9,10) to benign, borderline, and malignant tumours9-13 (Fig 1.1). 
Such tumours are slow-growing, often diagnosed prior to extensive metastasis, 
characterized by mutations in genes such as KRAS14-23, BRAF14-16,18,24, PIK3CA10,14,16,25,26, 
PTEN16,17,27-30, CTNBB1 (β-Catenin) 31, and ARID1A32-34, and exhibit relatively little 
genomic instability20. In contrast, mutations in these genes are seldom observed in Type 
II tumours (Table 1.1). Instead, Type II malignancies exhibit germline and somatic 
BRCA1/2 mutation35-41, near-universal TP53 mutation13,15,42-44, as well as numerous copy-
number abnormalities in a background of profound genomic instability20,42. Type II 
malignancies are primarily comprised of high-grade serous cancers (Fig. 1.1). These are 
highly proliferative tumours that metastasize early in their course, resulting in 
disseminated disease at the time of diagnosis. Therefore, according to Shih and Kurman’s 
model, epithelial ovarian tumorigenesis proceeds along two distinct paths, each of which 
is associated with its own set of enabling genetic aberrations.  
 
1.2.3 Origins of Epithelial Ovarian Cancer 
 
Traditionally, the ovarian surface epithelium (OSE), a single layer of relatively 
undifferentiated mesothelium covering the ovary49, was viewed as the source of all 
epithelial ovarian tumours. The “incessant ovulation” hypothesis originally proposed by 
Fathalla in 1971 maintained that ovulation-associated damage and repair of the ovarian 
surface exposed the OSE to sources of DNA damage, thereby predisposing it to 
malignant transformation50. This hypothesis was supported by epidemiologic evidence of 
decreased ovarian cancer risk with multiple pregnancies and oral contraceptive use in 
humans51, as well as experimental evidence of increased ovarian tumorigenesis in super- 
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Table 1.1: Mutations Frequencies in Type I and Type II Epithelial Ovarian Cancera 
 
 Low-Grade Pathway:  Type I  
High-Grade 
Pathway: 
Type II 
Gene Clear Cell 
Mucinous  
(or Mucinous 
Borderline) 
Endometrioid 
Low-Grade Serous 
(or Serous 
Borderline) 
 High-Grade Serous 
TP53 1213,16,45 1213,15,45,46 2013,17,45 6.915,46 44,47  8815,44,47 42,43 
KRAS 5016,18,19 5013,15,19,22,23 1017-19 3614,15,18,20,21,23  5
15,19,20,22,42 
21,48 
BRAF 0.516,18 015 3218,24 3614,15,18,24  0.515 24,42 
PIK3CA 3310,16,26 026 2026 4.414,25  125,42 
PTEN 6.6516,27 20.627-29 20.517,28-30 029  0.528,29,42 
aPercent of mutated cases, given as a median value from the cited studies 
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ovulated hens52. Tumours were thought to arise when OSE – which would have already 
accrued DNA damage over a lifetime of ovulations – became trapped in cortical inclusion 
cysts (CICs) and underwent malignant transformation and differentiation to one of the 
epithelial tumour histologies53. By such a mechanism, OSE-CICs were believed to give 
rise to all ovarian tumours. 
 
Despite this prevailing view, investigators began to question whether a single 
tissue-of-origin could yield the divergent genetic and clinical characteristics seen across 
epithelial ovarian tumours. Furthermore, while OSE/CIC-associated precursor lesions had 
been described for Type I tumours54, no such precursor lesion had ever been identified 
for highly-prevalent, highly-metastatic Type II tumours.  
 
Evidence for an alternate tissue-of-origin emerged when the precursor lesion of 
Type II tumours was discovered upon careful examination of prophylactically-removed 
Fallopian tubes from women at risk for developing ovarian cancer (BRCA1 or BRCA2 
mutation carriers). Peik at al. were the first to report in 2001 that 6/12 Fallopian tubes 
examined exhibited dysplastic changes in their epithelia, specifically in secretory (serous) 
cells55. Additional studies went on to demonstrate that these tubal intra-epithelial 
carcinomas (TICs) were preferentially located in the fimbria56 and, importantly, were 
present in patients with serous carcinomas57. Further analysis identified pre-malignant 
precursor lesions in normal Fallopian tube epithelium that preceded TICs. Specifically, 
Lee et al. discovered pre-malignant foci of p53 immunoreactivity (due to accumulation of 
a non-functional mutant protein): they termed these “p53 signatures”58. Similar to TICs, 
these ‘signatures’ were comprised exclusively of secretory (serous) cells and localized in 
the fimbria. Furthermore, signatures co-occurred with malignant TICs and serous 
carcinomas – sometimes even harboring identical p53 mutations58. Therefore, the 
formation of pre-malignant p53 signatures and their progression to early-malignant TICs 
were heralded as the missing early phases of serous tumorigenesis. 
 
These findings prompted Lee et al. to improve upon the two-pathway model of 
Shih and Kurman. Type II high-grade serous tumours are now believed to originate in the 
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fimbria as p53 signatures58. These can progress to TICs if they acquire additional genetic 
‘hits’. By exfoliating from the fimbria and implanting on nearby ovarian, uterine, or 
peritoneal surfaces, TICs rapidly giving rise to high-grade serous carcinomas7 (Fig. 
1.2A). Interestingly, this exfoliation-implantation model of tumorigenesis shares striking 
similarities with the process of intra-peritoneal dissemination (Fig. 1.2B), the 
predominant means of metastasis in ovarian cancer.  
 
1.2.4 Pathobiology of Epithelial Ovarian Cancer Metastasis 
  
 Metastasis has traditionally been defined as the spread of cancer cells from the 
primary site to form new tumours in distant organs, requiring transit through the 
circulatory or lymphatic systems59. However, in EOC, traditional blood-borne metastasis 
is uncommon. Instead, dissemination occurs primarily by an intra-peritoneal (IP) route 
whereby tumour tissue spreads throughout the abdominal/peritoneal cavity (recently 
reviewed by Sodek and colleagues60). Associated with IP metastasis is the production of 
ascites, a fluid accumulation in the peritoneal cavity seen in ~75% of advanced-stage 
ovarian cancers60-62. It is etiologically linked to increased filtration from peritoneal 
capillaries63 (mediated in large part by tumour-secreted vascular endothelial growth 
factor, or VEGF64,65) and impaired drainage through peritoneal lymphatics (caused by 
physical blockage of lymphatic drainage ducts by tumour tissue66,67). Large quantities 
(litres) of ascites fluid serve not only as a source of significant discomfort for patients, 
but also create a means of dispersal for metastasizing cells.  
  
 Exfoliated tumour cells suspended in ascites fluid are readily detectable and are 
sometimes collected for diagnostic cytology. They are found as solitary cells and as 
multicellular aggregates or “spheroids” (Fig. 1.2B). Isolation and analysis of spheroids 
was reported in 1987 by Allen and colleagues, who described them as compact to 
loosely-adherent clusters of variable size and morphology68. Since this initial report, 
ovarian cancer spheroids have been isolated and analyzed by several groups. Moreover, 
in vitro model systems have also been developed to facilitate more  detailed  investigation 
8 
 
 
Figure 1.2: High-grade serous ovarian cancers exhibit similarities in their 
mechanisms of tumorigenesis and intra-peritoneal metastasis.  
(A) High-grade serous ovarian tumours originate in the fimbrial epithelium as “p53 signatures” 
comprised of normal secretory cells. These progress to tubal intraepithelial carcinomas (TICs) 
through acquisition of additional genetic “hits”. TIC cells exfoliate and implant on nearby 
ovarian, uterine, or peritoneal surfaces, giving rise to high-grade serous carcinomas. (B) Cells 
again undergo exfoliation from established tumors. Suspended in ascites, single-cells or 
multicellular aggregates (spheroids) disperse throughout the peritoneal cavity. Re-attachment to 
peritoneal surfaces leads to secondary tumour formation, and ultimately, widespread intra-
peritoneal disease (carcinomatosis).  
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of their biology69-72. Thus far, the study of spheroids has focused on their mechanism of 
formation and their ability to re-attach to a substratum (reviewed by Shield et al.73).  
Aggregation of cells to form spheroids is mediated through extracellular matrix (ECM) 
proteins and the cell-surface receptors that bind them (integrin heterodimers and CD44): 
function-blocking antibodies against these receptors impair aggregate formation74,75, 
whereas incubation with soluble matrix proteins promotes aggregation75. Once formed, 
ascites spheroids maintain a propensity for re-attachment to ECM components as well as 
mesothelial cell monolayers71,72,76 that was shown to be integrin-dependent77. Sodek et al. 
demonstrated that compact spheroids possess invasive properties and rely on matrix 
metalloproteases to breach collagen I matrices78,79. Recent work from the Brugge lab has 
also demonstrated that once attached, EOC spheroids use myosin-generated force for 
mechanical displacement of mesothelial cells, allowing them to gain access to the sub-
mesothelial ECM for subsequent invasion69.  
  
 These reports have taken the first steps in understanding spheroid formation and 
re-attachement, but important questions about spheroid pathobiology remain. For 
instance, various stresses are associated with cell exfoliation, like the loss of cell-cell and 
extracellular matrix (ECM) attachment [e.g., accumulation of reactive oxygen species 
(ROS) and a sharp drop in ATP levels80], which leads to the eventual induction of 
detachment-mediated apoptosis (anoikis)81,82. It will be important to determine whether 
spheroids represent a means by which exfoliated tumour cells mitigate some of these 
cellular stresses, allowing their survival and subsequent seeding of metastatic lesions. 
  
 Since an exfoliation-implantation process has been described as a necessary early 
step in high-grade serous tumorigenesis, cellular mechanisms that promote tumour cell 
survival upon detachment may be ‘hard-wired’ from early on, equipping cells to not only 
establish primary tumours, but to also survive the challenges of intra-peritoneal 
metastasis. Therefore, investigating how these cells subsist under conditions of 
detachment – in other words, understanding the pathobiology of spheroids – should 
uncover key metastasis-promoting mechanisms. 
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1.2.5 Lethality of High-Grade Serous (HGS) Ovarian Cancer 
Metastasis 
 
It is estimated that 225,500 women worldwide83, including 22,240 in the United 
States84 and 2,600 in Canada85, were diagnosed with ovarian cancer in 2012. Although 
not among the most prevalent, this disease has the third-highest death-to-incidence ratio 
of all cancers, exceeded only by lung and pancreatic cancer83-85. Of these deaths, nearly 
70% occurred in patients with HGS cancer3,5,42. Moreover, since HGS cancers are Type II 
malignancies, the majority of patients (~61%) present with early and extensive intra-
peritoneal metastasis (Stage III-IV) – these patients experience a 5-year relative survival 
rate of only 27.3%86. Synthesizing this information, it is clear that the vast majority of 
ovarian cancer-associated deaths occur among patients with HGS, particularly those with 
metastatic disease. Therefore, a critical need exists to better understand the metastatic 
process of HGS tumours since this is a direct contributor to the high rate of mortality 
associated with this disease.   
 
1.2.6 Treatment of Ovarian Cancer  
  
 Although several improvements have been made in the treatment of ovarian 
cancer, its 5-year relative survival rate has climbed from 36% in 1977 to 44% in 200986. 
Cytoreductive surgery in patients with metastatic ovarian cancer is critical to dramatically 
reducing tumour burden87 and optimal surgical de-bulking (<1.5-2cm of remaining 
macroscopic disease) is associated with increased overall survival88. Chemotherapy has 
been utilized since the 1960s, but the introduction of platinum agents, their combination 
with taxanes 89, and the switch from cisplatin to carboplatin90 have all made incremental 
improvements in survival. In addition to chemotherapeutics, agents targeting VEGF 
(vascular endothelial growth factor; for example, Bevacizumab) have also shown promise 
for increasing progression-free survival91,92. Furthermore, the poly(ADP)ribose 
polymerase (PARP) inhibitor Olaparib demonstrated increased progression-free survival 
when used simultaneously with carboplatin-taxol and when continued as maintenance 
therapy93. Currently, clinical trials for numerous targeted agents are underway in ovarian 
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cancer, including those targeting members of the PI3K/AKT/mTOR 
(Phosphatidylinositol-3-Kinase/AKT/mechanistic Target of Rapamycin) signaling 
pathway. Despite these initially effective treatments, the aggressiveness of metastatic 
disease and its propensity for recurrence remain major obstacles to improving long-term 
survival6,87. Therefore, substantial need still exists for novel therapeutic strategies – 
preferably those targeting mechanisms uniquely-vital for metastatic and recurrent disease.  
 
1.2.7 Summary 
 
 Ovarian tumours can be broadly grouped into non-epithelial and epithelial 
neoplasms. Almost all malignant tumours are epithelial in histology, yet the development 
of these tumours follows two divergent paths, each involving unique genetic aberrations 
and different originating cell types. The Type II pathway yields high-grade cancers that 
metastasize early in their course by virtue of exfoliated cells and spheroids suspended in 
ascites fluid. These metastatic, high-grade serous cancers are unfortunately the most 
prevalent and most responsible for the high mortality associated with advanced-stage 
disease. Therefore, an improved understanding of the metastatic process is essential to 
more effectively treat women suffering from this disease.  
 
1.3 PI3K/AKT/mTOR Signaling in Ovarian Cancer 
 
1.3.1 Overview 
 
 Intra-cellular signaling can exert control over nearly all aspects of a cell’s 
behaviour. The PI3K/AKT/mTOR pathway is an essential controller of protein 
translation, cell growth, proliferation, and survival. Members of this pathway are proto-
oncogenes, as their activities are commonly upregulated in cancer and contribute to most 
of Hanahan and Weinberg’s original “Hallmarks of Cancer”94. This section will describe 
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how the PI3K/AKT/mTOR pathway becomes activated, how it contributes to 
oncogenesis, and the upregulation of its members in high-grade serous ovarian cancer. 
 
1.3.2 Pathway Activation 
 
1.3.2.1 Phosphatidylinositol-3-Kinases (PI3K)  
  
 The first PI3 kinase was identified in 1985 by Cantley and colleagues for its 
ability to phosphorylate the inositol rings of membrane phospholipids 
(phosphatidylinositols) at their 3’-OH position95. Further studies revealed the existence of 
numerous PI3 kinases grouped into three classes: Class I (A & B), II, and III. Class IA 
PI3K is most associated with downstream AKT/mTOR signaling96, whereas Class IB is 
more often associated with small G-protein (e.g., Ras) and G-protein coupled receptor 
signaling97. Furthermore, out of all the PI3Ks, mutations in the Class IA genes PIK3CA 
(encoding the Class IA p110α catalytic subunit)26 and PIK3R1 (encoding the Class IA 
p85 regulatory subunit)98 are associated with cancer.  
  
 In its inactive state, Class IA PI3K exists in the cytosol as a heterodimer of 
regulatory (p85) and catalytic (p110) subunits. This heterodimer must interact with trans-
phosphorylated tyrosine residues on the cytoplasmic tails of activated Receptor Tyrosine 
Kinases (RTKs) to become catalytically active99. It does so using the Src homology 2 
(SH2) domain of p85 either directly or through adaptor proteins like Insulin Receptor 
Substrate 1 (IRS1)100. RTK interaction recruits PI3K to the inner leaflet of the plasma 
membrane, relieves p85-mediated inhibition of the p110 catalytic subunit101, and brings 
the kinase into close proximity with its lipid substrate phosphatidylinositol-4,5-
bisphosphate [PI(4,5)P2]. It should be noted that p110 can also associate with the Ras 
oncoprotein (via its Ras-binding domain) to promote catalytic activity, thereby using 
oncogenic Ras signaling to drive PI3K/AKT/mTOR activity102. Once activated, PI3K 
then catalyzes the conversion of PI(4,5)P2 to phosphatidylinositol-3,4,5-trisphosphate 
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[PI(3,4,5)P3], which acts as a membrane-docking site for kinases containing plexstrin-
homology (PH) domains103 (Fig. 1.3).  
  
1.3.2.2 AKT Kinases 
 
 The AKT kinases are the central PH-domain containing proteins that are activated 
downstream of PI(3,4,5)P3 production. These kinases are cellular homologues of the viral 
oncogene v-akt104 discovered by Staal and colleagues in 1987105-107. AKT kinases 1, 2, 
and 3 are encoded by separate genes, each with its own tissue-specific pattern of 
expression: AKT1 is ubiquitously expressed108, AKT2 is expressed in insulin-sensitive 
tissues (liver, muscle, adipose) as it is important in regulating glucose uptake109, and 
AKT3 is expressed primarily in brain and testes110. All the kinases share the same domain 
structure consisting of an N-terminal PH domain, a linker region, a kinase domain, and a 
hydrophobic motif103.  
  
 To become activated, the AKT kinases are first recruited to the plasma membrane 
through interaction of their PH domains with PI(3,4,5,)P3103 which has been generated by 
active PI3K. PH-mediated membrane recruitment relaxes the conformation of AKT, 
allowing two subsequent phosphorylation events necessary for its activation111. The first 
phosphorylation of AKT1/2/3 occurs on Ser473/474/472 of the C-terminal hydrophobic 
motif and is deposited by mTOR complex 2 (mTORC2)112. Subsequently, 
phosphorylation on Thr308/309/305 in the kinase domain activation loop (T-loop) is 
achieved by 3’-phosphoinositide-dependent kinase 1 (PDK1), which has already been 
recruited to the membrane due to the higher affinity of its PH domain for PI(3,4,5)P3113. 
T-loop phosphorylation is thought to depend upon phosphorylation of the hydrophobic 
motif since this motif interacts with PDK1, stabilizing and bringing the kinase into close 
proximity with AKT for efficient phosphorylation114,115 (Fig. 1.3). Importantly, both of 
these phosphorylation events are necessary for maximal AKT activation96,112,114. Once 
active,     AKT     goes      on      to      phosphorylate      multiple      substrates,     some 
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Figure 1.3: Activation of the PI3K/AKT/mTOR Pathway.  
Activation of Receptor Tyrosine Kinases (RTKs) recruits Phosphatidylinositol-3-Kinase (PI3K) 
to the membrane to activate its catalytic activity. PI3K generates phosphatidylinositol-3,4,5-
trisphosphate [PI(3,4,5)P3] which acts as a membrane-docking site for the AKT kinases. AKT is 
recruited to the membrane and activated by phosphorylation on Ser473 by the mechanistic Target 
of Rapamycin Complex 2 (mTORC2), and on Thr308 by 3’-phosphoinositide-dependent kinase 1 
(PDK1). AKT phosphorylates and de-stabilizes TSC1/2, promoting activation of Rheb (Ras 
homolog enriched in brain). GTP-Rheb activates mTORC1, provided that it is localized to the 
lysosomal membrane in an amino-acid-dependent manner. mTORC1 phosphorylates ribosomal 
protein S6 kinase 1 (p70S6K) and the eukaryotic translation initiation factor 4E-binding protein 1 
(4E-BP1). This pathway can be attenuated by the Phosphatase and Tensin Homologue (PTEN), 
which reverses PI(3,4,5)P3 production, and the LKB1/AMPK (liver kinase B1/AMP-activated 
protein kinase) pathway, which inhibits mTORC1. 
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of which are critical in regulating the activity of mTOR. 
 
1.3.2.3 Mechanistic Target of Rapamycin (mTOR) Kinase 
Complexes 
  
 mTOR kinase was named for its role as the mechanistic (formerly mammalian) 
target of Rapamycin, an anti-fungal agent produced by the Streptomyces hygroscopicus 
bacteria discovered on Easter Island, or Rapa Nui, in 1975116. In mammalian cells, 
mTOR exists in two large kinases complexes: mTORC1 and mTORC2. mTOR complex 
2 (mTORC2) has already been mentioned, as it functions upstream of AKT to directly 
phosphorylate and promote its activation112. The upstream regulation of mTORC2 
remains under investigation, but appears to be controlled by PI3K signaling in a 
ribosome-dependent manner117.  
  
 In contrast to mTORC2, the activation of mTORC1 is more thoroughly 
characterized (Fig. 1.3). Much of its regulation converges upon the Tuberous Sclerosis 
Complex, a heterodimer of TSC1 (Hamartin) and TSC2 (Tuberin). TSC1/2 negatively 
regulates mTORC1 by converting the GTPase Rheb (Ras homolog enriched in brain) to 
its inactive GDP-bound state 118. AKT directly phosphorylates TSC2119, destabilizing the 
TSC1/2 complex leading to Rheb-mediated mTORC1 activation120. AKT also promotes 
mTORC1 activation independently of TSC1/2 through the phosphorylation of proline-
rich AKT substrate of 40kDa (PRAS40), preventing it from binding and sequestering the 
mTORC1 subunit Raptor121. Recent work has also revealed that for mTORC1 to be 
activated by these signals, it must translocate to the lysosomal membrane, a process that 
is dependent upon amino acid abundance and facilitated by Rag GTPase/Ragulator 
interactions 122,123. Thus, mTORC1 is activated by upstream AKT activity, but its 
regulation is also closely tied to nutrient availability.   
  
 Once activated, mTORC1 phosphorylates several proteins, but its two canonical 
targets are the ribosomal protein S6 kinase 1 (p70S6K) and the eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1) 124. Phosphorylation of p70S6K promotes 
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its activation, and in turn, the assembly of factors involved in protein translation125. 
Phosphorylation of 4E-BP1 prevents it from binding and sequestering the eukaryotic 
translation initiation factor 4E (eIF4E), freeing this protein to effect further complex 
assembly at the 5’-cap of mRNA126. Through phosphorylation of these and several other 
targets, mTORC1 executes its role as a key mediator of protein translation. 
 
1.3.2.4 Pathway Attenuation 
 
 The pathway members discussed above can also be de-activated by inhibitory 
feedback mechanisms. One key mechanism is the reversal of second-messenger 
production that is achieved by the phosphatase and tensin homologue (PTEN). This lipid 
phosphatase catalyzes the conversion of PI(3,4,5)P3 back to PI(4,5)P2127, reducing the 
available docking sites for PH-domain-containing kinases like AKT, and in doing so, 
attenuating all downstream pathway activity128 (Fig. 1.3). Aside from lipid phosphatases, 
the PHLPP1 and PHLPP2 (PH-domain and Leucine rich repeat protein phosphatases) can 
also attenuate pathway activity by directly de-phosphorylating AKT129 and p70S6K130. 
Other mechanisms of pathway attenuation downstream of AKT do not involve 
phosphatases: one important example is signaling through LKB1/AMPK (liver kinase 
B1/AMP-activated protein kinase). AMPK is activated by LKB1 in response to an 
elevated cellular AMP:ATP ratio (i.e., energy depletion conditions), depositing an 
activating phosphorylation on TSC2 to promote TSC1/2 activity and inhibit mTORC1118. 
Therefore, multiple mechanisms exist for negatively regulating this pathway, both 
upstream and downstream of AKT. 
 
1.3.3 Consequences of PI3K/AKT/mTORC1 Pathway Activation 
  
 The activation of this pathway in cancer contributes to most of Hanahan and 
Weinberg’s original Hallmarks of Cancer94 (Fig 1.4). Through amplification, mutation, 
and overexpression of RTKs and their ligands131-135, autocrine signaling loops are 
established  to  constitutively  activate  this  pathway,  thus  providing  self-sufficiency  in 
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Figure 1.4: Cellular Activities Regulated by PI3K/AKT/mTOR Signaling.  
AKT or mTORC1 phosphorylate the indicated targets to facilitate their activation (arrow) or 
inhibition (blocking arrow). Targets include the cyclin-dependent kinase inhibitors p21Cip1 and 
p27Kip1, Hypoxia-Inducible Factor 1 & 2 alpha (HIF1α & HIF2α), Bcl-2 Homology Domain 3 
(BH3)-only pro-apoptotic proteins, Forkhead Box O (FOXO) transcription factors, Matrix 
Metalloproteinases (MMP), Sterol Regulatory Element-Binding Protein 1 or 2 (SREBP1/2), the 
ribosomal protein S6 kinase 1 (p70S6K), and the eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1). The modulation of these targets leads to many of the Hallmarks of 
Cancer (Hanahan and Weinberg, 2000), as indicated by color-coded oval rings. 
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growth signals. The phosphorylation of cyclin-dependent kinase (CDK) inhibitors p21Cip1 
and p27Kip1 by AKT kinases leads to their cytoplasmic sequestration, allowing nuclear 
cyclin/CDK complexes to signal cell cycle progression in a dysregulated fashion136,137. 
To fuel this rapid cycling, high levels of mTORC1 activity promote protein 
translation125,126,138, lipid biosynthesis139, and energy production139. Therefore, 
upregulated activity of both AKT and mTORC1 drives unrestrained proliferation, 
endowing cancer cells with insensitivity to anti-growth signals. AKT/mTORC1 signaling 
also promotes angiogenesis by activating pro-angiogenic genes (e.g., VEGF) in a 
hypoxia-inducible factor alpha (HIF1α & HIF2α)-dependent manner140. AKT also 
negatively regulates the function and expression of Bcl-2 homology domain 3 (BH3)-
only pro-apoptotic proteins (e.g., BAD, BIM) through direct phosphorylation141,142, or by 
phosphorylation of Forkhead Box O (FOXO) transcription factors to prevent their 
expression143. In so doing, AKT prevents these pro-apoptotic genes from being 
transcribed and their protein products from inducing cell death, ultimately facilitating 
evasion of apoptosis. Finally, AKT kinase overexpression also results in increased 
adhesion, invasion, and migration144, properties that promote tissue invasion and 
metastasis. Therefore, given it’s ability to endow tumour cells with many of the 
Hallmarks of Cancer, the PI3K/AKT/mTOR pathway is clearly a driver of oncogenesis. 
 
1.3.4 Aberrant Pathway Activation in High-Grade Serous (HGS) 
Ovarian Cancer 
  
 The PI3K/AKT/mTOR pathway exhibits oncogenic activation in numerous 
cancers including ovarian. In HGS ovarian cancer, although mutations in pathway 
members are rare (Table 1.1), gene copy-number alterations are more common. Upstream 
of PI3K activation, alterations in RTKs that directly activate PI3K have been reported. 
The ErbB family of RTKs is an important example since its members, namely EGFR 
(epidermal growth factor receptor) and ERBB2 (Human Epidermal Growth Factor 
Receptor 2; HER2/Neu) are amplified in a subset of HGS ovarian cancers42,134,145,146. 
ERBB3 also exhibits increased activity in ascites-derived tumour cells from HGS 
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patients131. In addition, the platelet-derived growth factor receptors (PDGFRs) are over-
expressed133 and exhibit autocrine activation132 in serous cancers. In fact, their ligand 
(PDGF) was initially discovered due to its abundance in malignant ascites from ovarian 
cancer patients135.  
 
 Downstream of RTKs, PI3K is also altered in HGS cancers: amplification/copy-
number increases are relatively common25,26,147, as is increased PI3K activity as 
determined by in vitro kinase assays148. The AKT kinases also exhibit alteration in HGS 
cancers. One of the first ever reports of AKT2 gene alteration described its amplification 
and overexpression in ovarian cancer cell lines and tumour specimens149.  Additionally, 
copy number increases and/or mRNA over-expression of all three AKT genes25,150-152, 
elevated phospho-AKT (representing activation of all three AKT kinases)145,146,153, and 
elevated AKT2 activity (based on in vitro kinase assays)148 are observed in HGS tumours.  
 
 Downstream of AKT, mTORC1 signaling also exhibits increased activity.  
Although not mutated or amplified, the canonical mTORC1-targets p70S6K and 4E-BP1 
exhibit hyper-phosphorylation154,155. Finally, the deletion of phosphatases that attenuate 
pathway activation are also found in HGS tumours. Specifically, the lipid phosphatase 
PTEN (which was initially discovered due to its abrogation in cancer156) is deleted in a 
subset of HGS tumours28,29,152, as are the AKT- and p70S6K-inactivating protein 
phosphatases (PHLPPs).  
  
 In addition to published studies, an assessment of publicly-available genomics 
data also reveals activating alterations in several PI3K/AKT/mTOR pathway members. 
The Cancer Genome Atlas (TCGA) Project continually collects hundreds of tumour 
specimens from multiple disease sites to perform cross-platform genomic analysis. These 
data are constantly being generated as samples are acquired and processed, thus 
representing the most current and comprehensive resource for cancer genomics that is 
also publicly available. Using TCGA datasets from 538 patients with high-grade serous 
ovarian tumours, a visual “OncoPrint” diagram157 was generated to depict amplification, 
deletion, mRNA expression and mutation of all PI3K/AKT/mTOR pathway members 
20 
 
previously discussed (Fig. 1.5). These data suggest that activation of this pathway – 
suggested by alteration of any one of these genes – is observed in 404/538 (75%) of HGS 
ovarian cancers. 
 
1.3.5 Summary 
 
 Activation of the PI3K/AKT/mTOR pathway is initiated by RTKs that stimulate 
the lipid kinase PI3K to generate second messenger phospholipids. These recruit AKT to 
the membrane, activating it and the downstream kinase complex mTORC1.  The activity 
of these effector kinases promotes cell motility/invasion, angiogenesis, proliferation, as 
well as increased protein translation and lipid biosynthesis – all of which are cellular 
activities fueling oncogenesis. In HGS ovarian cancer, amplification of RTK genes, 
PIK3CA, and AKT genes, as well as deletion of PTEN, is prevalent. Therefore, the 
PI3K/AKT/mTOR pathway is a key driver of oncogenesis that is hyper-activated in a 
large proportion of HGS ovarian tumours.   
 
1.4 Quiescence 
 
1.4.1 Overview 
 
 Cellular quiescence is defined as a reversible exit from the cell division cycle.  
This section will provide a brief overview of the cell division cycle and its regulation 
followed by a discussion of the molecular mediators of quiescence, regulatory 
mechanisms governing its maintenance, and finally, the relevance of quiescence to cancer 
biology and therapy.  
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Figure 1.5: Alteration of the PI3K/Akt/mTOR Pathway in High-Grade Serous 
Ovarian Cancer. 
1.4.2 The cell division cycle  
 
 The process of cellular reproduction is collectively known as the cell division 
cycle. In the most basic sense, this consists of a synthesis (S) phase in which DNA is 
replicated and a mitotic (M) phase in which nuclear contents and cytoplasm are divided 
between two daughter cells158. Indeed in early embryos, the cell division cycle is 
comprised exclusively of these two phases, with cells rapidly copying their DNA and 
dividing159. However, once a multicellular embryo develops, two additional “gap” phases 
arise: gap phase 2 (G2) allows time for the repair of DNA damage and replication errors 
following S-phase, while gap phase 1 (G1) is a critical pause where the cell decides 
whether another round of replication will ensue or whether it will undergo terminal 
differentiation or apoptosis158. Alternatively, cells may exit the cell cycle temporarily 
(quiescence)159 or permanently (senescence)160. The inputs influencing this decision are 
complex and numerous, involving various environmental cues and signaling pathways158. 
However, most of these inputs converge upon a set of key cell cycle regulators: the 
pocket protein family members p107, p130, and pRB (Retinoblastoma protein)161 (Fig. 
1.6). 
  
1.4.3 Regulation of the cell division cycle 
 
 The pocket proteins interact with the E2F-family of transcription factors to 
exercise control over cell cycle progression. p107 and pRB are predominantly expressed 
during the cell division cycle161. In contrast, p130 expression is negligible in cycling 
cells, but is highly expressed during quiescence162. In their hypo-phosphorylated state, 
both pRB and p107 bind to E2Fs, a family of transcription factors that transactivate the 
expression of genes required for cell cycle progression161,163. Binding obscures the 
transactivation domains of E2Fs164,165, thus preventing the transcriptional activation of S-
phase genes such as cyclin E and c-myc166,167. When bound to E2Fs at their target gene 
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promoters, pRB and p107 also recruit chromatin-remodeling factors such as histone 
deacetylases (HDACs) that induce a compact chromatin  structure  and  make  E2F  target 
 
Figure 1.6: The cell division cycle and regulation of quiescence. 
The cell division cycle consists of a synthesis (S) phase and mitotic (M) phase separated by gap 
(G) phases G1 and G2. (A) In early to late G1 phase, cyclin-dependent kinase (CDK) complexes 
are low in abundance or bound by repressive CDK inhibitors (CKIs). The Retinoblastoma protein 
(pRB) and p107 remain hypo-phosphorylated, repressing the transcription of E2F-target genes via 
E2F binding and recruitment of histone deacetylases (HDACs). (B) To enter S-phase, CKIs are 
destabilized and degraded, allowing CDK complex-mediated phosphorylation of pRB and p107. 
They dissociate, freeing E2Fs to recruit histone acetyltransferases (HAT) and induce the 
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expression of target genes. (C) In quiescent (G0) cells, p130 is the most abundant RB family 
member, forming repressive DREAM (DP, RBL2/p130, E2F4, and MuvB) complexes at 
hundreds of E2F target gene promoters. The CKI p27Kip1 is also predominantly expressed in 
quiescent cells, repressing the activity of any CDK complexes. 
genes less accessible for transcription168,169. Therefore, through the actions of hypo-
phosphorylated p107 and pRB, cells remain arrested in G1 and are prevented from 
transitioning into S-phase (Fig. 1.6A). 
  
 In contrast, when hyper-phosphorylated, pRB and p107 are unable to bind and 
sequester their respective E2Fs, freeing them to bind target gene promoters, recruit 
histone acetyltransferases (HATs) to loosen chromatin structure, and subsequently 
transactivate the expression of genes for cell cycle progression161,170. Complexes of 
Cyclin Dependent Kinases (CDKs) and their activating Cyclins are responsible for pRB 
and p107 phosphorylation158,171. During G1 phase, Cyclin D-CDK4/6 complexes 
phosphorylate and partially inactivate p107 and pRB171-173. As a consequence, E-type 
Cyclin genes (which themselves are E2F-targets) are expressed and their protein products 
go on to bind and activate CDK2. Newly-formed Cyclin E-CDK2 complexes then initiate 
a feed-forward loop that results in hyper-phosphorylation and complete inactivation of 
pRB and p107, thereby freeing the E2Fs to execute a G1-to-S transition171-173(Fig. 1.6B). 
  
 In addition to regulation by Cyclins, CDK activity can also be controlled by two 
families of cyclin-dependent kinase inhibitors (CKIs): the INK4 and CIP/KIP proteins174. 
INK4 proteins (p15INK4a, p16INK4b, p18INK4c, p19INK4d) all selectively bind to CDK4 and 
CDK6, preventing their association with D-type cyclins and thereby inactivating Cyclin 
D–CDK4/6 complexes175. In contrast, CIP/KIP inhibitors (p27Kip1, p57Kip2, and p21Cip1) 
bind both the substrate-interacting domain of cyclins and the catalytic domain of CDKs 
to prevent ATP entry, thereby inhibiting all Cyclin-CDK complexes174,176. By inhibiting 
Cyclin-CDK activity, CKIs prevent phosphorylation and inactivation of pRB and p107, 
halting cell cycle progression (Fig. 1.6A). Upon mitogenic stimulation, however, these 
CKIs can be phosphorylated by a variety of kinases, resulting in their ubiquitination and 
degradation and the subsequent liberation of Cyclin-CDK complexes171,174(Fig. 1.6B). 
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1.4.4 Quiescence: exit from the cell division cycle 
  
 Cells that have exited the cell division cycle and are not actively proliferating are 
said to be quiescent, or in a G0 state. Quiescence can be induced by growth factor and/or 
nutrient depletion as well as contact inhibition. At the molecular level, quiescence 
harbors unique features that distinguish it from G1-phase arrest. For instance, quiescent 
cells exhibit reduced RNA content, as they significantly decrease the transcription of 
genes encoding ribosomal and translational RNA177,178. Quiescent cells are also 
differentiated by their predominant expression of p130 in favor of pRB and p107 – in 
quiescent cells, p130 is the most abundant of the three pocket proteins161,162.  
  
 The accumulation of p130 is not simply a marker of quiescence, but an essential 
mediator of the G0 state. During quiescence, abundant p130 protein complexes with 
E2F4 to repress E2F target genes and execute cell cycle exit162,179-182. Recently, 
Litovchick et al. demonstrated that p130, but not pRB or p107, forms repressive DREAM 
complexes (DP1/2, RB-like/p130, E2F4/5, and MuvB) at the promoters of over 800 E2F 
target genes involved in cell cycle progression, mitochondrial biogenesis, and 
metabolism183,184 (Fig. 1.6C). DREAM occupancy was necessary to repress 
transactivation of these genes, as depletion of several complex members led to their 
increased expression. Moreover, overexpression of DREAM complex members (or 
overexpression of p130 alone) was sufficient to retain cells in G0 despite mitogenic 
stimuli183.  Therefore, p130 is an abundant and essential mediator of the G0 state.  
  
 In addition to p130, establishment and maintenance of quiescence also requires 
high levels of the CKI p27Kip1 174(Fig. 1.6C). Like p130, p27Kip1 is highly expressed in 
quiescent cells185-187. It has been implicated as an essential mediator of quiescence as its 
deletion impairs cell cycle exit188,189, whereas its over-expression can induce growth-
factor insensitivity and a G0 state in cancer cells190. Therefore, in parallel with p130, 
p27Kip1 is also a major contributor to cellular quiescence. 
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1.4.5 Regulation of quiescence  
 
1.4.5.1 Glycogen Synthase Kinase 3 (GSK3)  
  
 In quiescent cells, p130 accumulates as a result of post-translational 
modifications, since its mRNA level remains relatively constant191. Multiple 
phosphorylation events are known to govern the activities of pocket proteins, including 
p130192. Like pRB and p107, Cyclin-CDK complexes act on p130 to generate a hyper-
phosphorylated species that is incapable of binding E2Fs and is associated with cell cycle 
progression181. Unlike pRB and p107, however, p130 undergoes specific phosphorylation 
events unique to G0 that are partly responsible for assembly of repressive p130-E2F4 
complexes180,192,193. Interestingly, this quiescence-specific phosphorylation of p130 
occurred independently of Cyclin-CDK complexes180. Recently, glycogen synthase 
kinase 3 (GSK3) was identified as a G0-specific p130 kinase194. Its activity resulted in 
the phosphorylation of three residues in the Loop domain of p130 (a non-conserved 
region that does not share sequence homology with pRB or p107195), protecting the 
protein from proteasome-mediated degradation and thus enhancing its stability194. 
Therefore, by phosphorylating p130, GSK3 contributes to its elevated expression in G0 
(Fig. 1.7).  
  
1.4.5.2 AKT Kinases 
  
 In addition to GSK3, upstream AKT kinases also control the expression of 
quiescence-associated proteins. As discussed previously, AKT promotes cell proliferation 
through activation of the cell cycle machinery and inactivation of its inhibitors196. On the 
other hand, downregulation of AKT activity by nutrient and/or growth-factor depletion 
has the opposite effect – not only does it stall proliferation, but it also stabilizes proteins 
critical for establishment of a G0 state188,197-200. In fact, it is AKT attenuation that permits 
downstream GSK3 activation and p130 phosphorylation in quiescent cells (discussed 
above), since AKT kinases are canonical repressors of GSK3201. In addition to  activating 
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Figure 1.7: AKT and DYRK1A/B regulate quiescence.  
AKT down-regulation de-stabilizes the SCF ubiquitin ligase complex due to under-
phosphorylation of SKP2, an essential complex member. As a result, p130 and p27Kip1 (SCF-
targets), become stabilized, and accumulate to promote quiescence. AKT also negatively 
regulates GSK3, p27Kip1, and the FOXO3a/4 transcription factors, thus its down-regulation allows 
p130 and p27Kip1 to accumulate and promote quiescence. Finally, DYRK1B directly 
phosphorylates the LIN52 DREAM complex subunit (promoting repressive DREAM complex 
formation at E2F-target gene promoters) and p27Kip1 (stabilizing and allowing its accumulation), 
thereby promoting quiescence.     
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GSK3, AKT attenuation also promotes p130 and p27Kip1 accumulation via the SCF 
(Skp1/Cul-1/F-box) ubiquitin ligase complex: when inactive, AKT fails to phosphorylate 
the critical SCF subunit p45/SKP2, causing its destabilization and preventing proper SCF 
complex formation197,198. This results in stabilization and accumulation of SCF-targets, 
namely p130199,200 and p27Kip1188. AKT attenuation contributes to p130 and p27 
expression by a third mechanism involving Forkhead transcription factors FOXO4 and 
FOXO3a: while AKT activity normally results in their nuclear export, under conditions 
of AKT attenuation, FOXOs are retained in the nucleus where they transactivate the 
expression of both p130 and p27Kip1202. Therefore, in cells with reduced AKT signaling, 
multiple mechanisms drive cell cycle exit by promoting the accumulation of p27Kip1 and 
p130 (Fig. 1.7). 
 
1.4.5.3 DYRK Kinases 
  
 In addition to AKT and GSK3, an additional mechanism regulates quiescence via 
the DYRK kinases. Friedman’s group has pioneered the characterization of DYRK1B in 
quiescence, first demonstrating its transcriptional downregulation in mitogen-activated 
cells203. They have also uncovered G0-specific phosphorylation events catalyzed by 
DYRK1B, specifically phosphorylation of Cyclin D1 leading to its de-stabilization204 and 
phosphorylation of p27Kip1 leading to its its accumulation, nuclear localization, and 
inhibition of CDK2205. Recent work from DeCaprio’s group has also demonstrated that 
both DYRK1A and DYRK1B directly phosphorylate a key member of the DREAM 
complex to facilitate its assembly; blocking DYRK activity not only prevented complex 
formation, but also impaired entry into the G0 state206. Taken together, these findings 
imply that the DYRK kinases function independently of AKT/GSK3 to actively promote 
cell cycle exit to a quiescent state (Fig. 1.7).  
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1.4.6 Quiescence in cancer and therapeutic resistance 
  
 Quiescence is highly relevant to cancer biology, since quiescent tumour cells are 
associated with therapeutic resistance. Most chemotherapeutic agents depend upon rapid 
proliferation for their activity: for instance, agents such as paclitaxel function by 
inhibiting mitotic spindle assembly, chromosome segregation, and cytokinesis207. 
Therefore, quiescent tumour cells are not subject to the primary modes of action of such 
drugs and accordingly exhibit chemotherapeutic resistance208,209. Additionally, 
quiescence endows cancer cells with increased survival under nutrient-poor and hypoxic 
conditions186,187; indeed, an increased fraction of non-cycling (Ki67-negative) cells are 
observed in under-vascularized regions of ovarian tumours210. Furthermore, quiescence in 
ovarian cancer cells promoted survival under sub-optimal growth conditions and upon 
treatment with chemotherapeutics185,211. Consequently, quiescence serves as a survival 
mechanism contributing to therapeutic resistance in cancer cells. 
 
1.4.7 Summary 
 
 Cellular quiescence is more than just cell cycle arrest. Instead, it is a molecularly 
definable state distinct from the cell division cycle that is actively entered into and 
maintained. By repressing E2F-target genes and inhibiting Cyclin-CDK complexes, 
respectively, p130 and p27Kip1 represent the best-known mediators of this state. 
Through their regulation by AKT, GSK3, and DYRK kinases, quiescence can be induced, 
maintained, but also reversed upon mitogenic stimulation. Importantly, G0 cells are 
commonly observed in tumours, representing a barrier to chemotherapeutic efficacy and 
possibly a mediator of resistance and disease recurrence. 
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1.5 Autophagy 
 
1.5.1 Overview 
 
 Autophagy is a cellular process that holds the potential to sustain cell viability 
when cancer cells are quiescent or during times of cellular stress and deprivation. The 
term autophagy is derived from the Greek words ‘auto’, meaning self, and ‘phagy’ 
meaning to eat. As this name implies, autophagy is a cellular self-digestion mechanism 
that facilitates the sequestration of cytoplasmic constituents in double-membrane vesicles 
(autophagosomes) and their delivery to lysosomes for degradation. This section will 
discuss autophagy’s regulation and execution by autophagy-related (ATG) proteins, its 
cellular functions, and its importance in cancer. 
 
1.5.2 Discovery of Autophagy and Autophagy-Related (ATG) 
Genes 
  
 Autophagy was discovered in 1957 when Clark & Novikoff, using transmission 
electron microscopy, first observed mitochondria sequestered within cytoplasmic 
vesicles212,213. Further studies revealed that these vesicles also contained lysosomal 
hydrolases, and that organelles within them (mitochondria, endoplasmic reticulum) were 
partly-digested214,215. The term ‘autophagosome’ subsequently emerged to define a 
double-membrane vesicle containing cytoplasmic constituents undergoing degradation216. 
This early work was all based on morphological analysis using electron microscopy – the 
study of autophagy was transformed, however, with the use of yeast genetic screens to 
identify essential autophagy-associated (ATG) genes.  
  
 The Ohsumi group conducted the first of such screens, identifying numerous Atg 
genes comprising the core molecular machinery responsible for regulating and executing 
autophagic degradation217. Homologs of these genes have since been discovered in higher 
eukaryotes, including humans, demonstrating the evolutionary conservation of this 
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process. The core machinery can be divided into three functional groups: (i) the 
uncoordinated-51-like kinase 1 (ULK1) complex (regulated by mTORC1), (ii) the Class 
III PI3K (PI3K C3) complex, and (iii) the Atg5-Atg12 and Atg8/LC3 ubiquitin-like 
conjugation systems. To perform autophagic degradation, the cell must deploy this core 
molecular machinery in a regulated and coordinated series of steps218, outlined in Figure 
1.8.  
 
1.5.3 Molecular Mechanisms of Autophagy 
  
1.5.3.1 mTORC1 connection to the ULK1/2 Kinase Complex  
  
 In addition to discovering Atg proteins, in 1998 Ohsumi’s group also revealed 
that yeast TOR kinase is a key autophagy regulator219. Its mammalian homologue, 
mTORC1, was similarly recognized as an important repressor of autophagy 220.  
 
 Only recently has mTORC1’s mechanism of autophagy repression been 
elucidated (Fig. 1.9A). This involves ULK1 or ULK2 (the mammalian homologues of 
yeast Atg1), either of which can exist in complex with ATG13, FIP200 (focal adhesion 
kinase family interacting protein of 200kDa), and ATG101 in mammalian cells. This 
complex localizes to the isolation membrane to promote autophagosome formation221-223, 
but is under the direct control of mTORC1: when active, mTORC1 associates with the 
ULK complex222, phosphorylating both ULK1/2 and ATG13 to suppress its catalytic 
activity at the membrane221-223. However, upon mTORC1 inhibition (e.g., by starvation, 
Rapamycin treatment, or energy depletion), mTORC1 dissociates, preventing the ULK 
complex from being repressively phosphorylated. ULK1/2 then phosphorylates residues 
on both ATG13 and FIP200, promoting catalytic activity of the whole complex and 
subsequently promoting autophagy221-223. The substrates of ULK1/2 that link its activity 
to the autophagic machinery have yet to be fully characterized, but a recent report has 
identified Ambra1 as a direct target whose phosphorylation by ULK1/2 promotes 
autophagy224. Autophagy is therefore negatively regulated by the interaction of mTORC1 
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Figure 1.8: Autophagic Degradation.  
Autophagy digests cytoplasmic material through a process of membrane sequestration and 
lysosome-mediated destruction. (A) Vesicle nucleation: isolation membrane thought to arise from 
the endoplasmic reticulum (ER). (B) Vesicle Elongation: nascent autophagosome lengthens 
around cytoplasmic material. (C) Vesicle Completion: autophagic membranes completely 
envelop and seal cargo within mature autophagosomes. (D) Docking & Fusion: mature 
autophagosome fuses with lysosomes, introducing cargo to lysosomal hydrolases. The 
autophagosome-lysosome fusion is known as an autophagolysosome (or autolysosome).  (E) 
Degradation & Recovery: Lysosomal enzymes mediate digestion of autophagic cargo. Liberated 
constituent biomolecules are returned to the cytoplasm via permeases. 
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Figure 1.9: Regulation of Autophagy Initiation.  
(A) mTORC1 can be activated to suppress autophagy or inactivated to induce autophagy by the 
stimuli listed (center). When active (left), it associates with and phosphorylates ATG13 and 
ULK1/2 to block catalytic activity of this complex. Upon inactivation (right), mTORC1 
dissociates and is unable to conduct these repressive phosphorylation. Thus, ULK1/2 can 
phosphorylate ATG13 and FIP200, activating the entire complex and promoting autophagy. (B) 
Formation of the Class III PI3K complex results in its allosteric activation and proper localization 
to the Isolation Membrane, where the catalytic activity of hVps34 (Class III PI3K) promotes 
membrane elongation. It also receives regulatory inputs from the ULK complex, through its 
activating phosphorylation of Ambra1  
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with the ULK complex; when mTORC1 dissociates, the resulting ULK complex 
activation promotes autophagy induction.  
 
1.5.3.2 The Class III PI3K Complexes 
 
 The Class III PI3K (PI3K C3 or hVps34) is the most conserved of the PI3Ks 225. 
Its integral role in vesicle nucleation and expansion of the isolation membrane thus 
highlights the ancestral and conserved nature of this process. In mammalian cells, PI3K 
C3 exists in a complex with its regulatory subunit p150, as well as Beclin1 and Atg14L226 
(Fig. 1.9B). Complex formation mediates the allosteric activation of PI3K C3227, which 
then catalyzes the conversion of PI to PI(3)P225. Proper complex localization is facilitated 
Atg14L228, ensuring that formation of PI(3)P occurs at early autophagosomes (isolation 
membranes) and their endoplasmic reticulum-derived precursors (“omegasomes”)229,230. 
PI(3)P enrichment recruits additional effector proteins important for membrane 
elongation229.  
  
 It should also be noted that an alternate PI3K C3 complex exists. This complex 
retains p150 and Beclin1 as subunits, but replaces Atg14L with UVRAG (UV-radiation 
resistance associated gene)231. Although the UVRAG-PI3K C3 complex can promote 
autophagy232, recent research argues for other autophagy-independent functions: 
specifically, in membrane-trafficking during phagocytosis233, endocytosis232,234, and 
cytokinesis234. Nonetheless, the canonical function of PI3K C3 is to direct the early 
phases of autophagosome formation, which it does in a core complex with p150, Beclin1, 
and Atg14L. 
 
1.5.3.3 The Ubiquitin-Like Conjugation Systems 
  
 Two highly-conserved ubiquitin-like conjugation systems are absolutely essential 
for the continued formation and completion of autophagosomes 235,236. These systems 
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utilize E1-like, E2-like and E3 ubiquitin ligase-like enzymes for the conjugation of the 
ubiquitin-like proteins ATG12 and LC3 to their targets237(Fig. 1.10).  
  
 The first system, which facilitates the conjugation of ATG12 to ATG5, involves 
activation and covalent binding of ATG12 to the E1-like enzyme ATG7238, subsequent 
transfer to the E2-like enzyme ATG10239, and final covalent attachment to its target 
ATG5240. The ATG5-ATG12 conjugate then associates non-covalently with ATG16L, 
and through self-oligomerization, forms a multimeric complex of ATG5-
ATG12/ATG16L units 235. This complex associates with their membranes during the 
elongation phase but dissociates as the autophagosomes approach completion 235,241.  
  
 Maturation and completion of autophagosomes also requires the conjugation of 
MAP1LC3A/B/C (Microtubule-Associated Protein 1 Light Chain 3 A/B/C; a mammalian 
homologue of yeast Atg8) to the lipid phosphatidylethanolamine (PE).  Full-length 
MAP1LC3A/B/C (LC3) is first cleaved by the cysteine protease ATG4 to expose a C-
terminal glycine residue, resulting in the species known as LC3-I242. This residue is the 
site of covalent attachment to the E1-like enzyme ATG7238 and subsequent transfer to the 
E2-like enzyme ATG3243. The final conjugation of LC3 to PE is performed by the 
previously-generated ATG5-ATG12 conjugate, which possesses E3 ligase-like 
activity244. Once LC3 has been conjugated to PE (forming the species ‘LC3-II’), ATG5-
ATG12-ATG16L also regulates its proper localization245, ensuring its insertion into both 
the inner and outer membranes of autophagosomes where it serves as a scaffold 
supporting membrane expansion and curvature237. Therefore, both ubiquitin-like 
conjugation systems converge on the membrane-insertion of LC3-II, thereby facilitating 
the expansion of autophagosomes around their cargo.  
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Figure 1.10: Regulation of Autophagosome Formation and Maturation. 
Two ubiquitin-like conjugation systems are essential for the generation of autophagosomes. The 
first (left), requires activation and covalent binding of ATG12 to the E1-like enzyme ATG7, 
subsequent transfer to the E2-like enzyme ATG10, and final covalent attachment to ATG5. The 
ATG5-ATG12 conjugate then associates with ATG16L, eventually forming a multimeric 
complex that localizes to nascent autophagosomes. The second conjugation system (right) begins 
with proteolytic cleavage of ATG8/LC3-I by ATG4, its transfer to ATG7 (E1-like), then to ATG3 
(E2-like), and finally – via the previously-generated ATG5-ATG12 conjugate – its ligation to 
phosphatidylethanolamine (PE) and insertion into the membranes of maturing autophagosomes. 
This processed form (LC3-II) is essential for autophagic vesicle expansion and completion.  
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1.5.4 Functions of Autophagy 
 
1.5.4.1 Homeostatic Autophagy 
  
 Autophagy is active at a basal level in all eukaryotes and maintains cellular 
homeostasis by clearing damaged organelles, large protein aggregates, and intracellular 
pathogens227,246-249.The importance of this cellular quality control function is highlighted 
by the fact that mice harboring targeted deletions of Atg5 or Atg7 accumulated damaged 
mitochondria and poly-ubiquitinated protein aggregates250-253. These accumulations led to 
dysfunction and death of mouse neurons and cardiomyocytes, causing progressive 
neurodegeneration and heart failure, respectively250,251,253. In humans, the deregulation of 
basal autophagy contributes to similar disease pathologies254. For example, in 
neurodegenerative disorders such as Parkinson’s disease, the characteristic accumulation 
of misfolded protein aggregates and dysfunctional mitochondria in neurons is 
exacerbated by inherited mutations in the PARK2 gene that impair autophagy255. 
Similarly, Danon disease (characterized by the accumulation of dysfunctional 
mitochondria in cardiomyocytes and myocytes) is associated with mutation in LAMP2, an 
autophagy-associated protein important for the docking/fusion of autophagosomes with 
lysosomes256. Therefore, basal autophagy plays an important role in maintaining cellular 
homeostasis to prevent disease. 
 
1.5.4.2 Autophagy Induction 
  
 In addition to functioning at a basal level to maintain cellular homeostasis, 
autophagy can also be upregulated as an adaptive response to cellular stresses. Numerous 
cellular stresses are capable of inducing autophagy, including starvation257, energy 
depletion258, ECM-detachment259, ER-stress and the Unfolded Protein Response 
(UPR)227, metabolic stress260, hypoxia261, ammonia262, and reactive oxygen species 
(ROS)263.  
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 These stimuli utilize a variety of mechanisms to induce autophagy, yet many 
converge upon mTORC1 and/or AMPK. As discussed above, attenuation of mTORC1 
activity liberates the ULK1 complex, thereby triggering autophagy induction. The 
LKB1/AMPK pathway induces autophagy in an mTORC1-dependent manner by 
phosphorylating TSC2118 and Raptor264 to attenuate mTORC1 activity.  Recent work has 
also revealed that AMPK directly phosphorylates ULK1 to promote its activity265 and 
that AMPK activation causes phosphorylation and stabilization of p27Kip1 266, both of 
which result in autophagy induction in an mTORC1-independent manner. Although other 
pathways have been identified, mTORC1 and AMPK represent the best-characterized 
mechanisms of autophagy induction that integrate various cellular stress signals. 
  
 Autophagy induction is a pro-survival mechanism since its targeted disruption in 
yeast, slime molds, plants, and nematodes consistently reduced their viability under 
conditions of metabolic stress249. Likewise, Atg5-/-, Atg7-/-, Atg3-/- mice die within 24 
hours of birth due to their inability to survive the neonatal starvation period 252,267,268. To 
promote survival, autophagy essentially recycles existing cytoplasmic structures 
(organelles, proteins, membranes), re-directing their constituent biomolecules 
(nucleosides, sugars, amino-acids, fatty acids) toward biosynthetic or energy-generating 
pathways227,247,249,269,270. This mechanism is supported by studies in which administration 
of methyl pyruvate (a substrate of the TCA cycle) was sufficient to rescue survival of 
autophagy-deficient cells exposed to prolonged metabolic stress269,270. Thus, autophagy 
induction by starvation promotes sustained viability by re-purposing intracellular 
resources and fueling ATP production.   
 
1.5.5 Autophagy in Cancer 
  
 One of the first diseases to be associated with autophagy was cancer271. Following 
years of study, however, the precise role of autophagy in cancer remains paradoxical, as 
both tumour-suppressive and tumour-promoting functions have been demonstrated.  
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1.5.5.1 Autophagy is Tumour-Suppressive 
  
 Autophagy is considered a tumour-suppressive mechanism based on evidence 
from human cancer and mouse models (Table 1.2). The human chromosomal locus 
17q21, which contains the Beclin1 gene (BECN1), exhibits single-copy loss in 
prostate272, breast273,274, and ovarian cancers275-279. Likewise, another PI3K C3 complex 
member, UVRAG, is mutated in gastric280 and colon281 cancers. Moreover, mice with 
heterozygous disruption of the Beclin1 gene (Becn1+/-) develop spontaneous tumours 
(lymphoma, lung carcinoma, hepatocellular carcinoma) and mammary hyperplasia at 
higher rates than wild-type littermates282,283. Additionally, the E3 ligase Parkin (PARK2) 
– which plays an essential role in autophagic degradation of defective mitochondria284 – 
is also deleted in a subset of breast and ovarian tumours285 and Park2-/- mice develop 
hepatocellular carcinomas286. Finally, mice harboring liver-specific Atg7 deletion or 
systemic mosaic deletion of Atg5 develop benign liver adenomas287. Taken together, 
these key examples provide strong evidence supporting a tumour-suppressive role for 
autophagy.  
 
 The mechanism underlying autophagy’s tumour-suppression, although not yet 
fully elucidated, appears to involve the maintenance of genomic stability. It has been 
demonstrated that both Becn1+/- tumours and Uvrag+/- mouse cells exhibit increased 
DNA damage, gene amplifications, aneuploidy, and genomic instability in response to 
metabolic stress260,295,296. Likewise, the benign liver adenomas found in Atg7-/- (liver 
specific) and Atg5-/- (mosaic) mice were associated with markers of genomic damage287. 
Genomic instability in autophagy-deficient cells is thought to occur as a result of 
abnormal accumulation of aggregated proteins and dysfunctional mitochondria – indeed, 
such structures have been observed in Atg5-/- liver adenomas287 as well as Parkin-
deficient cells297,298. These abnormal accumulations lead to ROS production and 
increased oxidative stress, which in turn can cause DNA damage and ultimately genomic 
instability260,295,299. Therefore, oxidative stress resulting from autophagy-deficiency can 
contribute to genomic instability and ultimately tumorigenesis. 
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Table 1.2: Selected Mouse Models of Autophagy Disruption 
 
 
  
  Genotype & Phenotype  
 Gene +/- -/- 
Conditional 
-/- References 
Class III 
PI3K 
Complex 
Becn1 
Viable; 
Malignant 
lymphoma 
& 
carcinoma 
Embryonic lethal  282, 283 
Pik3c3  Embryonic lethal  288 
Bif1  
Viable; 
Malignant 
lymphoma & 
carcinoma 
 289 
Ambra1A  Embryonic lethal  290 
Conjugation 
Systems 
Atg4c  
Viable; 
Carcinogen-
induced 
fibrosarcomas 
 291 
Atg3  Perinatal lethal  267 
Atg5  Perinatal lethal Benign liver adenomaB 268, 287 
Atg7  Perinatal lethal Benign liver adenomaC 252, 287 
Atg16lA  Viable  292 
Other 
Ulk1  Viable  293 
Park2  
Viable; 
Hepatocellular 
Carcinoma 
 286 
Lamp2  Viable  294 
AGene disruption via hypomorphic alleles; Bchimeric deletion; Cliver-specific deletion 
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1.5.5.2 Autophagy is Tumour-Promoting 
  
 Despite its well-documented suppressive role, autophagy is often upregulated in 
established tumours, serving to promote cancer cell growth and survival (Fig. 1.11). 
Autophagy induction in tumours has been demonstrated by elements of their 
microenvironment (e.g., hypoxia261,300) and byproducts of their own dysregulated 
metabolism (ammonia262, ROS301). A recent immunohistochemical analysis found that 
elevated expression and punctate staining of LC3B was common across a number of 
tumour types and was associated with increased proliferation, metastasis, and poor 
patient outcome302, thus suggesting a tumour-promoting role for autophagy. Indeed, in 
cultured tumour cells, autophagy upregulation has been shown to promote 
proliferation303,304 and preserve cell survival 305-308. Moreover, autophagy disruption 
impeded growth of Ras-driven xenograft tumours309,310 and delayed tumour progression 
in an established mouse model of breast cancer303.  
  
 The tumour-promoting function of autophagy is tied to aberrant tumour 
metabolism. Tumours often exhibit deregulated metabolism characterized by insufficient 
oxygen and substrates for energy production, as well as an abundance of metabolic waste 
products 311,312. Akin to its role in starving cells (described above), autophagy feeds these 
metabolically-hungry tumours by degrading cytosolic components and re-generating 
substrates needed to fuel the TCA cycle303,309,310,313. Autophagy simultaneously rids 
tumour cells of metabolic waste products and damaged organelles that would otherwise 
compound oxidative stress, cause excessive cellular damage and genomic instability, and 
eventually lead to apoptotic or non-apoptotic cell death304,306,314-317. Therefore autophagy 
in tumours not only fuels metabolic demands, but also mitigates the cellular collateral 
damage that results from metabolic dysregulation.  
  
 Importantly, autophagy can also be induced by anti-cancer therapies (radiation318, 
chemotherapy319, and targeted agents320). This therapy-induced autophagy was initially 
thought to cause type II, or autophagic, cell death – however, careful experimentation has 
revealed that in many such cases, autophagy only accompanied, rather  than  caused,  cell 
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Figure 1.11: Autophagy in Cancer. 
Autophagy functions to suppress tumorigenesis by limiting accumulation of reactive oxygen 
species (ROS), DNA damage, and genomic instability. Autophagy also promotes the progression 
of early malignancies by supplying metabolic substrates to fuel their growth as well as managing 
various cellular stresses – including those incurred from anti-cancer treatments.    
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death 321,322 (i.e., cell death with autophagy, as opposed to by autophagy323). Although 
some examples of bona fide cytotoxic autophagy have withstood scrutiny324,325, it is now 
accepted that therapy-induced autophagy instead promotes cell survival in most 
instances, since its blockade leads to increased cell death307,308,319,320,326-328. Therefore, 
autophagy predominantly serves as a cytoprotective mechanism in cancer cells exposed 
to therapeutics.   
 
1.5.6 Autophagy in Ovarian Cancer 
  
 Ovarian cancer typifies the paradoxical nature of autophagy’s role in cancer. As 
mentioned, the BECN1-containing chromosomal locus exhibits monoallelic deletion in 
65-87% of ovarian tumours275-279. Recent work has also revealed that Beclin1 protein 
expression is reduced in malignant tumours compared to normal ovarian tissue329, though 
it remains to be determined whether protein expression is actually reduced in ovarian 
tumours as a result of heterozygous loss at the BECN1 locus.  
 
 Aside from Beclin1, a very recent study by Kenzelmann et al. discovered that in 
response to DNA damage, p53 orchestrates an autophagy-stimulating transcriptional 
program that is important for p53-mediated tumour suppression330. These findings are 
relevant to ovarian cancer, since early TP53 mutation is a near-universal phenomenon in 
high-grade serous tumours. It is thus tempting to speculate that ablating p53-mediated 
autophagy contributes to the high degree of genomic instability characteristic of high-
grade serous ovarian tumours. Therefore, p53-driven, tumour-suppressive autophagy 
program in ovarian cancer remains a fascinating possibility that will require further 
investigation. 
 
 Despite the literature supporting a tumour-suppressive role for autophagy in 
ovarian cancer, numerous studies also report that ovarian tumour cells retain the capacity 
to upregulate autophagy (Table 1.3). Most of these studies  (66%; 19/29)  demonstrated 
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Table 1.3: Studies Reporting Autophagy Induction in Ovarian Cancer*  
Autophagy Inducer References 
Undetermined Effect of Autophagy Induction 
Mir-30d 335 
siRNA-mediated depletion of spliceosome core machinery 336 
L-asparaginase 337 
Src-inhibitor Saracarinib and estrogen receptor antagonist Fulvestrant 338 
siRNA-mediated depletion of RAB25 339 
mTORC1-inhibitor Everolimus and Arsenic Trioxide 340 
Proteasome inhibitors 341 
Vincristine and/or ectopic expression of mutant p53 (175H)  342 
Diindolylmethane,via ER-stress and AMPK 343 
Human umbilical cord Wharton’s jelly stem cell extracts 344 
Doxorubicin and the steroidal lactone Withaferin A, via ROS 345 
p38 mitogen activated protein kinase inhibitor SB202190 346 
Demethylating agents and/or HDAC inhibitors 347 
Physialis minima L. chloroform extract 348 
HIV protease inhibitor Saquinivir 349 
Anti-Her2/Neu Immunotoxins 350 
Phospho-enriched protein in astrocytes (PEA-15) 351 
Soy-derived isoflavenoid Genestein 352 
Resveratrol 353 
Cytoprotective Effect of Autophagy Induction 
Sphingosine analog and immunosuppressant FTY720 354, 355 
Cisplatin, via Protein Phosphatase 2A (PP2A) 356 
Simvastatin 357 
Cisplatin, via Nucleus Accumbens-1 (NAC-1) 358 
Radiation 359 
Cisplatin via p62/SQSTM1 360 
Arsenic Trioxide 361 
Aplasia Ras homologue member I (ARHI/DIRAS3)  328 
Cytotoxic Effect of Autophagy Induction 
Monofunctional platinum (II) complex (Mono-Pt) 362 
Src-/Abl-kinase inhibitor Dasatinib 363 
 
*Search strategy: Medline search for “autophag* AND ovarian cancer” on April 26 
2013 yielded 91 results, which were each examined for evidence of autophagy 
induction. If the study experimentally assessed the purpose of autophagy induction (e.g., 
blockade with autophagy inhibitors or siRNA depletion of ATG genes), articles were 
then classified based on whether autophagy hampered (2 articles) or promoted (8 
articles) cell viability. If such experiments were not conducted, articles were classified 
as “undetermined effect” (19 articles). 
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autophagy upregulation, but did not assess its effects on cell viability. Of the ten that did, 
two described autophagy-mediated cell death and eight demonstrated pro-survival 
autophagy. Therefore, while autophagy clearly remains inducible in ovarian cancer, its 
function is relatively uncharacterized and would therefore benefit from further study.  
 
1.5.7 Therapeutic Manipulation of Autophagy in Ovarian Cancer 
 
 The context-dependent nature of autophagy makes it difficult to modulate 
therapeutically in ovarian cancer. If acting as a tumour-promoting mechanism, blocking 
autophagy could deprive ovarian tumours of a key survival advantage, thereby enhancing 
the efficacy of anti-neoplastic agents. On the other hand, if autophagy is acting as a lethal 
self-cannibalization mechanism, blocking it could instead blunt therapeutic efficacy. The 
only autophagy inhibitors currently in clinical use are Chloroquine (CQ) and its 
derivative Hydroxychloroquine (HCQ), though targeted autophagy inhibitors are in pre-
clinical development331,332. One small trial of autophagy blockade (using CQ) in 
glioblastoma multiforme has yielded promising results333, and additional trials in other 
tumour types are underway334 (Table 1.4). Notably, none of these trials specify the 
inclusion of ovarian tumours. This may be due, at least in part, to the lack of consensus 
on autophagy’s role in this cancer. Therefore, further pre-clinical studies are needed to 
more thoroughly understand autophagy’s role in tumorigenesis, and in doing so, justify 
autophagy modulation as a therapeutic paradigm. To start, it will be important to 
investigate autophagy separately in the histologic sub-types of epithelial ovarian cancer 
given the dramatic pathologic and molecular heterogeneity among them. Furthermore, 
autophagy will need to be studied using in vitro and in vivo models that attempt to 
recapitulate the disease in the most physiologically-relevant context possible. Through 
such investigations, it will be possible to develop rational strategies for modulating 
autophagy in hopes of achieving greater therapeutic efficacy and improving outcomes for 
women who suffer from this disease.  
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Table 1.4: Clinical Trials of Autophagy Modulation in Cancer* 
Trial 
Identifier Condition Intervention(s) 
HCQ/CQA Combination Treatment 
NCT00933803 NSCLCB Carboplain, Paclitaxel, HCQ 
NCT01649947 NSCLCB Carboplain, Paclitaxel, HCQ 
NCT01480154 Advanced STC MK-2206, HCQ 
NCT01506973 Pancreatic Gemcitibine, HCQ 
NCT01206530 CRCD FOLFOX, Bevacizumab HCQ 
NCT01006369 mCRCD Capecitabine, Oxaliplatin, 
Bevacizumab, HCQ 
NCT01266057 Advanced Cancers Sirolimus, Vorinostat, HCQ 
NCT01023737 Malignant STC Vorinostat, HCQ 
NCT00909831 Metastatic STC Temsirolimus, HCQ 
NCT01634893 Refractory/Relapsed STC Sorafenib, HCQ 
NCT00813423 Refractory Advanced STC Sunitinib, HCQ 
NCT01748500 Prostate Pantoprazole 
NCT01828476 Prostate ABT-263, HCQ 
NCT01128296 Pancreatic Gemcitabine, HCQ 
NCT00568880 MME Bortezomib, HCQ 
NCT01510119 RCCF Everolimus, HCQ 
NCT01144169 RCCF Neo-adjuvant HCQ 
NCT01687179 LG Sirolimus, HCQ 
NCT01438177 Refractory/Relapsed MME VELCADE, Cyclophosphamide, CQ 
HCQ/CQA Single-Agent Treatment 
NCT01292408 Breast HCQ 
NCT00969306 SCLCH CQ 
NCT01023477 DCISI Chloroquine 
NCT00962845 MelanomaJ HCQ 
Assessment of Autophagy Biomarkers - No HCQ/CQA 
NCT01210274 MDS or AMLK Azacitidine 
NCT01092728 Melanoma Dasatinib 
NCT01358045 BCCL Calcitrol, Diclofenac 
NCT01497925 Prostate ADI-PEG 20 
NCT01009437 Breast Ritonavir 
NCT01594242 MME Bortezomib 
 
*ClinicalTrials.gov search terms used: “cancer” and “autophagy”; 
AHydroxychloroquine/Chloroquine; BNon-small cell lung carcinoma; CSolid Tumours; 
DColorectal Carcinoma (m: metastatic); EMultiple Myeloma; FRenal Cell Carcinoma; 
GLymphangioleiomyomatosis; HSmall Cell Lung Carcinoma; IDuctal Carcinoma In Situ; 
JResectable Stage II/IV; KMyelodysplastic Syndromes or Acute Myeloid Leukemia; 
LBasal Cell Carcinoma 
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1.5.8 Summary 
 
 Autophagy is an evolutionarily-conserved cellular self-digestion mechanism that 
facilitates sequestration of cytoplasmic components and their delivery to lysosomes. This 
mechanism is orchestrated by dedicated molecular machinery and carefully regulated by 
nutrient- and energy-sensing complexes that integrate multiple upstream signals. 
Autophagy is important for maintaining cellular homeostasis, since disruption of its basal 
activity promotes neurodegeneration, myopathy, and tumorigenesis. It can also be 
upregulated beyond basal levels, serving to moderate cellular stresses and promote cell 
survival. Autophagy upregulation plays a cytoprotective role in tumours, supporting their 
deregulated metabolism, but also mitigating the cytotoxic effects of anti-cancer therapies. 
In ovarian cancer, there is interest in clarifying the context-specific functions of 
autophagy to determine how its therapeutic modulation may benefit patients.  
 
1.6 Scope of Thesis 
 
 A process of cell exfoliation, survival in suspension, and re-implantation is 
critical in mediating the earliest stages of high-grade serous tumorigenesis. This sequence 
appears to be conserved over the course of tumour evolution, since it also defines intra-
peritoneal metastasis. Given the propensity of ovarian tumour cells to continually 
undergo cycles of cellular detachment and re-implantation, we hypothesized that they 
harbor important molecular adaptations enabling survival under such conditions. Our 
goal was therefore to identify and characterize some of these mechanisms, as doing so 
could uncover novel therapeutic paradigms for this disease. 
  
 To conduct our investigation, we first established an in vitro model of the 
exfoliation-survival-implantation process using patient-derived ovarian tumour cells in a 
non-adherent culture environment (Chapter 2). Using this model, we characterize the 
formation of in vitro spheroids and their resemblance to those routinely extracted from 
patient ascites. Intriguingly, we find that spheroid cells exist in a quiescent state based on 
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the upregulation of its defining molecular mediators. We also demonstrate autonomous 
down-regulation of AKT activity upon spheroid formation, and suggest that this plays a 
role in mediating quiescence. Finally, we demonstrate that upon re-attachment to an 
adherent surface, spheroids reactivate proliferative mechanisms in an AKT-dependent 
manner. Together, these studies uncover reversible alterations to the biology of metastatic 
ovarian cancer cells that occur in association with non-adherent spheroids.   
  
 In agreement with reduced AKT activity in spheroids, we also demonstrate an 
autonomous induction of autophagy (Chapter 3). Moreover, pharmacologic inhibition of 
any residual AKT activity in spheroids augments their upregulation of this process. In 
adherent cells as well, we show that pharmacologic AKT inhibition robustly induces 
autophagy. Interestingly, our work goes on to demonstrate that upregulation occurs 
independently of Beclin1 despite the canonical role for this protein as an autophagy-
inducer. Thus, we uncover a non-canonical autophagy program in ovarian cancer cells 
that is stimulated by down-regulation of AKT activity. 
 
 Building upon our analysis of autophagy (Chapter 4), we next demonstrate that its 
upregulation can be blocked using three approaches: siRNA-mediated depletion of ATG 
genes, the Specific and potent autophagy inhibitor 1 (Spautin1), and the classical 
autophagy blocker Chloroquine (CQ). We then show that by any approach, blockade 
results in significantly decreased cell viability. Moreover, we find that the combination of 
AKT inhibition and autophagy blockade reduces viability in a synergistic manner. Taken 
together, our findings establish autophagy a cytoprotective mechanism upregulated in 
metastatic ovarian cancer cells cultured as spheroids and/or subjected to AKT inhibition. 
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Chapter 2  
 
2 Modulation of AKT activity is associated with reversible 
dormancy in ascites-derived epithelial ovarian cancer 
spheroids 
 
2.1 Introduction 
 
Metastasis of epithelial ovarian cancer (EOC) is most often the cause of disease-
associated mortality. In the majority of cases, disease has spread beyond the ovaries at the 
time of diagnosis 1. Cytoreductive surgery and adjuvant chemotherapy (platinum-taxane 
combination regimens) may achieve optimal tumor debulking, but the persistence of 
microscopic disease often results in recurrence in the form of additional metastatic 
lesions 2. Disseminated disease is likely a major factor in lowering the average five-year 
relative survival rate for EOC to only 43.8%, making this cancer the fifth most lethal 
among women and the most lethal of the gynaecologic malignancies 3. Consequently, an 
improved understanding of the cellular biology of EOC metastasis and its underlying 
molecular mechanisms will shed light on novel therapeutic options. 
 
At the cellular level, EOC metastasis begins when tumor cells are shed into the 
peritoneal cavity where they exist in suspension as single cells or multi-cellular 
aggregates/spheroids. 4. The presence of EOC cells and spheroids contributes to the 
accumulation of large quantities of fluid in the peritoneal cavity (malignant ascites), a 
common feature of advanced-stage EOC 5.  Once suspended in ascites, solitary EOC cells 
and spheroids diffuse throughout the peritoneal cavity and are believed to seed the 
formation of secondary lesions 4.  
 
It has been suggested that small pockets of “dormant” cells somehow persist 
during and after treatment of metastatic EOC 2, remaining undetectable to current 
screening methodologies and shielded from front-line chemotherapeutics. These dormant 
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cells may be capable of reactivation when growth conditions are favorable 6, going on to 
seed the formation of secondary lesions.  
 
An important characteristic of dormancy is cellular quiescence, or exit from the 
cell cycle into a G0 or non-dividing state. Quiescence can be defined as a reversible cell 
cycle arrest accompanied by the accumulation of regulatory proteins necessary for the 
maintenance of this state: specifically, p130/RBL2 (a pRB-related pocket protein) and 
p27Kip1 (a cyclin-CDK inhibitor), both of which increase in expression during G0 7-10. 
Although quiescence is an emerging concept in the study of ovarian cancer 11, it has 
never been formally characterized in EOC cells cultured under non-adherent conditions. 
This is surprising given that spheroids are thought to comprise a key phase of the 
metastatic cascade 4,12-16. Consequently, it is of great interest to determine if quiescence is 
prevalent in spheroid cells. Such a finding would implicate spheroids as pockets of 
”dormant” cells that – by virtue of their non-cycling state – could elude 
chemotherapeutics and contribute to metastasis. 
 
In addition, the regulation of quiescence in ovarian cancer remains even less 
characterized. One study has centered around the role of Mirk/dyrk1b in directly 
regulating p130 11; however, the regulatory mechanisms controlling this cellular state are 
no doubt multifaceted, including activation of quiescence-promoting factors (e.g., 
Mirk/dyrk1B) as well as de-activation of proliferation-promoting pathways. One such 
pathway may be phosphatidylinositol 3-kinase (PI3K)/AKT, a canonical promoter of cell 
cycle entry 17, and as such, a negative regulator of quiescence. It is well established that 
PI3K/AKT signaling is important in ovarian cancer pathogenesis 18-25 and can promote 
proliferation 26, survival 27,28, as well as migration and invasion 29,30 in ovarian cancer 
cells. However, these studies have not examined the possibility of endogenous de-
activation of AKT activity at some point during the metastatic process, a change that 
could potentiate dormancy characterized by quiescence.  
 
Herein, we sought to (i) determine whether spheroids undergo reversible 
quiescence, (ii) explore the association of this phenomenon with PI3K/AKT signaling, 
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and (iii) perform our studies in a disease-relevant manner using clinical specimens. We 
initiated our studies on native spheroids filtered directly from patient ascites, observing 
no increase in proliferation over time.  To extend these findings, we obtained and utilized 
primary EOC cells from patient ascites samples and cultured them in suspension at 
sufficient density to facilitate aggregation of bulk tumor cells. Under these conditions, 
EOC cells rapidly clustered to form quiescent spheroids with downregulated AKT 
signaling, yet retained their capacity to reattach to a favourable substratum and proliferate 
in an AKT-dependent manner.  
 
2.2 Materials and Methods 
 
2.2.1 Establishment of primary cultures from ascites 
 
 Ascitic fluid collected from chemotherapy-naive patients at time of paracentesis 
or debulking surgery was used to generate primary ascites cell cultures as described 
previously31. Patient samples used in this study were high-grade carcinomas of the serous 
subtype and at least stage III disease (Appendix B). The presence of epithelial cancer 
cells in these cultures was confirmed by expression of epithelial cell adhesion molecule 
(EpCAM) and lack of CD45 expression, as assessed by flow cytometry. All work with 
patient materials has been approved by The Univeristy of Western Ontario Health 
Sciences Research Ethics Board (Protocol number 12668E). 
 
2.2.2 Isolation of spheroids from ascites fluid 
 
 Native spheroids were isolated by filtration through a 40µm cell-strainer (Becton 
Dickinson, Franklin Lakes, NJ), washed with PBS into a collection tube containing a 
10% formalin solution for immediate fixation, or resuspended in growth medium and 
cultured in vitro. The presence of epithelial cancer cells was confirmed by flow-
cytometric detection of EpCAM. 
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2.2.3 Cell culture  
 
 The human ovarian cancer cell line OVCAR3 was purchased from the American 
Type Culture Collection (ATCC; Manassas, VA) and cultured in RPMI-1640 (Wisent, St. 
Bruno, Canada) supplemented with 5% fetal bovine serum (FBS; Wisent). Primary 
cultures of cells or spheroids were maintained in a 1:1 mixture of MCDB 105: M199 
(Sigma, St. Lewis, MO) supplemented with 10% FBS (Wisent) and 50µg/ml penicillin–
streptomycin (Wisent). Cells were maintained in a 37°C humidified atmosphere of 95% 
air and 5% CO2.  
 
 Adherent cells were maintained on tissue culture-treated polystyrene (Sarstedt, 
Newton, NC). Non-adherent cultures (native and in vitro spheroids) were maintained on 
Ultra-low Attachment plates (ULA; Corning, Corning, NY), which are coated with a 
neutral hydrophilic gel to prevent cell attachment. To form in vitro aggregates, single-cell 
suspensions of 1 x 105 cells/mL were seeded directly to ULA plates. This methodology 
follows techniques of aggregate formation previously described in the EOC spheroid 
literature12,16,32,33.  
 
2.2.4 Cell number & viability assays  
 
 Adherent cells were trypsinized and resuspended in FBS-containing medium to 
first generate a single-cell suspension. Non-adherent spheroids were exposed to trypsin-
EDTA for 10-20 minutes with vortexing and trituration to disaggregate cells. Trypsin was 
inactivated using a small volume of FBS. To enumerate viable cells, Trypan Blue reagent 
(Gibco/Invitrogen, Carlsbad, CA) was applied (1:1 dilution) and cells counted in a 
hemacytometer (triplicates, two counts per replicate). To determine whether cells seeded 
to non-adherent culture maintained viability as clusters or as solitary cells, they were 
allowed to re-attach to tissue culture plastic and stained with HEMA3 (Fisher, 
Kalamazoo, MI) following 2, 4, 8, 12, and 24h periods in non-adherent culture. HEMA3 
staining was performed 24h after cells/spheroids were allowed to re-attach to tissue 
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culture plastic (i.e., re-attachment was allowed to proceed for 24h following re-seeding to 
tissue culture plastic, following which, HEMA3 staining was done). Wells were imaged 
using an Olympus IX70 inverted microscope with ImagePro software to generate random 
fields of view across the plate. Mean single-cells/field and mean spheroids/well were 
quantified at 2h and 12h using ImageJ software (NIH, Bethesda, MD). 
 
2.2.5 Ki67 immunohistochemical staining  
 
 OVCAR3 intact spheroids or single-cell suspensions of adherent cells were 
embedded in 1% agarose (w/v). Agarose pellets then underwent paraffin embedding and 
sectioning (Molecular Pathology, Robarts Research Institute, London, ON), followed by 
Ki-67 immunohistochemistry (Dept. of Pathology, Univeristy Hospital, London, ON). 
Images were captured using an Olympus AX70 upright microscope ImagePro software 
and Ki-67-positive nuclei counted (min. 1,000 nuclei per culture condition). 
 
2.2.6 Flow cytometry  
 
2.2.6.1 Propidium Iodide (PI) Staining 
 
 Single-cell suspensions were generated as described above, fixed in 95% ethanol, 
and stored at 4°C. For staining, cells were pelleted and resuspended in PI Staining 
Solution (PBS with 2% FBS, 0.25µg/µL RNase, 10µg/mL PI), incubated at 37°C for 30 
min, then overnight at 4°C. The following day, labeled cells were passed through 40µm 
cell-strainers to remove large particles and flow cytometry performed on a Beckman 
Coulter Epics XL-MCL to quantify cell cycle proportions (experiments in triplicate, 
10,000 events per replicate). Histograms depicting cell count over PI intensity were 
generated using the FlowJo software (Ashland, OR).  
 
2.2.6.2 BrdU/PI Staining  
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 Adherent or non-adherent cells were pulse-labeled with 10µM 
bromodeoxyuridine (BrdU; GE Healthcare, Buckinghamshire, UK) for 2h. Single-cell 
suspensions were fixed in 95% ethanol and stored at 4°C. For staining, cells were 
sequentially resuspended and pelleted in the following solutions: 2N HCl/0.5% TritonX-
100, 0.1M NaB4O4 pH 8.5, mouse anti-BrdU primary antibody (1:50; Becton Dickinson), 
anti-Mouse FITC-conjugated secondary antibody (1:250; Vector Laboratories, 
Burlingame, CA), and PI Staining Solution [PBS with 2% FBS, 0.25µg/µL RNase, 
10µg/mL PI]. Following this, subsequent steps were carried out as described for ‘PI 
Staining’ above. 
 
2.2.6.3 EpCAM and CD45 Staining  
 
 Single-cell suspensions were incubated in a 2% FBS solution containing anti-
EpCAM PE-conjugated antibody (1:50; Becton Dickinson) or anti-CD45, PC5-
conjugated antibody (1:50; Beckman Coulter). EpCAM or CD45 expression was 
quantified using a Beckman Coulter Epics XL-MCL flow cytometer with at least 10,000 
events counted per test.  
 
2.2.7 Immunoblotting  
 
 Cell lysates were obtained using a modified radioimmunoprecipitation assay 
(RIPA) buffer [50mM HEPES pH7.4, 150mM NaCl, 10% glycerol, 1.5mM MgCl2, 1mM 
EGTA, 1mM sodium orthovanadate, 10mM sodium pyrophosphate, 10mM NaF, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1mM PMSF, 1X protease inhibitor 
cocktail (Roche, Laval, QC)]. Cells were washed once in PBS followed by addition of 
lysis buffer. Protein concentration of each lysate was determined using Bradford’s 
method34 and 25-30µg of protein resolved by 8% or 14% SDS-PAGE, transferred to a 
polyvinylidene difluoride membrane (PVDF; Roche), and blocked with 5% skim milk in 
TBST (10mM Tris-HCl, pH 8.0, 150mM NaCl, 0.1% Tween 20). Membranes were 
washed in TBST and incubated overnight at 4°C with antibodies (1:1000 in 5% skim 
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milk/TBST or 5% BSA/TBST). Immunoreactive bands were visualized by incubating for 
1h at room temperature with a peroxidase-conjugated anti-rabbit or anti-mouse IgG 
(1:10,000 in 1% skim milk/TBST; GE Healthcare) followed by exposure to enhanced 
chemiluminescence reagent (ECL Plus; GE Healthcare).  
 
2.2.8 Antibodies and other reagents  
 
 Antibodies were obtained against pAkt-Ser473 (#9271; Cell Signaling 
Technology, Danvers, MA), total AKT1/2/3, p27, p130 (H-136 sc-8312; C-19 cs-528; C-
20 sc-317; Santa Cruz Biotechnology, Santa Cruz, CA), p45SKP2 (REF 323300; 
Invitrogen, Carlsbad, CA), and actin (A 2066; Sigma, Saint Louis, MO). Akt inhibitor 
VIII (Akti-1/2) was purchased from EMD/Calbiochem (Merck, Darmstadt, Germany). 
 
2.2.9 Spheroid dispersion assay  
 
 Day 3 spheroids were re-attached to 48-well tissue culture-treated plates (one 
spheroid/well) and treated with DMSO or Akti-1/2 (5µM) at 24h post-attachment. Phase 
contrast images were captured at 72h using an Olympus IX70 inverted microscope and 
ImagePro software and dispersion area quantified using ImageJ (NIH, Bethseda, MD). 
 
2.2.10 BrdU cytochemistry on dispersing spheroids 
 
 Day 3 spheroids were re-plated to glass coverslips in 24-well plates and treated 
with DMSO or Akti-1/2 (5µM) at 24h post-attachment. At 72h, dispersing spheroids were 
labeled with BrdU (OVCAR3 pulse-labeled for 2h; EOC samples labeled overnight), 
fixed in a buffered 10% formalin solution, washed with PBS, and permeabilized with 
0.1% Triton X-100 in PBS. This was followed by sequential incubations and washes in 
2N HCl/0.5% Triton X-100, 0.1M NaB4O4 pH 8.5, mouse anti-BrdU primary antibody 
(1:100; Becton Dickinson), anti-Mouse FITC-conjugated secondary antibody (1:250; 
Vector Laboratories), and 4',6-diamidino-2-phenylindole (DAPI; 1:5000; Sigma). Stained 
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coverslips were inverted and mounted on glass slides with VectaShield mounting 
medium (Vector Laboratories). Fluorescence images were captured using an Olympus 
AX70 upright microscope and ImagePro software. 
 
2.2.11 Statistical analysis  
 
 Data were expressed as mean ± SEM. All statistical analysis was performed using 
two-tailed Student t-tests. All tests of significance were set at p < 0.05.  
 
2.3 Results 
 
2.3.1 Primary EOC cells form non-adherent spheroids resembling 
those found in patient ascites 
 
To perform controlled analyses of spheroid biology, we utilized a reproducible in 
vitro method of non-adherent culture similar to established methods of aggregate 
formation described in the EOC spheroid literature12,16,32,33. Our objective for this study 
was not to culture ovarian cancer-initiating cells (i.e., use stem cell selection medium or 
limiting dilutions to generate cancer-initiating cell-derived spheroids35). Instead, primary 
EOC cells isolated and cultured from patient ascites were seeded to Ultra low-Attachment 
(ULA) cultureware in full growth medium where they rapidly clustered to form 
multicellular aggregates or spheroids (Fig. 2.1A). OVCAR3 cells and all patient EOC 
samples tested thus far were able to form these structures, shown in brightfield images 
(Fig. 2.1B) and histological sections stained with hematoxylin & eosin (Fig. 2.1C). Mean 
size and number were calculated for five EOC samples (Fig. 2.1D), revealing both 
properties to be reproducible within EOC samples. Additionally, the number of spheroids 
decreased over time in all samples tested (Fig. 2.1D; upper panel), though there was no 
consistent trend in size (Fig. 2.1D; lower panel). Histological analysis of spheroids 
generated in vitro, compared to native spheroids from patient ascites, did not reveal 
significant differences in morphology (Fig. 2.1E).     
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Figure 2.1: EOC cells in suspension culture form multicellular spheroids that 
resemble native spheroids in patient ascites.  
(A) Schematic diagram of in vitro spheroid formation. (B) Brightfield images of spheroids at day 
3 of formation. (C) Images of day 3 spheroids embedded in paraffin, sectioned, and H&E-stained. 
(D) Mean spheroid number and size were quantified per patient sample by pooling replicates 
from three independent experiments. (E) Brightfield image of native EOC98 spheroids filtered 
directly from ascites, and of three patient samples that were paraffin-embedded, sectioned, and 
H&E-stained.   
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2.3.2 Both native and in vitro spheroids experience decreased cell 
proliferation 
 
To initiate our studies of cell proliferation, we analyzed native spheroids filtered 
directly from patient ascites fluid. These were maintained in non-adherent culture over 
seven days during which time cell counting was performed (Fig. 2.2A). EOC98 and 
EOC114 viable cell number remained unchanged, whereas EOC100, following an initial 
decrease in cell number, reached a plateau and did not significantly increase over 
subsequent days. Although EOC101 exhibited an initial 1.40-fold increase in cell 
number, there was no further increase observed between days three and seven. Therefore, 
native spheroids in non-adherent culture did not experience a significant change in cell 
number over time.  
 
To evaluate whether in vitro EOC spheroids exhibited a similar trend, single-cell 
suspensions of OVCAR3 and primary EOC cells were seeded to non-adherent culture and 
cell number subsequently assessed over a seven-day time course. In most EOC samples, 
an initial decrease in cell number was followed by a general plateau or reduced rate of 
decline following day three (Fig. 2.2B). Although OVCAR3 cells and EOC42 appeared 
to initially increase in number, this was soon followed by a decline and subsequent 
plateau that was similar to other EOC samples (Fig. 2.2B). This is in stark contrast to 
what is seen in adherent EOC cell lines and primary cells36, which increase in cell 
number over time. A closer examination of cell viability during spheroid formation was 
performed by collecting non-adherent cultures at 2, 4, 8, 12, and 24h time points and re-
seeding them to tissue culture plastic, thereby assessing the capacity of cells to re-attach 
as a measure of viability. This assay revealed that by approximately 8-12h in non-
adherent culture, the number of single, unclustered cells had dropped dramatically, 
presumably as they underwent detachment-mediated apoptosis (i.e., anoikis37). All 
remaining viable cells were those that had clustered to form spheroids (Fig. 2.2C).   
 
 To assess whether the remaining viable cells were experiencing decreased 
proliferation, Ki67 immunostaining was performed on OVCAR3 spheroids, revealing a  
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Figure 2.2: Both native and in vitro spheroids experience decreased cell 
proliferation. 
Cell viability was assessed over seven days by Trypan Blue exclusion for (A) native spheroids 
and (B) in vitro spheroids. Viability is depicted as a proportion of viable cells relative to day 1 
and 0, respectively. (C) Left: EOC primary cells seeded to non-adherent culture were removed at 
indicated time points and re-attached to 6-well tissue culture dishes. Re-attached cells were 
stained with HEMA3 and imaged. Right: Graphs were generated from counts in random fields of 
view (single cells) or complete wells (clusters). (D) PI analysis of DNA content was performed in 
non-adherent and adherent (sub-confluent) cells by flow cytometry. Graphs were generated using 
FlowJo software (Ashland, OR). Cell cycle proportions are reported as Mean ± SEM.  
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dramatic reduction in Ki67-positive nuclei to 13.6±0.5% compared to 24±0.5% Ki67-
positive nuclei in actively proliferating monolayer cells (p < 0.001; Fig. S2.1)  
 
To further characterize reduced proliferation, we assessed whether cells were 
undergoing arrest in a particular phase of the cell cycle. Using PI staining for DNA 
content and quantifying by flow cytometry, we compared cells in spheroids to 
proliferating adherent cultures. EOC39 cells, as early as 6h in non-adherent culture, 
demonstrated a significant decrease in S-phase proportion (2.5±0.6% S-phase compared 
to 11.6±0.4% in adherent cells) and in G2/M-phase proportion (12.9±1.8% G2/M-phase 
compared to 22.7±0.7% in adherent cells; p < 0.05; Fig. 2D). This was accompanied by a 
notable accumulation of cells in G1/G0  (83.4 ± 2.6% G1/G0-phase compared to 
63.8±0.8% in adherent cells; p < 0.05).  Similar trends were consistently observed in 
another seven EOC primary cell samples (Table 2.1). Therefore, EOC cells in spheroids 
experience decreased proliferation, having either transiently arrested at the G1/S-phase 
transition or exited the cell cycle into G0. 
 
2.3.3 Spheroids exhibit growth arrest in G0 
 
We next set out to determine whether spheroids are comprised of quiescent (G0) 
cells. To provide a molecular description of quiescence, the expression of p130/RBL2 
and p27Kip1 were assessed by Western blot. p130 is essential for maintenance of G0, 
forming repressive complexes on E2F target-gene promoters to suppress cell cycle-
dependent transcription8. p27Kip1, a cyclin-CDK inhibitor, has also been implicated as an 
essential mediator of quiescence: its deletion can abrogate cell cycle exit10, while its over-
expression can induce quiescence and growth-factor insensitivity in cancer cells 9. In 
OVCAR3, we observed significant increases in p130 and p27Kip1 expression in spheroids 
(Fig. 2.3A). In multiple EOC samples, spheroids exhibited 2.1±0.18-fold increase in p130 
(p < 0.001; n = 17) and a 4.5±0.85-fold increase in p27Kip1 levels (p < 0.01; n = 12) 
compared to their adherent counterparts (Fig. 2.3B). Therefore, elevated expression of 
quiescence-associated proteins suggests that spheroid cells exist in a quiescent state. 
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Table 2.1: EOC primary cells experience reduced cell cycle kinetics when cultured 
as spheroids. 
 
  
 Cell cycle phase (%, Mean ± SEM) 
 Adherent/Proliferating Day 3 Spheroid 
 G1/G0 S G2/M G1/G0 S G2/M 
EOC39 63.8 ± 0.8 11.6 ± 0.4 22.7 ± 0.7 85.8 ± 3.0* 2.7 ± 1.4* 9.9 ± 1.2* 
EOC27 69.3 ± 0.5 11.0 ± 0.4 18.5 ± 0.4 83.6 ± 1.2* 3.3 ± 0.3* 10.0 ± 0.9* 
EOC33 69.7 ± 2.3 11.2 ± 0.8 18.2 ± 2.1 90.5 ± 0.6* 2.5 ± 0.4* 4.3 ± 0.3* 
EOC50 63.9 ± 0.6 18.6 ± 0.3 12.1 ± 0.1 81.2 ± 0.3* 3.0 ± 0.3* 7.0 ± 0.3* 
EOC75 63.9 ± 1.1 13.9 ± 0.3 18.3 ± 0.4 73.9 ± 0.3* 4.5 ± 0.3* 12.6 ± 0.2* 
EOC68 71.7 ± 0.5 15.9 ± 0.7 11.0 ± 0.1 82.6 ± 1.4* 3.7 ± 0.3* 6.7 ± 0.4* 
EOC65 71.7 ± 0.7 7.3  ± 0.2 18.9 ± 0.7 77.7 ± 0.4* 2.1 ±0.03* 18.3 ± 0.3 
EOC104 65.2 ± 0.5 21.2 ± 2.3 10.2 ± 2.1 82.9 ± 0.4* 2.6 ± 0.2* 9.7 ± 0.2 
*Statistically significant differences between spheroid and adherent cells (p < 0.05). 
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Figure 2.3: EOC spheroids express markers of quiescence that correlate with 
reduced AKT phosphorylation.  
(A) OVCAR3 and primary EOC cells were seeded to parallel adherent (A) and non-adherent (S) 
cultures. After 72 hours, spheroids or monolayers were lysed and 25-30µg of protein subjected to 
8% (pAKT-Ser473 and total AKT) or 12% (p130, SKP2, and p27Kip1) SDS-PAGE and Western 
blot. Blots were stripped and probed for total AKT. Actin was used as a loading control. (B) 
Western blots of primary EOC cells were quantified by densitometry and results displayed in bar 
graphs (spheroid as a proportion of adherent). Statistical significance is indicated by ** p<0.01 
and ***p<0.001 (pAKT, n = 12; SKP2, n = 10; p130, n = 17; p27Kip1, n = 12) 
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2.3.4 Quiescence in spheroids is associated with reduced AKT 
phosphorylation 
 
The PI3K/AKT pathway is well-established as a key player in all forms of cancer 
including EOC2. Active AKT forms an important signaling node in this pathway, exerting 
broad regulation over cell survival and proliferation (reviewed in Ref. 17). To assess the 
role of AKT, we monitored its phosphorylation at serine 473 (pAKT) and discovered that 
it was reduced in spheroids. Levels of pAKT-Ser473 were reduced to 35.2±4.3% of that 
seen in parallel adherent cells in OVCAR3 cells (Fig. 2.3A) and in twelve patient samples 
(p < 0.001; Fig. 2.3B). 
 
AKT kinases possess several mechanisms by which they can stimulate 
proliferation38, and as a result, negatively regulate quiescence.  We focused on AKT 
regulation of the F-box protein p45SKP2 (SKP2), as SKP2 can exert strong post-
translational regulation over both p130 and p27Kip1. AKT stabilizes SKP239,40, preventing 
its degradation. SKP2 in turn facilitates SCF-mediated ubiquitination and degradation of 
p130 and p27Kip1, allowing cells to escape quiescence and re-enter the cell cycle41,42. 
However, in the absence of active AKT signaling, SKP2 is less stable and thus is 
expressed at a lower level, allowing accumulation of quiescence-promoting proteins (e.g., 
p130 and p27Kip1). We found that SKP2 levels in spheroids of OVCAR3 and ten EOC 
primary cells were significantly decreased to 61.5±7.7% of the level in parallel adherent 
cultures (p < 0.001; Fig. 2.3A, B). 
 
Given that reduced pAKT in spheroids correlated with decreased proliferation, 
decreased SKP2, and increased p130, and p27Kip1 protein levels, we wanted to more 
directly determine the role of AKT in mediating these changes. Using a chemical 
inhibitor of AKT kinases (Akti-1/2; EMD Biosciences), dose-dependent inhibition of 
AKT phosphorylation was achieved in adherent monolayers of OVCAR3 (Fig. 2.4A) and 
four EOC samples (data not shown). Treatment of adherent OVCAR3 cells with 5µM 
Akti-1/2 for 72h significantly reduced the number of viable cells to 41.6±0.05% of 
86 
 
 
 
 
 
Figure 2.4: Inhibition of AKT activity induces quiescence in adherent OVCAR3 
cells.  
(A) OVCAR3 adherent cells were treated with increasing Akti-1/2 concentration (0.01, 0.05, 0.1, 
0.5, 1.0, 2.5, 5.0, and 10.0µM). Complete loss of pAKT was achieved at a dose > 2.5 µM. 
OVCAR3 adherent cells were treated with DMSO or Akti-1/2 (5µM) at 24h post-seeding. 
Following 72h treatment: (B) viability was assessed by Trypan Blue exclusion counting and 
depicted as a proportion of viable cells relative to control; (C) cells were pulse-labelled for 2h 
with BrdU and BrdU/PI cell cycle analysis performed by flow cytometry; and (D) cells were 
lysed and Western blot performed to assess p130, SKP2, and p27Kip1 levels. Actin was used as a 
loading control. Statistical significance is indicated by *p < 0.05 and **p < 0.01.  
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DMSO controls (p < 0.001; Fig. 2.4B). This decrease was not due to cell death since the 
number of dead cells was not significantly increased with Akti-1/2 treatment (p < 0.05). 
Therefore, a reduction in cell proliferation, rather than increased cell death, likely 
contributed to the decreased cell number observed. To more directly assess proliferation, 
BrdU/PI analysis was performed. This revealed a significant shift in cell cycle 
distribution when cells were treated with Akti-1/2 (Fig. 2.4C): specifically, a significant 
accumulation of cells in G1/G0- and G2/M-phases (p < 0.05), and a 60.7% decrease in S-
phase (p < 0.001). Finally, Western blot of lysates obtained from Akti-1/2-treated cells 
revealed decreased SKP2 and increased p130 and p27Kip1 protein levels upon inhibition 
of AKT phosphorylation (Fig. 2.4D). Therefore, the quiescent phenotype of EOC 
spheroids with low pAKT is recapitulated in adherent EOC cells when subjected to 
chemical inhibition of AKT activity.  
 
2.3.5 Spheroids initiate AKT-dependent cell proliferation upon re-
attachment  
 
Given that the final phase of EOC metastasis involves attachment and growth of 
spheroids on peritoneal surfaces, we next asked whether in vitro spheroids, which have 
become quiescent, are capable of re-initiating growth as well. We performed re-
attachment experiments and found that EOC spheroids readily adhere to surfaces 1-2h 
post-seeding, followed by rapid dispersion to form an expanding monolayer (Fig. 2.5A). 
To test whether AKT phosphorylation is important for dispersion, we inhibited AKT 
activity during this process, which significantly reduced cell dispersion by 25.1 – 58.7% 
in five patient samples (p < 0.05; Fig. 2.5B).  
 
Therefore, spheroid dispersion was at least partly dependent upon AKT activity; 
however, it remained unclear whether this was due to the role of AKT-mediated 
proliferation or motility. To address this, we used BrdU incorporation to label cells in 
dispersion areas. Immunocytochemical staining showed that dispersing cells had 
incorporated BrdU, implying re-entry to the cell cycle (Fig. 2.5C). Furthermore, Akti-1/2 
treatment significantly reduced incorporation by 74.1% in OVCAR3 (p < 0.001) and by  
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Figure 2.5: Spheroids re-attach and form proliferative ‘dispersion zones’ in an 
AKT-dependent manner.  
(A) EOC10 day 3 spheroids were seeded to adherent culture and dispersion was imaged at 4, 24, 
and 72h post-attachment (left to right). (B) Dispersing spheroids ± Akti-1/2 [5µM] were imaged 
and dispersion area quantified (at least 10 dispersion zones per treatment group). Dispersing 
spheroids of (C) OVCAR3 and primary EOC cells or (D) native EOC98 dispersing spheroids 
were labeled with BrdU and immunofluorescence was performed to detect BrdU-positive nuclei. 
At least 4,000 nuclei were counted per treatment group. Statistical significance is indicated by *p 
< 0.05), **p < 0.01 and ***p < 0.001.  
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29.2 – 76.8% in primary EOC spheroids (p < 0.05; Fig. 2.5C). To determine if AKT 
activity is required for re-attachment of native spheroids, these were collected directly 
from fresh EOC patient ascites, seeded to standard tissue culture plastic, and treated with 
Akti-1/2. AKT inhibition of native EOC98 spheroids produced a 63.5% reduction in 
dispersion zone proliferation (p < 0.001; Fig. 2.5D). Therefore, cells emerging from in 
vitro and native spheroids following re-attachment depend upon AKT activity to re-
establish proliferation.  
 
2.4 Discussion 
 
Multicellular spheroids are commonly observed in the malignant ascites of EOC 
patients and an appreciation for their role in the metastatic program has been developing 
over recent years 4,12-16. We hypothesized that these structures may represent an important 
example of the “dormant pockets” of cells theorized to promote metastasis and 
recurrence. To address this concept, we conducted an in-depth investigation of spheroid 
pathobiology by establishing a disease-relevant biological model. Using this model, we 
have demonstrated quiescence in spheroids that is characterized most notably by reduced 
AKT activity, as well as increased p130/RBL2 and p27Kip1 expression and decreased 
SKP2 levels. Quiescence is reversed, however, upon re-attachment to an adherent 
substratum, allowing ‘resting’ cells to emerge, disperse, and proliferate in an AKT-
dependent manner. Importantly, native spheroids filtered from patient ascites were 
analyzed directly and were also found to consist of non-proliferating cells that are 
capable of re-initiating AKT-dependent proliferation  
 
These data suggest a mechanism in which reduced AKT activity in spheroids 
destabilizes SKP2, limiting SKP2-mediated degradation of p130 and p27Kip1 to promote 
quiescence. This is reversed upon spheroid dispersion, however, involving re-activation 
of AKT to drive cell cycle re-entry. Therefore, EOC cells may utilize the AKT pathway 
and its downstream effectors to dynamically regulate what has been referred to as a 
“dormant-to-proliferative metastatic switch” 1,43. 
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To our knowledge, this work is the first to describe spheroid formation-induced 
dormancy in EOC cells. We have specifically defined quiescence, a necessary 
characteristic of dormancy, by increased expression of p130 and p27Kip1. Accumulation 
of these proteins to mediate cell cycle exit can be invoked under acute conditions in 
ovarian cancer cells, such as serum starvation 11,44. However, we have demonstrated an 
identical response in EOC spheroids even when cultured in full-serum, thus confirming 
quiescence as a robust phenomenon within these structures. The induction of quiescence 
with a concomitant reduction in AKT phosphorylation is also a novel finding in ovarian 
cancer, which is supported by related observations in other cancer types such as pleural 
mesothelioma 45 as well as studies of anoikis in EOC cell lines 46.  
 
The literature contains some examples of ovarian cancer cell lines that maintain 
proliferation when cultured as spheroids 32, apparently contradicting our findings. 
However, the use of such highly proliferative lines may artificially “drown out” dynamics 
in proliferation occurring during the metastatic process. By utilizing ascites-derived 
primary cells and native spheroids formed within the peritoneal cavity, we are thus able 
to observe alterations in proliferation that we would not have otherwise had the 
opportunity to study. Additionally, we have extended our findings to OVCAR3 cells so 
as to demonstrate the reproducibility of reversible dormancy in a cell line model that 
harbors less extensive abrogation of proliferative control than others. 
 
Importantly, we have also demonstrated that spheroids can re-attach and disperse 
on adherent surfaces. Whereas prior studies have focused on the importance of cell 
adhesion during reattachment32,47,48, including recent work from the Brugge lab 33, our 
interest in quiescence led us to characterize cell proliferation during spheroid cell 
dispersion. Our data reveals for the first time that dispersion is a proliferative process that 
occurs in an AKT-dependent manner, thereby characterizing an important yet unstudied 
aspect of this phenomenon. Furthermore, given that AKT has previously been shown to 
increase cell attachment, migration, and invasion in ovarian cancer cells 29,30, it is 
possible that in addition to proliferation, these processes may also contribute to AKT-
dependent dispersion.  
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We have used multiple clinical specimens in our study to ensure the consistency 
of these findings. Regardless of inherent heterogeneity across EOC patient samples 21,49,50 
and despite the fact that independent samples are known to exhibit divergent genotypic 
and phenotypic profiles 51,52, we have demonstrated notable reproducibility in our results, 
further emphasizing their physiological relevance. That is, we have found reversible 
dormancy to be a conserved property of metastatic EOC spheroids. When viewed in an 
evolutionary context, one could speculate that spheroid formation and dormancy may 
represent broadly advantageous adaptations that equip EOC cells to withstand the 
assortment of selection pressures inherent to patient ascites, mediating their survival 
during the metastatic process.    
 
In summary, we have shown that EOC cells withdraw to a temporary state of 
dormancy by aggregating to form multicellular spheroids, yet retain their capacity to 
rapidly re-enter the cell cycle upon re-attachment. We conclude that spheroids present in 
patient ascites exist as dormant structures that retain their ability to seed and grow as 
secondary metastatic lesions. Further studies elucidating the events by which AKT and its 
effectors contribute to EOC metastasis in a biologically-relevant and tractable model 
system as highlighted here should reveal new therapeutic targets for marked 
advancements in the treatment of this insidious disease. 
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Figure S2.1: OVCAR3 spheroid cells exhibit a decrease in Ki67-positive nuclei 
compared to adherent counterparts.  
Intact spheroids and single-cells suspensions of adherent cells were embedded, sectioned, and 
subjected to Ki67 immunohistochemical staining. At least 1,000 nuclei were counted per culture 
condition to determine the Ki-67 positive percentage. ***p < 0.001 
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Chapter 3  
 
3 Metastatic ovarian cancer cells induce autophagy in a 
Beclin1-independent manner upon AKT inhibition or 
spheroid formation 
 
3.1 Introduction 
 
Metastatic disease represents the lethal majority of ovarian cancers, thus an 
understanding of the mechanisms underlying this process is essential to properly treat it. 
In the U.S. alone, an estimated 22,280 new cases of ovarian and 15,500 deaths were 
reported last year1. Although the 5-year relative survival for localized disease confined to 
the ovary is 92.5%, the majority of women (61%) are diagnosed with metastatic disease 
(Stage III-IV), for which survival is only 27.3%2. Metastasis in ovarian cancer is 
characterized by disease dissemination within the intra-peritoneal compartment3, 
mediated by single cells and multicellular aggregates (spheroids) present in ascites fluid4. 
Spheroids are thought to serve as important vehicles of dissemination that ultimately 
form secondary tumors5. Prior studies have demonstrated that spheroid formation protects 
ovarian cancer cells from anoikis (detachment-mediated apoptosis)6, suppresses 
PI3K/AKT signaling to promote quiescence7, and impart chemotherapeutic resistance 8-
10. Yet spheroids retain the ability to re-attach and displace cells lining the peritoneal 
cavity11, disaggregate12-15, and re-enter the cell cycle in an AKT-dependent manner7.  
 
Delineating the mechanisms that afford ovarian cancer cell spheroids resistance to 
the challenges of metastasis provide platforms for novel therapeutic development. We 
have uncovered macroautophagy (autophagy) as one potential survival mechanism 
utilized by spheroid-bound cancer cells. It is a highly-conserved mechanism that operates 
as basal to maintain homeostasis. Autophagy orchestrates the sequestration of 
cytoplasmic contents in membrane-bound vesicles and their subsequent lysosome-
mediated degradation. It also facilitates turnover of damaged or defective organelles, 
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removal of misfolded or aggregated proteins, and destruction of intracellular pathogens16, 
ridding the cell of harmful components and liberating constituent biomolecules to fuel 
metabolic and biosynthetic pathways17. Autophagy is negatively regulated by the 
PI3K/AKT pathway – specifically by the downstream activity of mechanistic target of 
Rapamycin complex 1 (mTORC1). If mTORC1 activity is suppressed, however, an 
autophagy-inducing complex is allowed to form and convey activating signals to 
downstream effectors.  
 
Autophagy effectors are mammalian homologues of autophagy-related, or “atg,” 
proteins originally discovered in yeast. Among these, the yeast Vps30/atg6 homologue 
Beclin1 has been studied extensively. It functions in a core complex with Class III PI3K 
(PI3K C3) 18 and p15019 and is required to initiate autophagy20, although several 
autophagy-independent functions have also been described. Mouse models of Beclin1 
disruption have revealed its importance in normal physiology and development, since 
mice with homozygous Becn1 gene disruption die by embryonic day 7.521.  Heterozygous 
mice (Becn1+/-) are viable but they develop malignancies at higher rates than wildtype 
littermates22. Analogously, the human chromosomal locus containing the BECN1 gene 
(17q21) exhibits single-copy loss in prostate23, breast24,25, and ovarian cancers 26-30, thus 
implying a tumor suppressive function for Beclin1 – and for autophagy by extension.  
 
Although it is accepted that Beclin1 and autophagy are suppressed during 
tumorigenesis, autophagy upregulation in established tumors has been also described31. 
To integrate this seemingly opposing evidence, it has been suggested that while 
homeostatic autophagy initially curtails tumorigenesis in normal cells, the process can be 
induced in tumor cells as an adaptive response. Autophagy in this context can mitigate 
intrinsic stresses that typify tumor cell pathobiology (e.g., high metabolic demands32, 
ROS accumulation33, ER-stress34), as well as extrinsic stresses imposed by anti-neoplastic 
agents35 or by the tumor microenvironment (e.g., hypoxia36,37, reduced nutrient38 and 
growth factor supply39, and poor clearance of metabolic waste40). What remains unclear, 
however, is by what mechanism autophagy would be upregulated in tumors whose 
formation was enabled by its initial downregulation: in other words, would tumor-
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associated autophagy still depend upon an effector gene (e.g., BECN1) that was partially 
deleted during tumorigenesis? We suspect that in such cases, autophagy induction 
mechanisms undergo adaptation, circumventing otherwise-indispensible genetic 
requirements and now drive autophagy by an alternate (i.e., Beclin1-independent) 
mechanism. 
 
Given the inherent cellular stresses associated with metastasis, particularly with 
intraperitoneal dissemination, we hypothesized that ovarian tumor cells would retain the 
capacity to upregulate autophagy despite prevalent BECN1 mono-allelic deletion. Here 
we show that autophagy was upregulated simply by spheroid formation in metastatic 
ovarian cancer cells as well as by pharmacologic inhibition of AKT/mTORC1 signaling. 
Assessing Beclin1 protein abundance, we were surprised to discover that it was expressed 
at comparable levels in all samples. Even using data obtained from The Cancer Genome 
Atlas project, we found Beclin1 protein expression to be maintained regardless of gene 
copy-number. To test its requirement for autophagy induction, we performed siRNA-
mediated knockdown of Beclin1 in ovarian cancer cell lines.  Strikingly, this had no 
effect on autophagy in any cell line tested. In contrast, efficient knockdown of other 
effectors successfully inhibited both basal autophagy and its upregulation. Taken 
together, these data demonstrate that spheroid formation and AKT/mTORC1 inhibition 
stimulate Beclin1-independent autophagy upregulation in metastatic ovarian cancer cells. 
 
3.2 Materials & Methods 
 
3.2.1 Isolation of solid tumor tissue and spheroids from ascites 
fluid  
 
 All work with patient materials has been approved by The University of Western 
Ontario Health Sciences Research Ethics Board (Protocol numbers 12668E and 16391E). 
Solid tumor tissue from metastatic lesions was obtained from consenting patients at time 
of debulking surgery and processed as described in Appendix C. Briefly, tissue was 
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quickly dissected into cubes ~2-5 mm2 in size, wrapped in aluminum foil, frozen on dry 
ice, and stored at -80°C. To generate lysates, samples taken out of -80°C were mixed 
with dry ice pellets (to prevent thawing) and ground using a mortar and pestle. The 
powdered sample was then added to an appropriate volume of lysis buffer (see below for 
preparation) to generate protein lysates. Spheroids present in ascitic fluid at time of 
collection were isolated by filtration through a 40µm cell-strainer (Becton Dickinson, 
Franklin Lakes, NJ) then gently rinsed off the membrane with PBS and into a collection 
tube. Spheroids were embedded in cryo-matrix (Fisher, Ottawa, ON) and frozen on dry 
ice and stored at -80°C. The presence of epithelial cancer cells in solid tumor or ascites 
samples was confirmed by flow cytometry detection of epithelial cell adhesion molecule 
(EpCAM). Briefly, solid tumor was processed as described in Appendix C and ascites 
spheroids were disaggregated as described below. Resultant single-cell suspensions were 
immediately incubated in 2% FBS containing anti-EpCAM, PE-conjugated antibody 
(1:50; Becton Dickinson). EpCAM expression was quantified using a Beckman Coulter 
Epics XL-MCL flow cytometer with at least 10,000 events counted per test. 
 
3.2.2 Establishment of primary cultures from ascites 
 
 Ascitic fluid collected from consenting patients at time of paracentesis or 
debulking surgery was used to generate primary ascites cell cultures as described 
previously41. Primary cultures of ascites cells were maintained in a 1:1 mixture of MCDB 
105 medium: medium 199 medium (Sigma, St. Lewis, MO) supplemented with 10% FBS 
(Wisent) and 50 µg/ml penicillin–streptomycin (Wisent). These cultures could be 
expanded and passaged ~4-5 times following thawing from an initial cryopreservation.  
 
3.2.3 Culture of ovarian cancer cell lines 
 
 Human ovarian cancer cell lines were purchased from the American Type Culture 
Collection (ATCC; Manassas, VA) and cultured in Dulbecco's modified Eagle's medium 
(DMEM; CaOV3, SKOV3), RPMI-1640 (OVCAR3, OVCAR8, HeyA8), or Alpha 
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modified Eagle’s medium (AMEM; OVCA429) (Wisent, St. Bruno, Canada) 
supplemented with 5% fetal bovine serum (FBS; Wisent). The cell line EOC147-E2 is a 
clone derived from the EOC147 primary sample that has been continuously cultured for 2 
years. EOC147-E2 cells were maintained in DMEM/F12 medium (Gibco/Invitrogen, 
Carlsbad, CA) supplemented with 10% FBS. To establish stable expression of eGFP-
LC3B, sub-confluent (~60-70%) OVCAR8 cells were transfected with the pBMN-ires-
puro-eGFP-LC3B construct and transferred to Puromycin-containing selection medium 
(1µg/mL). Following a period of selection, emerging clones with robust eGFP expression 
were isolated, expanded, tested for starvation-induced puncta formation, and cryo-
preserved until needed.  All cells were maintained in a 37°C humidified atmosphere of 
95% air and 5% CO2. Adherent cells were maintained on tissue culture-treated 
polystyrene (Sarstedt, Newton, NC). Non-adherent cells were maintained on Ultra-low 
Attachment (ULA) cultureware (Corning, Corning, NY) which is coated with a 
hydrophilic, neutrally charged hydrogel to prevent cell attachment. Single-cell 
suspensions of specific concentrations were seeded to ULA plates to form spheroids over 
time.  
 
3.2.4 Immunofluorescence 
 
 Analysis of LC3 protein localization by immunofluorescent staining was 
performed on sections of cryo-embedded ascites spheroids or cells on coverslips. To 
generate sections of ascites spheroids, frozen blocks were sectioned on a Shandon 
cryostate at 6µm, mounted on slides, and stored at -20°C until needed. Cultured cells 
were seeded on coverslips and allowed to attach overnight before treatment with Akti-
1/2. Both cells on coverslips (following 24h of treatment) and spheroid sections were 
then fixed in a buffered 10% formalin solution, washed with PBS, and permeabilized 
with 0.1% Triton X-100 in PBS. This was followed by overnight incubation with anti-
LC3 primary antibody (1:250). The next day, after PBS washes, cells/sections were 
incubated with anti-rabbit FITC-conjugated secondary antibody (1:250; Vector 
Laboratories) for 1h, followed by PBS washes and a 5 min. incubation with 4',6-
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diamidino-2-phenylindole (DAPI; 1:5000; Sigma, St. Lewis, MO). Stained coverslips 
were inverted and mounted on glass slides with VectaShield mounting medium (Vector 
Laboratories). Fluorescence images were captured using an Olympus AX70 upright 
microscope and ImagePro software. 
 
3.2.5 Immunoblotting 
 
 Cell and tissue lysates were obtained using a modified radioimmunoprecipitation 
assay (RIPA) buffer [50mM HEPES pH 7.4, 150mM NaCl, 10% glycerol, 1.5mM 
MgCl2, 1mM EGTA, 1mM sodium orthovanadate, 10mM sodium pyrophosphate, 10mM 
NaF, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1mM PMSF, 1X protease 
inhibitor cocktail (Roche, Laval, QC), 250 mM β-glycerophosphate]. Cells were washed 
once in PBS followed by addition of lysis buffer. Protein concentration of each lysate 
was determined using the method described by Bradford42. Total protein (25-30 µg) was 
resolved by 8% or 10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane 
(PVDF; Roche, Laval, QC), and blocked with 5% skim milk in TBST (10 mM Tris.HCl, 
pH 8.0, 150 mM NaCl, 0.1% Tween 20). Membranes were washed in TBST and 
incubated (overnight 4°C) with specific antibodies (1:1000 in 5% BSA/TBST). 
Immunoreactive bands were visualized by incubating (1hr, room temperature) with a 
peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:10,000 in 1% skim milk/TBST; 
GE Healthcare) followed by exposure to enhanced chemiluminescence substrate reagent 
(ECL Plus; GE Healthcare). Immunoblots were imaged using radiographic film or the 
Chemidoc MP Imaging System (BioRad, Mississauga, ON) via the ImageLab image 
acquisition software (v4.1; BioRad, Mississauga, ON). Quantifications were performed 
on acquired images using in-built analysis features (‘Volume Tools’) of the software. 
 
3.2.6 Antibodies and other reagents 
 
 Antibodies against pAkt-Ser473 (#9271), Akt (#, p-p70S6K(#9234), LC3B 
(#2775), Beclin1 (#3738S), Atg5 (#2855S), Atg7 (D12B11; #8558S), p4EBP1-Thr37/46 
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(236B4; #2855S), 4EBP1 (#9452) were obtained from Cell Signaling Technology 
(Danvers, MA). Anti-p70S6K antibody (S-04; sc-100423) was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA) and anti-actin antibody (A 2066) came from 
Sigma. Akt inhibitor VIII (Akti-1/2) was purchased from EMD/Calbiochem (#12408; 
SanDiego, CA) and Chloroquine was purchased from Sigma (C-6628). The pBMN-ires-
puro-eGFP-LC3B construct was a generous gift from Craig McCormick (Dalhousie 
University, Halifax, NS). 
 
3.2.7 Transmission Electron Microscopy 
 
 Adherent cells or spheroids treated with Akti-1/2 or vehicle control for 24h were 
harvested in cold fixative comprised of 2.5% glutaraldehyde in PBS pH 7.2-7.4. Adherent 
cells were washed once in PBS then scraped in fixative for collection, whereas spheroids 
were washed in PBS, pelleted, then re-suspended in fixative. Cells were left in fixative no 
longer than 16h, washed four times in PBS, and stored at 4°C in their final wash. Samples 
were incubated for 1h in 1% osmium tetroxide in buffer, then embedded in 2% agarose 
plugs for ease of handling. Following dehydration in a graded series of acetone solutions 
(20, 50, 70, 90, 95, 100, 100, 100%), samples were transferred to liquid Epon 812 epoxy 
resin. Samples were poured into moulds and baked overnight at 60°C, solidifying into 
blocks that were trimmed for sectioning. At the Biotron Facility (University of Western 
Ontario), sections were cut on an Ultramicrotome (60nm thickness), picked up on copper 
mesh grids, and stained with uranyl acetate and lead citrate before examination on a 
Phillips CM10 Transmission Electron Microscope with digital imaging system.  
 
3.2.8 Acquisition of The Cancer Genome Atlas (TCGA) data 
 
 TCGA datasets for ovarian serous cystadenocarcinoma samples were downloaded 
from the University of California Santa Cruz Cancer Genomics Browser (https://genome-
cancer.ucsc.edu)43 and from the Memorial Sloan-Kettering Cancer Center’s cBio Portal 
for Cancer Genomics (http://www.cbioportal.org/)44. Array comparative genomic 
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hybridization data was acquired at the Broad TCGA genome characterization center 
using the Affymetrix Genome-Wide Human SNP Array 6.0 platform. Raw data was 
analyzed using the GISTIC2 method to generate gene-level copy-number variation 
(CNV) estimates and downloaded either as either thresholded copy-number calls or as 
log2-transformed CNV values. mRNA expression data was acquired by the University of 
North Carolina TCGA genomic characterization center using Agilent 244K custom gene 
expression G4502A_07_3 microarrays. Raw data that was processed to yield gene-level 
transcription estimates that were downloaded as log2 ratios normalized to a reference 
signal or as z-scores. Finally, protein expression data was generated and processed at the 
MD Anderson Cancer Center TCGA proteome characterization center using reverse-
phase protein array (RPPA) technology as described45 and downloaded either natural log-
transformed values or as z-scores.  
 
3.2.9 siRNA Transfection 
 
 For RNAi-mediated knockdown of gene expression, we utilized Dharmacon 
siGENOME SMARTpool reagents (Thermo Scientific, Waltham, MA), each containing a 
mixture of 4 unique siRNAs [Non-Targeting Control Pool #2 (D-001206-14-05), BECN1 
(M-010552-01), ATG5 (M-004374-04), and ATG7 (M-020112-01)]. Cells were seeded 
to 6-well plates at a density of 200,000 cells/well in antibiotic-free medium and allowed 
to attach overnight. The next day, siRNA and transfection reagent (DharmaFect #1, T-
2001-02) were each diluted in a separate tubes containing 200uL of serum-free medium. 
Following 5 min incubation, siRNA-containing medium was added to DharmaFect-
containing medium. This mixture was allowed to incubate for 20 min to allow liposome 
formation and siRNA loading. Antibiotic-free complete medium was then added to a 
final volume of 2mL and plated onto cells. Transfected cells were split 1:2 into new 6-
well plates 48h later and allowed to attach overnight. The next day, cells were re-
transfected exactly as before, so as to achieve more efficient and sustained knockdown 
for an extended period of time. Cells were re-seeded for subsequent experimentation 24h 
later. 
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3.2.10 Graphing and statistical analysis 
 
 All graphs were generated using GraphPad Prism 5 (GraphPad Software, San 
Diego, CA) or Microsoft Excel 2011 for Macintosh (Microsoft Corporation, Redmond, 
WA). Data were expressed as Mean ± SD or Mean ± SEM, as indicated. All statistical 
analyses [Student’s t-test, Analysis of Variance (ANOVA) with Tukey’s Multiple 
Comparison Test, as well as Correlation and Linear Regression Analysis] were performed 
using GraphPad Prism 5 (GraphPad, San Diego, CA). Tests of significance were set at p 
< 0.05. 
 
3.3 Results 
 
3.3.1 Spheroid formation is sufficient to upregulate autophagy in 
metastatic ovarian cancer cells. 
 
We hypothesized that one important stimulus for autophagy induction may be the 
process of spheroid, or multicellular aggregate, formation. To assess this, we collected 
tumor tissue and ascites fluid from consenting patients with advanced-stage (metastatic) 
epithelial ovarian cancer. We assessed autophagy first in spheroids filtered directly from 
patient ascites and embedded in cryo-matrix. Immunofluorescence staining for 
microtubule-associated light-chain 3 (LC3) protein was performed on frozen sections of 
these spheroids, revealing a cytoplasmic localization that was often concentrated into 
discrete puncta, indicative of autophagosomes (Fig. 3.1A). To study spheroid-mediated 
autophagy in greater detail, ascites-derived primary tumor cells (EOCs) from multiple 
patients were cultured under non-adherent conditions to form spheroids in vitro, thus 
simulating the fluid-suspension phase of ovarian cancer metastasis. We obtained protein 
lysates from cells cultured in this way and performed immunoblots for LC3, since the 
cleaved and lipidated form of this protein (LC3-II) is identifiable as a differentially 
migrating species and indicates the presence of autophagosomes. As early as 4h 
following  detachment  and  seeding  to  non-adherent  culture,  a  significantly  increased 
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Figure 3.1: Autophagy is induced during spheroid formation in metastatic ovarian 
cancer cells.  
(A) Spheroids filtered from patient ascites fluid for immunofluorescence analysis. Nuclei (blue) 
and cytoplasmic LC3 staining (green) are visible. Orange arrowheads indicate LC3 puncta. Scale 
Bar: 20 µm. (B) EOC cells were seeded to non-adherent 6-well plates and lysates obtained at 
indicated time points. Immunoblot data from EOC67 (top) and quantification of LC3-I and LC3-
II expression relative to Actin (bottom; n = 3 EOCs). (C) Immunoblot quantifications of parallel 
adherent (ADH) and (SPH) cultures of multiple EOCs (n = 10) at 24h (left) and 72h (right). Bars: 
Mean ± SEM. LC3-I and LC3-II levels were compared using the Student’s t-test (*p<0.05; 
**p<0.01) 
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abundance of LC3–II was observed; by approximately 24h (once aggregates/spheroids 
have formed), the ratio of LC3-II to LC3-I was greatest (p<0.01; Fig. 3.1B). This 
increased LC3-II:LC3-I ratio was maintained through 72h of non-adherent culture, 
despite a decrease in the absolute amounts of these species over that time (Fig. 3.1B). In 
addition to time-course analysis, we also assessed paired adherent/spheroid samples from 
10 EOCs, verifying significantly increased LC3-II relative to LC3-I at both the 24h and 
72h timepoints (p<0.05; Fig. 3.1C). Taken together, these data describe an increase in 
autophagy as a result of cell detachment and non-adherent culture to form spheroids.   
 
3.3.2 Further upregulation of autophagy in spheroids and adherent 
cells is achieved with allosteric AKT inhibition. 
 
Another way that autophagy can be induced is with the use of inhibitors targeting 
PI3K/AKT/mTOR pathway; since PI3K/AKT/mTORC1 activity negatively regulates 
autophagy, inhibition serves to de-repress and permit its induction above basal levels46. 
Agents inhibiting PI3K, AKT, and/or mTOR kinases have been developed for the clinic 
and are currently being tried in multiple disease sites, including gynaecologic cancers 
such as ovarian (ClinicalTrials.gov). We have previously shown that the AKT kinase 1 
and 2 inhibitor (Akti-1/2), an allosteric inhibitor of AKT activation, yields dose-
dependent inhibition of AKT phosphorylation in NIH:OVCAR3 cells to cause cell-cycle 
arrest without increasing cell death7. We have seen similar dose-dependent inhibition (as 
evidenced by loss of phosphorylation at Ser473 of AKT) in multiple primary EOC cells 
and EOC147-E2, a cell line derived from the EOC105 primary culture. Here we 
demonstrate that in adherent cultures subjected to AKT inhibition, de-phosphorylation of 
AKT was accompanied by reduced phosphorylation of p70S6K and 4EBP1 (downstream 
targets of mTORC1 that indicate its level of activity; Fig. 3.2A). This correlated with an 
increase in LC3 processing (i.e., increased LC3-II:LC3-I ratio), indicating an increase in 
autophagosomes. In spheroids, however, even without AKT inhibition we observed 
autonomous suppression of mTORC1 activity that correlated with increased LC3 
processing relative to adherent  cultures.  Treatment  of  spheroids  with  Akti-1/2  further 
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Figure 3.2: AKT inhibition upregulates autophagy in adherent cells and augments 
autophagy upregulation in spheroids. 
Subconfluent (~80%) adherent (ADH) cultures and spheroid cultures (SPH) were subjected to 
24h of Akti-1/2 treatment (EOCs: 5µM; EOC147-E2 ADH: 3.5µM; EOC147-E2 SPH: 1µM). 
SPH treatment was initiated at time of seeding until 24h post-seeding. Lysates were then obtained 
and immunoblot performed for indicated proteins (ppp = multi-phosphorylated species; p = less 
phosphorylated species). (B) Sub-confluent (~60%) adherent cells were treated (24h) with Akti-
1/2 (5µM) and subjected to immunofluorescence analysis. Nuclei (blue) and cytoplasmic LC3 
staining (green) are visible. Orange arrowheads indicate LC3 puncta. Scale Bar: 20µm. 
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suppressed AKT/mTORC1 signaling beyond that achieved by spheroid formation alone, 
resulting in a further increase in LC3-II:LC3-I. These trends were observed in EOC147-
E2 and multiple primary EOCs, four of which are depicted (Fig. 3.2A). To confirm that 
increased LC3 processing corresponded with an increase in autophagosomes, we also 
conducted immunofluorescence staining for LC3, revealing an increase in cytoplasmic, 
LC3-associated puncta that were apparent in both adherent and spheroid cells upon AKT 
inhibition (Fig. 3.2B).   
 
3.3.3 Autophagy in spheroids and adherent cells is in flux and 
proceeds to completion 
 
We also performed autophagic flux experiments to distinguish autophagy 
induction from late-stage blockade, since both can result in an increase in autophagosome 
abundance47. If autophagy has truly been induced, an agent that blocks clearance of 
autophagosomes should result in a further increase in LC3-II, whereas if autophagy were 
already inhibited, any further increase could not occur. We used the antimalarial 
lysomotropic agent chloroquine (CQ) to halt the clearance of autophagosomes in 
adherent cultures and spheroids. A short (4h) treatment with CQ resulted in a buildup of 
LC3-II in untreated adherent cells and spheroids and further accumulation in cells treated 
with Akt-1/2 (Fig. 3.3A), thus indicating autophagic degradation was underway. 
Additionally, to verify that autophagy was not only being induced and in flux, but that 
autophagic degradation was being carried to completion, transmission electron 
microscopy (TEM) was performed. We examined ultra-thin sections of fixed cells for 
cytoplasmic vesicles bounded by double-membranes, the contents of which were 
undergoing degradation (i.e., autophagolysosomes or APLs). By TEM, we observed 
APLs in untreated spheroids, and to greater extent in spheroids and adherent cells treated 
with Akti-1/2. APLs were nearly undetectable in untreated adherent cultures (Fig. 3.3B; 
APLs in Akti-1/2-treated cells were identified by A. M. Cuervo, Albert Einstein College 
of Medicine, New York, personal communication).  
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Figure 3.3: Autophagy upregulation is in flux and proceeds to completion in both 
adherent cells and spheroids.   
Subconfluent (~80%) adherent (ADH) cultures and spheroid (SPH) cultures were subjected to 
24h treatment with Akti-1/2 (EOCs: 5µM; EOC147-E2 ADH: 3.5µM; EOC147-E2 SPH: 1µM). 
SPH cultures were treated at time of seeding until 24h post-seeding. (A) CQ pulse (50µM) was 
administered for final 4-5h immediately before cell lysis. Immunoblot and quantification (relative 
to actin) was performed for indicated proteins. (B) EOC67 was treated as described, then 
subjected to TEM sample prep. and analysis; Orange arrowheads indicate Autolysosomes 
(autophagosomes fused with lysosomes). Scale bars: 500nm  
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Therefore, based on experiments revealing enhanced LC3 processing, increased 
autophagosomes that are in flux, and abundant late-stage autophagolysosomes (APLs) 
containing degraded cytoplasmic material, we conclude that autophagy is upregulated 
and proceeds to completion in metastatic ovarian cancer cells. This occurs autonomously 
during spheroid formation as well as when adherent cells or spheroids are subjected to 
AKT inhibition.  
 
3.3.4 Although single-copy loss of the BECN1 gene is common in 
ovarian cancer, tumors retain similar levels of Beclin1 protein 
expression 
 
Following our observation of robust autophagy induction in metastatic ovarian 
cancer cells, we wished to assess expression of Beclin1 in these samples given its role as 
a canonical autophagy-effector. In order to quantitatively assess the expression of Beclin-
1 in a large number of serous ovarian tumors (91.1% of which are from metastatic, Stage 
III-IV cases), we interrogated level 3 array comparative genomic hybridization (aCGH), 
mRNA expression microarray, and reverse phase protein array (RPPA) data generated by 
The Cancer Genome Atlas (TCGA) project. Starting with aCGH data that was processed 
to yield gene-level copy-number calls, we found that 425/559 ovarian tumours (76%) 
possessed hemizygous deletion of the BECN1 gene (Fig. 3.4A). This confirms earlier 
reports of single-copy loss in ~70% of ovarian tumors23,27-29. To determine whether 
BECN1 copy-number correlated with expression, we plotted mRNA microarray data 
against copy-number calls and found that single-copy loss of BECN1 yielded a significant 
reduction in mRNA expression (Fig. 3.4B). To assess expression at the protein level, we 
plotted TCGA RPPA data in a similar manner, yet were surprised to find only a modest 
reduction in Beclin1 protein abundance that was not statistically significant; in fact, all 
tumors exhibited a similar range of Beclin-1 protein expression seemingly irrespective of 
copy-number (Fig. 3.4C). Using log2-transformed copy-number data, we also performed 
regression analysis to measure the correlation between BECN1 copy number and gene 
expression. This analysis revealed a positive correlation between copy-number and 
mRNA level (Fig. 3.4D) but no correlation between copy-number and protein  level  (Fig.  
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Figure 3.4: Beclin1 protein expression is not significantly decreased in ovarian 
tumors despite prevalent single-allele loss.   
(A) Gene copy-number calls at the BECN1 locus are depicted for 559 ovarian serous 
cystadenocarcinoma tumors (red & pink = high-level & low-level amplification, respectively; teal & 
blue = heterozygous & homozygous deletion, respectively). OncoPrint obtained from cBioPortal.org. 
(B,C) BECN1 mRNA (microarray; n = 482) and protein (quantitative RPPA; n = 398) expression data 
were transformed to z-scores and depicted as functions of copy-number. One-way ANOVA with 
Tukey’s Test was performed (**p<0.01; ***p<0.001). (D,E) Original log2-transformed mRNA 
expression (n = 527) and ln-transformed protein expression (n = 397; re-transformed to log2 values) 
data depicted as a function of log2-transformed copy-number values. Correlation and linear regression 
analysis performed: line of best fit, Pearson’s r, Goodness-of-fit R2, and p-values all reported.  
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3.4E). Similarly, metastatic tumor samples and ascites-derived primary cultures obtained 
by our lab exhibited similar levels of Beclin1 protein expression: samples identified as 
the highest- and lowest-expressers were assessed on the same immunoblot (Fig. 3.5A), 
demonstrating only modest differences in protein abundance that were analogous to the 
narrow range of expression observed in TCGA protein data (Fig 3.4B,C). We also probed 
these blots for LC3 and found that processing varied across all samples tested. 
Interestingly, we noted that elevated LC3-II:LC3-I was observable even in those samples 
with the lowest Beclin1 expression (Fig. 3.5A). Therefore, despite prevalent hemizygous 
loss of the BECN1 gene in ovarian cancer, expression of its protein product was not 
correspondingly decreased. Instead, all tumors exhibited detectable levels of Beclin1 
protein and a narrow range of expression. 
 
3.3.5 Knockdown of Beclin-1 has no effect on autophagy 
upregulation in ovarian cancer cells 
 
Thus far, we have shown that metastatic ovarian cancer cells retain not only the 
capacity to upregulate autophagy, but also Beclin1 protein expression. Consequently, we 
wondered whether their maintenance of Beclin1 was important in enabling autophagy 
upregulation. We first re-examined our findings (Figs. 3.1, 3.2, 3.3), particularly in EOCs 
found to express relatively low levels of Beclin1 protein. If Beclin1 remained important 
for autophagy, we reasoned that such samples may be less able to undergo the process. 
However, we were surprised to find that basal LC3 processing was no less extensive than 
in other samples with more abundant Beclin1 (Fig. 3.5A). Likewise, we have already 
demonstrated that samples such as EOC67 and EOC129 (Beclin1 low-expressers) 
exhibited robust induction of autophagy similar to that observed in all other EOCs tested 
(Fig. 3.1, 3.2, 3.3).  
 
It is possible, however, that cells with reduced Beclin1 expression have adapted 
such that they can upregulate autophagy using only a limited amount of this protein. To 
address this possibility, we first sought to identify ovarian cancer cell lines with low 
(versus high) BECN1 expression. Using datasets from the Cancer Cell Line Encyclopedia 
113 
 
 
Figure 3.5: In metastatic ovarian cancer cells and cell lines, Beclin1 exhibits only 
subtle decreases in protein expression.   
(A) Lysates were obtained from fresh-frozen samples of metastatic tumor samples and early-
passage cultures of ascites-derived cells. Immunoblot was performed for indicated proteins and 
Beclin1 expression quantified. (C) Log2-transformed mRNA expression data for 52 ovarian 
cancer cell lines [Cancer Cell Line Encyclopedia (CCLE) datasets] displayed as a function of 
BECN1 copy number (red ‘x’ = ovarian lines used in our lab. (C) Immunoblot for Beclin1 was 
performed on indicated lines. Quantification performed on two independent lysates (adherent 
cultures, ~80-100% confluent). Bars: Mean ± SD. 
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(CCLE) project48, BECN1 copy-number and mRNA expression level was plotted for 52 
ovarian cancer cell lines (Fig 3.5B). We then selected commonly-used lines with two 
copies (HEYA8, SKOV3, OVCAR8) or mono-allelic deletion (OVCAR3, CAOV3) of 
BECN1 for further analysis. Immunoblot for Beclin1 identified relatively low- and high-
expressing lines, in general agreement with their mRNA expression levels from the 
CCLE (Fig. 3.5C). EOC147-E2 cells were also identified as a relatively low-expresser 
(Fig. 3.5C), with comparable expression to CAOV3 cells (which is heterozygous for 
BECN1). 
 
To determine whether even low levels of Beclin1 protein remained essential for 
autophagy, we performed siRNA-mediated knockdown of BECN1 expression on the 
EOC147-E2 cell line, given its identification as a low-expresser. As a comparator, we 
also performed knockdown in HEYA8 cells to test whether this cell line’s high Beclin1 
expression was indicative of increased dependence on this protein for autophagy. 
Transfection with pooled siRNAs against BECN1 efficiently reduced Beclin1 protein 
compared to pooled non-targeting (NT) siRNAs in both EOC147-E2 (Fig. 3.6A) and 
HEY A8 cells (Fig. 3.6B). Efficient reduction of Beclin1 protein did not affect basal LC3 
processing, and strikingly, nor could it ablate autophagy upregulation mediated by AKT 
inhibition (Fig. 3.6A,B). Additionally, Beclin1 depletion was unable to prevent the 
formation of eGFP-LC3 puncta in OVCAR8 cells expressing eGFP-labeled LC3B (Fig. 
3.6C). In stark contrast, knockdown of essential autophagy effectors ATG5, ATG7, or 
both was able to reduce autophagic degradation, as evidenced by diminished LC3 
processing (Fig. 3.6A,B) and formation of eGFP-LC3B puncta (Fig. 3.6C). Therefore, 
although autophagy in metastatic ovarian cancer cells requires other key effector proteins, 
we found Beclin1 to be dispensable for the process.     
 
3.4 Discussion 
 
 Although loss of a BECN1 allele is thought to promote tumorigenesis through 
impairment   of   autophagy,   established   tumors   are   nonetheless   able  to  upregulate 
115 
 
 
Figure 3.6: Beclin1 depletion has no effect on autophagy induction.   
Cells were transfected with Control siRNAs or siRNA pools targeting BECN1, ATG5, ATG7, or 
ATG5+7. Transfection was repeated 72h later, and following overnight incubation, cells were 
seeded to adherent 6-well plates. (A) EOC147-E2 cells were treated for 24h with either DMSO or 
Akti-1/2 (3.5µM) at 10-12 days post-transfection (n = 4 experiments). (B) Hey A8 cells were 
treated for 24h with DMSO/Akti-1/2 (5µM) at 72h post-transfection (n = 2 experiments). Lysates 
were collected and immunoblot performed for indicated proteins. (C) OVCAR8-eGFP-LC3 cells 
were subjected to identical transfections, and 72h post-transfection, treated with DMSO/Akti-1/2 
(5µM). 24h post-treatment, images were captured using an Olympus IX70 inverted microscope 
and ImagePro software. Scale bar: 10µm.  
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autophagy in response to cellular stress. Indeed, the ovarian cancer metastatic process 
necessarily involves numerous cellular stresses5,11,49, many of which are known 
autophagy inducers (e.g., detachment50, nutrient depletion51,52, hypoxia37). We therefore 
wondered whether metastatic ovarian cancer cells retained the capacity to induce 
autophagy despite prevalent BECN1 mono-allelic deletion, and if so, how essential 
Beclin-1 was for this induction. Here we show that cells are indeed capable of robust 
autophagy induction, but this occurs independently of Beclin1. Specifically, we 
demonstrate autophagy upregulation by culturing cells under non-adherent conditions to 
form spheroids or by subjecting them to AKT inhibition. In assessing the contribution of 
Beclin1, we found that autophagy induction was robust in all primary cultures and cell 
lines tested, irrespective of Beclin1 expression level. Moreover, we were unable to ablate 
autophagy despite efficient siRNA-mediated knockdown of Becln1 protein.  
 
To our knowledge, this report is the first to describe autonomous autophagy 
upregulation during tumor-sphere formation. Previous work by Fung et al. described 
autophagy induction in luminal cells of mammary acini as they underwent extracellular 
matrix (ECM) detachment50. Our model, though different in many ways, is analogous to 
ECM-detachment since it also involves disengagement of cells from a substratum 
followed by fluid suspension. Thus, our work is in agreement with the findings of Fung et 
al., and extends their findings in non-tumorigenic epithelial cells to epithelial ovarian 
cancer cells. Since Fung et al. also showed that detachment-initiated autophagy promoted 
cell survival, we are interested in assessing this during ovarian cancer spheroid formation. 
It will be important to conduct viability assays in which cells are subjected to autophagy 
blockade during spheroid formation or upon AKT inhibition. Given that autophagy is 
known to promote survival in established tumor cells, we propose that metastatic ovarian 
cancer cells upregulate this mechanism for a similar purpose. 
 
A comparison of spheroid-associated autophagy with that stimulated by 
pharmacologic means has provided important insights into the mechanism by which 
autophagy is induced during spheroid formation. To stimulate autophagy 
pharmacologically, we inhibited the PI3K/AKT/mTOR pathway at the level of AKT, 
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resulting in mTORC1 suppression and de-repression of the autophagy machinery. Our 
previous work revealed autonomous downregulation of AKT activity in spheroids7, thus 
we initially postulated that this was causally linked to spheroid-mediated autophagy. 
However, our current observations revealed discordance in the timing of these two 
events: specifically, we observed that while autophagy was robustly induced by the first 
24h of spheroid formation, AKT phosphorylation was retained in several EOC samples 
until 48-72h. In contrast, the timing of mTORC1 de-activation was always tightly 
correlated with increased LC3 processing, even in the presence of undiminished AKT 
phosphorylation. Taken together, these observations suggest that the mechanism of 
autophagy induction in spheroids is not necessarily AKT-dependent, instead an 
intervening mechanism downstream of AKT appears to be suppressing mTORC1 activity 
to induce autophagy. This mechanism is an active area of investigation in our lab. Thus 
far, we have learned that the liver kinase B1/AMP-activated protein kinase 
(LKB1/AMPK) pathway is activated early in spheroid formation (Peart et al., 
unpublished). AMPK activation can promote autophagy by de-activating mTORC1 
though phosphorylation of TSC1/253 and Raptor54, as well as by phosphorylation and 
activating the autophagy-inducer kinase ULK132. Therefore, we suspect involvement of 
this pathway in spheroid-mediated autophagy. Moreover, recent work by Avivar-
Valderas et al. showed that LKB1/AMPK activation during ECM-detachment promoted 
autophagy in mammary cells and mouse embryonic fibroblasts55. Thus, it will be 
important to modulate LKB1/AMPK signaling in our model of spheroid formation to 
evaluate its contribution to autophagy induction.   
 
A key finding of this study is the apparent dispensability of Beclin1 for autophagy 
upregulation in ovarian cancer cells. Our analysis of Beclin1 abundance revealed that its 
range of expression was unexpectedly similar across all ovarian tumors, even those with 
loss of one BECN1 allele. Based on this, we initially hypothesized that maintenance of 
Beclin1 expression in ovarian tumor cells implied its importance for autophagy. 
However, we were surprised to discover that knockdown of Beclin1 had no effect on 
autophagy, suggesting that these cells possess Beclin1-independent mechanisms to 
upregulate the process. Despite its canonical role as an essential autophagy effector, 
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evidence of Beclin1-independent autophagy has been accumulating in recent years: in 
neuronal56,57, macrophage58, breast cancer59, and ovarian cancer60 cell lines, autophagy 
was induced independently of Beclin1 by exposure to staurosporine, hydrogen peroxide, 
resveratrol, or arsenic trioxide, respectively. Conversely, an alternate form of autophagy 
has been described that occurs independently of the autophagy-effectors Atg5, Atg7, and 
LC3 – but retains dependence on Beclin161. These reports highlight redundancies in 
autophagy machinery, demonstrating that the absence of certain key effectors (e.g., 
Beclin1) is not sufficient to cripple the process. Given the importance and evolutionary-
conservation of autophagy, it is conceivable that ovarian tumor cells – while still 
requiring other effector proteins – have adapted their autophagy machinery so as to not 
rely on Beclin1. 
 
Nonetheless, the sustained expression of Beclin1 might imply its continued 
importance in ovarian tumor cells, perhaps in serving other autophagy-unrelated 
functions. Such functions have been suspected of Beclin1 since mouse models of its 
disruption were generated. While mice with homozygous Becn1 disruption (Becn1-/-) die 
by embryonic day 7.521, Atg5-/- and Atg7-/- mice, in contrast, are able to complete 
embryonic development. However, they die within 24h due to autophagy insufficiency 
during the neonatal starvation period51,52. Furthermore, the tumor spectrum of Becn1+/- 
mice also differs from other mouse models of autophagy disruption: mono-allelic Beclin1 
deletion in mice gives rise to hepatocellular carcinomas, lung carcinomas, and 
lymphomas22. In contrast, despite effectively ablating autophagy, tissue-specific deletion 
of Atg7 or mosaic deletion of Atg5 was less tumorigenic: both developed benign liver 
adenomas62, but never the hepatocellular carcinomas seen in Becn1+/- mice. This 
discordance in both knockout phenotype as well as tumor spectrum suggests additional 
functions of Beclin1 separate from its role in autophagy. Indeed, evidence for specific 
autophagy-independent functions continue to be described for Beclin1, including its role 
in Toll-Like Receptor-mediated phagocytosis in macrophages63 and in cytokinesis and 
endocytic degradation of the Epidermal Growth Factor Receptor (EGFR) in HeLa cells64. 
These examples represent alternative functions for Beclin1 when in complex with Class 
III PI3K, p150 and other co-factors. Most recently, however, Fremont et al. have 
119 
 
demonstrated a critical role for Beclin1 in kinetochore assembly and chromosome 
congression that is not only autophagy-independent, but also independent of the PI3K C3 
and p150 core complex 65. Therefore, strong in vitro and in vivo evidence describes 
Beclin1 as a multi-functional protein, and although we have demonstrated its 
dispensability for autophagy upregulation, its expression may be retained for alternate 
autophagy-independent functions.  
 
This study describes autophagy upregulation in metastatic ovarian cancer cells 
that occurs irrespective of Beclin1 expression and is unaltered by siRNA-mediated 
Beclin1 knockdown. We propose that while Beclin1 and autophagy may initially be 
downregulated to promote ovarian tumorigenesis, metastasizing tumor cells later gain the 
ability to upregulate autophagy – however, these cells no longer require Beclin1 to do so. 
These findings not only illustrate the redundancy of autophagic degradation mechanisms, 
but also demonstrate the ability of tumor cells to relentlessly adapt and evolve, 
circumventing any molecular barriers to their continued growth and survival. 
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Chapter 4  
 
4 Autophagy upregulation promotes the viability of 
metastatic ovarian cancer cells treated with an AKT 
inhibitor. 
 
4.1 Introduction 
 
 The need for new and more effective therapeutics in ovarian cancer is highlighted 
by the low rate of survival experienced by patients. Although women with localized 
disease experience a 5-year survival rate of 92.5%, they comprise the minority of 
patients1. Unfortunately, the vast majority of women with ovarian cancer are diagnosed 
with metastatic disease, which dramatically decreases their survival probability to only 
27.3%1. Standard treatment of ovarian cancer, which involves cytoreductive surgery and 
chemotherapy, can be very effective initially at reducing tumor burden and prolonging 
life2. However, these and other advances have achieved only an 8% increase in 5-year 
survival over a span of approximately 32 years1.  
 
 Clearly there is a need for therapeutic strategies that provide greater survival 
benefit. To this end, numerous targeted therapies are being developed and are currently 
undergoing clinical trials in ovarian cancer. Agents such as Bevacizumab and Olaparib 
that exploit alterations in angiogenesis and DNA damage responses pathways, 
respectively, have both demonstrated promising improvements in progression-free 
survival3-5. Inhibitors of PI3K/AKT/mTOR signaling are also of great interest, since this 
pathway exhibits activating alterations in a large proportion of ovarian tumors6. However, 
clinical trials of these agents have thus far proved disappointing7,8. For example, 
inhibition of Epidermal Growth Factor Receptor (EGFR) family members such as EGFR 
and ErbB2/HER2 (receptor tyrosine kinases that lie upstream of PI3K/AKT/mTOR 
signaling) has yielded response rates of only 0%-7% in ovarian cancer9-11. Likewise, a 
phase II trial of the mTORC1 inhibitor Temsirolimus showed insufficient benefit in 
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progression-free survival to warrant subsequent phase III study12. The failure of such 
agents is likely a complex phenomenon, but might involve upregulation of a cellular 
survival mechanism known as autophagy. 
 
 Macroautophagy (autophagy) is a conserved self-digestion mechanism that 
functions at basal levels in eukaryotic cells to maintain homeostasis and promote survival 
under conditions of cellular stress13-16. It can be upregulated by a variety of stimuli, 
including anti-cancer therapeutics. Inhibitors of the PI3K/AKT/mTOR pathway 
specifically are known to potently induce autophagy through their inhibition of 
mTORC1, a canonical autophagy repressor17-19. Therapy-induced autophagy has been 
shown to also promote tumor cell survival by a variety of mechanisms20-23, thereby 
blunting the effectiveness of such therapies. Given that phase I/II clinical trials of 
PI3K/AKT/mTOR pathway inhibitors are currently underway in ovarian cancer 
(clinicaltrials.gov), it is essential to determine whether ovarian tumor cells upregulate 
autophagy as a response to these agents, and if so, whether it promotes tumor cell 
survival. If this is the case, a novel strategy may involve combinatorial autophagy 
blockade to maximize therapeutic efficacy. 
 
 To address these questions, we first generated cultures of metastatic ovarian 
cancer cells using patient-derived ascites (fluid in the peritoneal cavity that accumulates 
as a result of metastatic disease and contains malignant cells24). Importantly, ascites 
contains readily-observable multi-cellular aggregates or spheroids25-28 and their 
dissemination throughout the peritoneal cavity is considered critical for seeding the 
formation of secondary metastases25-27,29,30. Therefore, using both adherent and spheroid 
cultures, we subjected metastatic ovarian cancer cells to PI3K/AKT/mTOR pathway 
inhibition achieved by the allosteric AKT kinase inhibitor Akti-1/2. Our previous work 
demonstrated that autophagy is indeed upregulated by AKT inhibition in both adherent 
cells and spheroids. Moreover, in spheroids, AKT inhibition served to augment an 
already-elevated level of autophagy. Given these findings, we were interested to 
determine what impact autophagy upregulation was having on ovarian cancer cell 
viability. 
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 In the this study, our aim was to determine the consequences of blocking 
autophagy upregulation, hypothesizing that this would deprive ovarian cancer cells of a 
key survival mechanism and lead to a loss of viability. To achieve autophagy blockade in 
ovarian cancer cells, three approaches were taken: siRNA-mediated depletion of 
autophagy-related (ATG) proteins as well as treatment with the novel Specific and Potent 
Autophagy Inhibitor 1 (Spautin1) and the classical autophagy-inhibitor Chloroquine 
(CQ). In both adherent and spheroid cultures, blocking autophagy using any of these 
approaches led to decreased cell viability. Moreover, we found that combined AKT 
inhibition and autophagy blockade reduced viability in a synergistic manner. Autophagy 
upregulation therefore represents a cell survival mechanism in metastatic ovarian cancer 
cells, the blockade of which augments the effectiveness of AKT inhibition at decreasing 
cell survival. 
 
4.2 Materials & Methods 
 
4.2.1 Culture of ovarian cancer cell lines and ascites-derived cells  
 
 All work with patient materials has been approved by The University of Western 
Ontario Health Sciences Research Ethics Board (Protocol # 12668E and 16391E). 
Primary cultures of ascites cells were established as described in Chapter 3. Human 
ovarian cancer cell lines OVCAR8 and Hey A8 were purchased from the American Type 
Culture Collection (ATCC; Manassas, VA) and the OVCA429 cell line was a generous 
gift from Barb Vanderhyden (Ottawa Hospital Research Institute, Ottawa, ON). The cell 
line EOC147-E2 is a clone derived from the EOC147 primary sample that has been in 
continuous culture for 2 years. All cell lines and ascites-derived primary cultures were 
grown as described in Chapter 3. 
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4.2.2 Cell Viability Assays  
 
4.2.2.1 alamarBlue  
 
 Adherent cells were seeded to 96-well flat bottom tissue culture plates (EOCs: 
2,500-5,000/well; EOC147-E2 5,000/well) and treated following overnight incubation. At 
least 72h post-treatment, AlamarBlue reagent (Invitrogen, Carlsbad, CA) was mixed with 
fresh complete medium according to manufacturer’s instructions and added to each well. 
Using a microplate spectrophotometer (Wallac 1420 Victor 2; Perkin-Elmer, Waltham, 
MA), fluorescent signal was generated using 560nm excitation wavelength and recorded 
at 590nm. Experiments were performed in triplicate or greater and fluorescence readings 
were normalized to cells treated with vehicle control.  
  
4.2.2.2 CellTiter-Glo  
 
 Cells were seeded to 24-well ultra-low attachment plates (ULA) at a density of 
5.0x104 per well to form spheroids as previously described25 and treatment was initiated 
at time of seeding. At 72h post-treatment, spheroids were collected, pelleted, and briefly 
loosened/disaggregated by trypsinization (~5 min.). CellTiter-Glo reagent (Promega, 
Madison, WI) was prepared according to manufacturer’s instructions and added to 
spheroids in trypsin (1:1 volume ratio). Approximately 200µL of the mixture was added 
to a white-walled 96-well micro-plate and luminescence signal was detected using a 
microplate spectrophotometer (Wallac 1420 Victor 2; Perkin-Elmer, Waltham, MA). 
Experiments were performed in triplicate or greater and luminescence readings were 
normalized to cells treated with vehicle control. 
  
4.2.2.3 Cell Counting  
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 Cells were seeded to adherent 6-well tissue culture plates (1.5x104/well) and to 
24-well ultra-low attachment plates (ULA) at a density of 5.0x104 per well to form 
adherent and spheroid culture, respectively. Treatment was initiated immediately in 
spheroid cultures and following an overnight incubation in adherent cells. Following 
treatment incubation time (72h), adherent cells were trypsinized and resuspended in FBS-
containing medium to first generate a single-cell suspension. Spheroids were exposed to 
trypsin-EDTA for 10-20 minutes with vortexing and trituration to disaggregate cells. 
Trypsin was inactivated using a small volume of FBS. To enumerate viable cells, Trypan 
Blue reagent (Gibco/Invitrogen, Carlsbad, CA) was applied (1:1 dilution) and cells 
counted in a hemacytometer (two counts per replicate of experimental triplicates).  
 
4.2.3 Immunoblotting, antibodies and other reagents 
 
 Whole-cell protein lysates were obtained and immunoblots performed as 
described in Chapters 2 and 3. Antibodies against LC3B (#2775) and Beclin1 (#3738S), 
were obtained from Cell Signaling Technology (Danvers, MA). Anti-Actin antibody (A 
2066) and Chloroquine (C-6628) were obtained from Sigma. Akt inhibitor VIII (Akti-
1/2) was purchased from EMD/Calbiochem (#12408; SanDiego, CA). Spautin1 was 
obtained from Cellagen Technology (#C3430-2s; San Diego, CA). For RNAi-mediated 
knockdown of gene expression, we utilized Dharmacon siGENOME SMARTpool 
reagents (Thermo Scientific, Waltham, MA), each containing a mixture of 4 unique 
siRNAs [Non-Targeting Control Pool #2 (D-001206-14-05), ATG5 (M-004374-04), and 
ATG7 (M-020112-01)]. Cells were transfected  
 
4.2.4 Combination Index Analysis 
 
  Interaction effects of drug combinations (CQ+Akti-1/2 or Spautin1+Akti1-1/2) 
were assessed using combination index (CI) and isobologram analysis, as described 
previously33. EC50 values for each were determined empirically using the alamarBlue 
viability assay (described above) and non-linear curve fit analysis (described below). 
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Based on their individual EC50s, serial dilutions of either drug alone and their 
combination were generated such that a 1:1 equipotent ratio was maintained at all 
dilutions. Viability assays were conducted as described above, and the readings analyzed 
using the CalcuSyn 2.0 Software (BioSoft, Cambridge, UK) to generate isobolograms 
and CI scores. The isobologram is generated by plotting EC50 values for each drug as x- 
and y-intercepts that are connected by a line segment. A single point that represents the 
CI score is also plotted. A CI value to the left, overlapping, or to the right of the line 
segment indicates synergistic, additive, or antagonistic effects, respectively. 
Correspondingly, CI values of <1, =1, and >1 indicate synergistic, additive, or 
antagonistic effects, respectively. 
 
4.2.5 Graphing and statistical analysis 
 
 Graphs were generated using GraphPad Prism 5 (GraphPad Software, San Diego, 
CA) or Microsoft Excel 2011 for Macintosh (Microsoft Corporation, Redmond, WA). 
Data were expressed as Mean±SD or Mean±SEM as indicated. All statistical analyses 
[Student’s t-test, Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison 
Test, and Non-Linear Curve-Fit Analysis to generate and compare EC50 values] were 
performed using GraphPad Prism 5.  Tests of significance were set at p < 0.05. 
 
4.3 Results 
 
4.3.1 Knockdown of ATG5 and ATG7 reduces ovarian cancer cell 
survival upon AKT inhibition 
 
 It is well established that autophagy is a pro-survival mechanism. Therefore, we 
hypothesized that metastatic ovarian cancer cells subjected to AKT inhibition were 
inducing autophagy to preserve their viability. To test this, we knocked down the 
expression of critical autophagy-related proteins using RNAi, thereby disabling 
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autophagy upregulation. Our previous studies demonstrated that ATG6/BECN1 
knockdown was insufficient to ablate autophagy upregulation in ovarian cancer cells, 
whereas reducing of ATG5 and/or ATG7 expression resulted in efficient downregulation 
of autophagy based on processing of the canonical autophagy marker LC3 (assessed by 
immunoblot and fluorescence microscopy; see Chapter 3, Fig. 3.6). Thus, for the present 
study, we again transfected the EOC147-E2 cell line (a clone of the ascites-derived 
primary sample EOC147) with negative control siRNA (siNT) or with siRNAs targeting 
ATG5 and/or ATG7 and assessed the effect that this had on cell viability.  
  
 In adherent cells and spheroids that were not subjected to AKT inhibition (DMSO 
vehicle control), decreasing basal autophagy via ATG gene knockdown had modest 
effects on viability. In fact, we observed that autophagy blockade by single-gene 
knockdown of ATG5 or ATG7 generally did not affect cell viability in untreated adherent 
cells or spheroids (Fig. 4.1A,C). However, the combined knockdown of ATG5 and ATG7 
significantly reduced cell viability: adherent cells exhibited a 25% decrease (Fig. 4.1A), 
and spheroids suffered a more drastic ~50% decrease (Fig. 4.1C). These experiments 
were conducted in FBS-containing culture media. Therefore, even at basal levels, 
autophagy appears important for the viability of metastatic ovarian cancer cells, in both 
adherent and spheroid cultures.  
  
 In addition to blocking basal autophagy, we also assessed the effect of blocking 
autophagy upregulation. Autophagy-competent and -deficient cells (made so by siRNA 
transfection) were treated with Akti-1/2, an allosteric AKT inhibitor that we have 
previously characterized as an autophagy inducer in metastatic ovarian cancer cells (Fig. 
3.2-3.3). In adherent cultures subjected to AKT inhibition, we found that knockdown of 
both ATG5 and ATG7, as well as of ATG5 alone, led to a 35% and 25% drop in cell 
viability, respectively (Fig. 4.1B). Likewise, in spheroids exposed to Akti-1/2, 
knockdown of ATG7 or both ATG5 and ATG7 reduced viability by ~25% and ~55%, 
respectively   (Fig. 4.1D).   Therefore, blocking Akti-1/2-mediated upregulation of 
autophagy led to a dramatic decrease in cell viability, implying cytoprotective functions 
for this process in the context of AKT inhibition.  
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Figure 4.1: AKT inhibition combined with siRNA-mediated autophagy blockade 
reduces cell viability.  
EOC147-E2 cells were transfected with Non-Targeting siRNAs or siRNA pools targeting ATG5, 
ATG7, or both. Transfection was repeated 72h later, and following overnight incubation, cells 
were seeded to their respective culture condition. (A,B) Adherent cultures were maintained on 
tissue culture-treated plates. Quadruplicate wells were treated with (A) DMSO vehicle control or 
(B) Akti-1/2 (3.5µM) and viability assessed by alamarBlue assay at 72h post-treatment (n = 4 
experiments). (C,D) Spheroids were formed in Ultra Low-Attachment plates. Triplicate wells 
were treated with (C) DMSO vehicle control or (D) Akti-1/2 (1µM) and viability assessed by 
CellTiter-Glo (n = 2 experiments). Bars: Mean ± SEM relative to Control siRNA. One-way 
ANOVA performed with Tukey’s Test. Different letters denote statistically significant 
differences among treatment conditions (p<0.01). 
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4.3.2 Autophagy blockade mediated by the Specific and Potent 
Autophagy Inhibitor 1 (Spautin1) reduces the viability of 
ovarian cancer cells subjected to AKT inhibition 
  
 In addition to depletion of ATG proteins, we also tested chemical means of 
blocking autophagy in metastatic ovarian cancer cells. The Specific and potent autophagy 
inhibitor 1 (Spautin1) was the first targeted autophagy inhibitor to be published. It is a 
small molecule that inhibits USP10 and USP13, two ubiquitin-specific peptidases 
responsible for stabilizing members of the autophagy-inducing Class III PI3K (PI3K C3) 
complex34. By inhibiting USP10/13, Spautin1 causes the degradation of multiple complex 
members (Beclin1, ATG14L, p150, and C3 PI3K), and in turn, blocks autophagy 
induction (Fig. S4.1).  
  
 Here we utilized Spautin1 for the first time in ovarian cancer cells, demonstrating 
that it can effectively block autophagy upregulation in EOC147-E2 cells and ascites-
derived epithelial ovarian cancer cells (EOCs), cultured under both adherent and non-
adherent conditions (Fig. 4.2A). Densitometry of LC3 immunoblots from five EOCs was 
used to quantify these changes, revealing that Spautin1 co-treatment significantly reduced 
levels of LC3-II (the autophagosome-associated LC3 species) to near basal levels (Fig. 
4.2B). Additionally, in a clone of the OVCAR8 ovarian cancer cell line expressing an 
eGFP-LC3B construct, Spautin1 co-treatment prevented the shift from diffuse to punctate 
eGFP-LC3B cellular localization that occurs upon AKT inhibition (Fig. 4.2C).    
  
 Interestingly, despite its published mechanism of action34, Spautin1-mediated 
autophagy blockade did not correlate with a reduction in Beclin1 protein expression (Fig. 
4.2A,B), suggesting that Beclin1 protein level was not critical for Spautin1’s mechanism 
of action. This may be a common feature of ovarian cancer cells, since we made similar 
observations in the ovarian cancer cell lines OVCA429, HEY, and HEYA8  (Fig. S4.2A). 
We have confirmed that HeLa cervical carcinoma cells did exhibit reduced Beclin1 levels 
with Spautin1 co-treatment (Fig. S4.2B), which is in agreement with the original 
characterization of Spautin1 by Liu et al.34. To test the contribution of Beclin1 to 
Spautin1-mediated   autophagy   blockade,  we  also  compared  the  effects  of   Spautin1  
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Figure 4.2: Autophagy upregulation is blocked by the Specific and Potent 
Autophagy Inhibitor 1 (Spautin1).  
(A,B) Cells were seeded to 6-well adherent (ADH) or non-adherent (SPH) culture dishes. Non-
adherent cells were treated at time of seeding and adherent cells treated 12h after seeding to allow 
adhesion (Akti-1/2 5µM; Spautin1 10µM). Lysates were obtained 24h post-treatment and 
immunoblot performed for indicated proteins. (B) Representative blots of EOC147-E2 and 
EOC67 cells are depicted. (B) Quantification of band intensity of LC3-II or Beclin1 normalized 
to Actin for n = 5 EOC samples. Bars: Mean ± SEM. One-way ANOVA with Tukey’s Multiple 
Comparison Test compared means (*p<0.05; **p<0.01). (C) OVCAR8-eGFP-LC3 cells were 
seeded (3.0x105 cells/well) to 6-well plates and treated following overnight incubation (Akti-1/2 
5µM, Spautin1 10µM). Images captured 24h post-treatment, images were captured using an 
Olympus IX70 inverted microscope and ImagePro software. Scale bar: 10µm 
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treatment on Beclin1-expressing and -depleted cells. We found that comparable 
autophagy blockade was achieved by Spautin1 irrespective of Beclin1 expression, since 
at least a ~50% reduction in LC3-II was observed in either case (Fig. S4.2C). Taken 
together, these data demonstrate that Spautin1 efficiently blocks Akti-1/2-mediated 
autophagy upregulation and that this appears to occur in a Beclin1-independent manner. 
  
 Given that Spautin1 efficiently inhibited autophagy upregulation, we then asked 
what effect simultaneous treatment with Akti-1/2 and Spautin1 would have on cell 
viability. Multiple EOCs were treated with Akti-1/2, Spautin1, or both, and cell viability 
was assessed. Single-agent Akti-1/2 was used at a previously-determined concentration 
that: (i) inhibited AKT phosphorylation, (ii) induced autophagy, and (iii) achieved a 50% 
reduction in cell viability (EC50). Spautin1 was used at a concentration that consistently 
blocked autophagy induction (Fig. 4.2). Treatment with single-agent Spautin1 had a 
modest effect on all EOCs tested, resulting in no greater than a 30% loss of viability, 
while single-agent Akti-1/2 (EC50) led to an approximate 50% drop in viability (Fig. 
4.3A). When cells were treated with both agents in combination, a decrease in viability of 
≥75% was observed in all EOCs, which was greater than that of either agent alone (Fig. 
4.3A). These trends were found to be highly statistically significant when data from 
individual EOCs were pooled (p<0.001; Fig. 4.3B). Identical experiments were 
conducted with the EOC147-E2 cell line, also revealing that combination treatment 
reduced cell viability by a significantly greater amount than either agent alone (p<0.001; 
Fig. 4.3C). Therefore, our results indicate that in metastatic ovarian cancer cells, 
suppression of autophagy induction by Spautin-1 compromises cell viability. 
 
4.3.3 AKT inhibition combined with Chloroquine (CQ)-mediated 
autophagy blockade reduces ovarian cancer cell viability  
 
 In addition to the novel autophagy-inhibitor Spautin1, we also used the 
lysomotrophic agent Chloroquine (CQ) to block autophagy. CQ is a small molecule that 
disrupts lysosome function by altering intra-lysosomal pH. Since lysosomes are essential 
for  the  degradation  of  autophagic   cargo,  CQ-mediataed  lysosomal  dysfunction  thus 
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Figure 4.3: AKT inhibition combined with Spautin-1 treatment reduces cell 
viability.  
Cells were seeded to 96-well adherent plates the day before treatment. Triplicate wells were 
treated (Akti-1/2 EC50, Spautin1 10µM) and following 72h incubation, viability measured by 
alamarBlue. (A) For each EOC samples, viability readings were normalized to DMSO vehicle 
control. Bars represent Mean ± SD. (B) Normalized viability data from all EOCs were pooled (n 
= 10 EOC samples) and one-way ANOVA performed. (C) EOC147-E2 cells were treated 
identically, repeated experiments (n = 3) pooled and one-way ANOVA with Tukey’s Multiple 
Comparison Test performed. Bars represent Mean ± SEM. Different letters denote statistically 
significant differences (p<0.001). 
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inhibits autophagy35. Unlike early-stage autophagy blockade that limits the formation of 
autophagosomes and thus decreases LC3-II (e.g., Spautin1), CQ blocks autophagy in its 
final stages, instead preventing the clearance of autophagosomes (Fig. S4.1). As a result, 
un-degraded autophagosomes accumulate within the cell, manifesting as an over-
abundance of LC3-II.  
 
 We have previously demonstrated LC3-II accumulation upon CQ treatment of 
adherent cells and spheroids (see Chapter 3, Fig. 3.3A). Here cells were treated with CQ 
(50µM), Akti-1/2 (EC50), or both, and their viability assessed. In multiple EOCs, 
treatment with CQ  or Akti-1/2 alone led to reductions in viability of 35-50% and ~50%, 
respectively (Fig. 4.4A). Their combination, however, yielded a more pronounced loss of 
viability (70-95%) (Fig. 4.4A). When data from all 8 EOCs were subsequently pooled, 
these trendsw ere found to be statistically significant (p<0.001; Fig. 4.4B). Similar results 
were also obtained from identical experiments using the EOC147-E2 cell line (p<0.001; 
Fig. 4.4C). Therefore, CQ-mediated autophagy blockade, on its own or in combination 
with AKT inhibition, significantly decreases cell viability.  
  
 Although LC3-II accumulation is observed upon CQ treatment (see Chapter 3, 
Fig. 3.3A), this observation is not sufficient to infer the completeness of autophagy 
blockade. This is due to a lack of “reference points” against which to compare autophagy 
inhibition. For example, whereas relative effectiveness of autophagy inhibition can be 
inferred by measuring a decrease in LC3-II from a reference level, such comparisons 
cannot be made with drugs like CQ that increase LC3-II abundance. Therefore, as we 
were unable to empirically determine the CQ dose at which autophagy is abolished,  we 
opted to treat cells with a range of CQ concentrations. CQ was titrated alone or in 
combination with fixed-dose AKT inhibition so as to test both the effect of blocking basal 
autophagy (DMSO vehicle control) as well as blocking autophagy upregulation (Akti-
1/2). Readings for either condition were normalized to their individual controls and non-
linear curve-fit analysis performed to generate CQ EC50 values (example curve-fit 
depicted in Fig. 4.4D). In EOC147-E2 cells, comparison of cells treated with DMSO vs. 
Akti-1/2 revealed a significant difference in their  CQ  EC50s:  specifically,  Akti-1/2  co- 
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Figure 4.4: AKT inhibition combined with Chloroquine (CQ) treatment reduces cell 
viability.  
96-well adherent plates seeded the day before treatment. (A,B,C) Triplicate wells treated for 72h 
with Akti-1/2 (EC50) and CQ (50µM), and viability assessed by alamarBlue. (A) Viability 
readings normalized to vehicle control (DMSO) for individual EOC samples. Bars: Mean ± SD. 
(B,C) Normalized viability data pooled from (B) all EOC samples (n = 8) and (C) all experiments 
with EOC147-E2 cells (n = 3). Bars: Mean ± SEM. Different letters denote statistically 
significant differences, based on one-way ANOVA with Tukey’s Test (p<0.001). (D, E) 
Triplicate wells treated with a range of CQ doses (0, 2.5, 5.0, 10, 25, 50, 75, 100, 150, 250µM) 
combined with either DMSO or Akti-1/2 (EC50) and viability assessed at 72h. (D) Non-linear 
curve-fit analysis and EC50 comparisons performed for EOC147-E2 cells (p<0.001). (E) CQ 
EC50 comparisons for EOC147-E2 cells and all EOCs. Bars: Mean ± 95% confidence interval.  
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treatment caused a 67% decrease from 68.4µM to 22.7µM, suggesting that AKT 
inhibition sensitized these cells to autophagy blockade by CQ (Fig. 4.4D). Similar results 
were observed across multiple EOCs: although they exhibited a broad range of sensitivity 
to CQ (EC50s of 25µM–150µM) in the absence of autophagy induction (i.e., DMSO 
vehicle control), significant decreases of 32-78% were observed in the presence of Akti-
1/2 in nearly all cases (Fig. 4.4E). Taken together, these findings demonstrate that AKT 
inhibition sensitizes metastatic ovarian cancer cells to the deleterious effects of CQ-
mediated autophagy blockade. 
   
4.3.4 Spheroids are more resistant to single-agent treatment than 
adherent cells, but remain highly sensitive to the 
combination of AKT inhibition and autophagy blockade 
  
 Given our finding that autophagy blockade led to decreases in adherent cell 
viability, we wished to determine whether similar effects were observed in spheroid cells. 
To test this, we treated EOCs in both culture conditions with fixed doses of Akti-1/2 
alone, an autophagy inhibitor alone (Spautin1 or CQ), or their combination. Data from 
individual EOCs were pooled and statistical analysis conducted to directly compare these 
treatments between adherent cells and spheroids. We observed a similar response to 
Spautin1 in spheroid and adherent cells, as both exhibited minimal decreases in viability 
(Fig. 4.5A). In the case of Akti-1/2 treatment, however, spheroid-based cells were 
dramatically less sensitive than their adherent counterparts, exhibiting only a 10% 
reduction in viability (as compared to 50%). Yet despite their lack of response to  single-
agent Akti-1/2, spheroid cells remained highly-sensitive to its combination with Spautin1, 
as co-treatment was just as potent as it was in adherent cells (#p<0.001; Fig. 4.5A).  
  
 Similar observations were made upon CQ treatment. Whereas spheroids exhibited 
de-sensitization to both single-agent CQ and Akti-1/2 treatment compared to adherent 
cells (*p<0.001), they retained equivalent sensitivity to combination treatment (Fig. 
4.5B). We also conducted Trypan Blue exclusion cell counting (identifies viable cells) in 
a large number of adherent and spheroid EOC cultures subjected to similar CQ ± Akti-1/2 
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Figure 4.5: Spheroids are more sensitive to combined AKT and autophagy 
inhibition than either modality alone.  
Cells were seeded to parallel adherent (ADH) and non-adherent (SPH) cultures and treated 
following overnight incubation or at time of seeding, respectively. Cell viability was quantified 
by alamarBlue (ADH) or CellTiter-Glo (SPH) and normalized to DMSO vehicle control (not 
depicted). Normalized viability data from individual EOC samples (n = 7) treated with (A) Akti-
1/2 (EC50) ± Spautin1 (10µM) or (B) Akti-1/2 (EC50) ± CQ (25µM) were pooled (n = 7 EOC 
samples) and depicted as Mean ± SEM. One-way ANOVA with Tukey’s Multiple Comparison 
Test was performed (*p<0.001). Drug combination more effectively decreased viability 
compared to single-agent treatment (#p<0.01) 
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combination treatments and observed that spheroids were slightly less sensitive than 
adherent cells to CQ alone, but exhibited a much more pronounced drop in viability when 
CQ and Akti-1/2 were combined (Fig. S4.3). Taken together, these data imply that while 
spheroids are able to resist the effects of either AKT inhibition or autophagy blockade 
alone, their combination yields dramatic reductions in cell viability.      
 
4.3.5 AKT inhibition and autophagy blockade work in a synergistic 
manner to reduce ovarian cancer cell viability 
 
 Thus far we have demonstrated that co-treatment of ovarian cancer cells with 
AKT inhibition and autophagy blockade reduces cell viability to a greater extent than 
either alone. However, it remained to be determined whether these treatments were acting 
merely in an additive (i.e., their combined effect was simply the sum of either effect 
alone) or synergistic manner (i.e, the combined effect is greater than additive). Synergy 
implies that one agent enhances the effect of the other. It is valued over an additive effect 
since either agent can be used at lower doses (thus reducing toxicity), while still 
achieving greater therapeutic efficacy. To assess synergy, we performed isobologram 
analysis, which provides a quantitative combination index (CI) value as a measure of 
drug interaction36. Briefly, using EC50s as a starting point (Table S4.1), serial dilutions 
of either drug alone and their combination were generated with a 1:1 ratio of equipotency 
at all dilutions (see X-axis in Fig. 4.6A). Cell viability data were obtained for each 
condition (EOC129 data depicted in Fig. 4.6A) and CI analysis performed using these 
data (isobologram and CI value depicted in Fig. 4.6B). A CI score <1, =1, or >1 indicates 
synergistic, additive, or antagonistic effects, respectively. For EOC129 and all other 
EOCs tested, the combination of Akti-1/2 and Spautin1 was found to be synergistic as all 
values were <1 (Fig. 4.6C). Synergy was also observed for the Akti-1/2 CQ combination 
(in all but one EOC), albeit to a lesser degree (Fig. 4.6D). CI analyses were also 
performed in EOC147-E2 cells, revealing a synergistic-to-additive effect of Spautin1 co-
treatment and an additive effect of CQ co-treatment (Fig. 4.6E). In conclusion, 
combination treatment with AKT inhibition and autophagy blockade synergistically 
reduces the viability of the majority of metastatic ovarian cancer cells. 
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Figure 4.6: The combination of AKT inhibition and autophagy blockade 
synergistically reduces cell viability of metastatic ovarian cancer cells.  
(A) Triplicate wells of adherent cells were treated with either drug alone or in combination (A = 
Akti-1/2, S = Spautin1) and viability assessed by alamarBlue 72h post-treatment. EOC129 data 
are depicted. Bars: Mean ± SD. (B) Isobologram of Combination Index data for EOC129. X- and 
Y-intercepts represent the calculated Akti-1/2 and Spautin1 EC50s, respectively. CI score 
coordinates represent interaction effect of two drugs when used at their EC50s. CI scores for (C) 
Akti-1/2 and Spautin1 treatment or (D) Akti-/2 and CQ at their EC50 doses are depicted as 
horizontal bars. (E) EOC147-E2 cells were subjected to identical analysis and CI scores (at EC50 
doses) from 3 repeated experiments are depicted as horizontal bars. 
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4.4 Discussion 
 
 Combinatorial autophagy blockade is an emerging paradigm in cancer treatment, 
providing a means of sensitizing tumor cells to existing or investigational therapeutics. It 
is based on the premise that tumor cells upregulate autophagy to mitigate the deleterious 
effects of anti-cancer agents. Consequently, blocking therapy-induced autophagy 
deprives them of an important survival mechanism. In agreement with this concept, our 
present work demonstrates that metastatic ovarian cancer cells treated with an AKT 
inhibitor upregulate autophagy to promote their survival, since its blockade resulted in 
significantly decreased cell viability. Our work therefore supports a pro-survival role for 
autophagy upregulation in this context and suggests that its therapeutic inhibition may be 
a treatment strategy worth exploring in ovarian cancer.  
 
 This study assessed the role of autophagy upregulation not only in adherent 
cultures, but also in multicellular aggregates (i.e., spheroid cultures), as these are 
considered important for ovarian cancer metastasis. Given our previous finding of 
elevated autophagy simply due to spheroid formation, and its further upregulation upon 
AKT inhibition (see Chapter 3, Fig. 3.1-3.3), we expected spheroids to be acutely 
sensitive to autophagy blockade. Indeed, spheroids subjected to non-pharmacologic 
means of autophagy blockade appeared more sensitive to ATG5+ATG7 knockdown than 
their adherent counterparts (Fig. 4.1C,D). However, autophagy blockade by 
pharmacologic means did not yield similar results: Spautin1 treatment was equally 
ineffective in both culture conditions and CQ was significantly less effective in adherent 
cultures.  
 
 We suspect that these results may be attributable to the general drug-resistant 
phenotype that is inherent to multicellular aggregates (reviewed in Ref.37), rather than a 
specific insensitivity to autophagy blockade. Indeed, it is well established that three-
dimensional or “tumor-sphere” culture of ovarian cancer cells endows them with 
resistance to chemotherapeutics38-43. Furthermore, our results presented in Figure 4.5 also 
demonstrate reduced sensitivity to Akti-1/2 treatment, indicating that spheroid cells can 
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also resist targeted agents. Thus, spheroids may be less sensitive to autophagy-blocking 
drugs by virtue of general drug resistance mechanisms, rather than being specifically 
unresponsive to autophagy blockade. This general drug-resistant state could explain why 
spheroids were sensitive to non-pharmacologic means of autophagy blockade (i.e., RNA 
interference; Fig. 4.1C,D), but not autophagy-blocking drugs that can be circumvented by 
spheroid-associated drug-resistance mechanisms. Overall, we conclude that autophagy 
blockade in spheroid cells is in fact detrimental to their survival, but it is unclear why this 
effect is less potent than would be predicted based on their high levels of autophagy. 
   
 As a clinical agent, Chloroquine (CQ) has been used as an anti-malarial for 
decades and is well-tolerated with minimal toxicity in patients. CQ (or its derivative 
HCQ) is currently being tried clinically as an autophagy inhibitor in combination with 
targeted anti-cancer agents (clinicaltrials.gov). For example, although trials of the mTOR 
inhibitor Temsirolimus have demonstrated a 0% stable disease rate in patients with 
metastatic melanoma, its combination with HCQ achieved stable disease in 4/5 (74%) of 
patients with this cancer in a phase I trial (AACR 2011 Abstract #4500)44. Likewise, two 
controlled, randomized trials in glioblastoma multiform revealed that CQ administration 
in combination with standard therapy increased mean overall survival by at least two-fold 
compared to controls treated with standard therapy alone45,46. Although preliminary, these 
studies highlight the potential of CQ combination treatment as a new therapeutic 
paradigm in cancer. To date, no similar trials have been initiated specifically for ovarian 
cancer. However, our work indicates that further pre-clinical evaluations of autophagy 
blockade in ovarian cancer are warranted. 
 
 In addition to CQ, there is interest in developing alternate autophagy inhibitors 
with improved pharmacokinetic properties (such as the recently-published molecule 
Lys05, a dimeric form of CQ47) as well as alternate mechanisms of action (such as 
Spautin1, the first targeted autophagy inhibitor to be published34). In our hands, Spautin1 
potently blocked autophagy upregulation by Akti-1/2, leading to synergistic decreases in 
viability in all patient-derived cultures tested. The original characterization of Spautin1 
by Liu et al. determined that Class III PI3K complex members, but particularly the 
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autophagy regulator ATG6/Beclin1, are all de-stabilized by administration of this drug 
and that their proteasomal degradation subsequently mediates autophagy blockade34. We 
have used HeLa cells (one of the cell lines used by Liu et al.) to assess this mechanism in 
our hands, finding that autophagy blockade does indeed correlate with decreased Beclin1 
protein levels (Fig. S4.2B). In contrast, in all ovarian cancer cells we have tested, 
Spautin1 achieved efficient autophagy blockade despite Beclin1 levels remaining 
unchanged, suggesting that Spautin1 is functioning in a Beclin1-independent manner. 
This finding is not without precedent: of the 3 reports of Spautin1’s use since its original 
publication, one assessed Beclin1 expression, and they too noted that Beclin1 levels 
remain unchanged despite efficient autophagy blockade48. Moreover, our data are in 
keeping with our previous demonstration that autophagy upregulation is a Beclin1-
independent process in ovarian cancer cells (see Chapter 3). Taken together, these data 
call for further studies to fully elucidate Spautin1’s mechanism of action, but nonetheless 
establish this drug as a highly-efficacious autophagy inhibitor in metastatic ovarian 
cancer cells. 
 
 Our finding that autophagy mediates ovarian tumor cell survival raises important 
questions about the cellular mechanisms underlying this function. Specifically, it remains 
to be determined whether autophagy promotes cell survival by protecting cells from 
apoptotic or non-apoptotic cell death, as this has been demonstrated in other systems 
17,18,20,49,50. To address this question, it will be important to conduct apoptotic or necrotic 
cell death assays to determine if either is occurring upon autophagy blockade. Aside from 
preventing cell death, autophagy upregulation in ovarian cancer cells may also be 
influencing cell proliferation. This possibility can be tested by performing BrdU-labeling 
and cell cycle analysis as was done in Chapter 2. Such techniques would also be useful to 
further investigate the unexpected increase in cell viability observed with ATG7 
knockdown (Fig. 4.1A). Since ATG7 knockdown achieves only partial autophagy 
blockade (see Chapter 3, Fig. 3.6C and Ref.51), and since it is established that partial 
autophagy disruption – rather than its complete ablation – is known to promote mammary 
hyperplasia and tumorigenesis52,53, we hypothesize that ATG7 knockdown could prompt a 
subtle increase in cell proliferation which manifests as the apparent increase in cell 
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viability that we have observed. Overall, through further investigation of cell cycle 
kinetics as well as apoptotic and necrotic cell death mechanisms, the mechanism by 
which autophagy promotes cell survival in metastatic ovarian cancer cells can be 
elucidated. 
 
 Overall, our work represents an important pre-clinical investigation into the utility 
of autophagy blockade in combination with targeted therapies. Moreover, by 
demonstrating the sensitivity of ascites-derived metastatic tumour cells to autophagy 
inhibition, our work supports the application of this therapeutic paradigm to patients with 
metastatic high-grade serous carcinoma, representing the majority of women with ovarian 
cancer. Presently, the allosteric AKT inhibitor MK-2206 (an analog of Akti-1/2), is under 
investigation at the phase II level in advanced ovarian, Fallopian tube, and peritoneal 
carcinoma (NCT01283035). With the trial of this and other PI3K/AKT/mTOR inhibitors 
in ovarian cancer, it will be important to determine whether autophagy is being 
upregulated in tumor cells as a compensatory response. If this is the case, our study 
suggests that combinatorial autophagy blockade may significantly enhance cytotoxicity, 
providing a novel therapeutic strategy that will hopefully lead to improved survival for 
patients suffering from this devastating disease.  
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Table S4.1: Single-agent EC50* values (μM) for ovarian cancer cells used in 
Combination Index analysis 
 Drug 
 Akti-1/2 Spautin1 Chloroquine 
EOC118 8.2 23.1 37.9 
EOC81 9.1 27.6 44.1 
EOC105 4.7 55.7 35.5 
EOC122 5.1 25.2 34.8 
EOC129 10.9 13.6 45.5 
EOC147-E2 4.9 11.5 68.4 
*EC50 determined using non-linear curve-fit analysis of amalarBlue viability for a range of drug 
concentrations as described in Materials & Methods (Section 4.2) 
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Figure S4.1: Autophagy blockade is achieved using multiple approaches in ovarian 
cancer cells.  
The Specific and Potent Autophagy Inhibitor 1 (Spautin1) targets the Ubiquitin Specific 
Peptidase (USP) 10 and 13, preventing them from stabilizing members of the Class III PI3K 
complex. Consequently, complex degradation prevents the induction of autophagy at the isolation 
membrane. siRNA-mediated knockdown of ATG5 and ATG7 expression prevents the processing 
and localization of LC3-II to expanding autophagosomes, thus abrogating their formation. 
Chloroquine (CQ) is a lysomotropic agent that de-acidifies lysosomes, nullifying pH-dependent 
lysosomal hydrolases and leading to a buildup of LC3-II-positive autophagosomes.	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Figure S4.2: Spautin1 blocks autophagy by a Beclin1-independent mechanism in 
ovarian cancer cells.  
Cells were seeded to 6-well adherent plates and treated following overnight incubation (Akti-1/2 
5µM; Spautin1 10µM). Lysates were obtained 24h post-treatment and immunoblots performed 
for indicated proteins. (A) Blots of ovarian cancer cell lines OVCA429, HEY and HEYA8 are 
depicted, as well as (B) the HeLa cervical carcinoma cell line. (C) EOC147-E2 cells were first 
transfected with a Non-Targeting siRNA, or an siRNA pool targeting BECN1. Either condition 
was treated as previously described and immunoblot performed. Levels of indicated proteins were 
quantified and depicted relative to Actin (loading control). 
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Figure S4.3: EOC spheroids exhibit greater sensitivity to combined Akti-1/2 and CQ 
treatment.  
Cells were seeded to (A) adherent (n = 11 EOC samples) or (B) spheroid (n = 12 EOC samples) 
cultures. Treatment (concentrations as indicated) was initiated following overnight incubation or 
at time of seeding, respectively. Viability was quantified 72h post-treatment by Trypan Blue cell 
counting and normalized to DMSO vehicle control for each EOC. Normalized data were pooled 
and one-way ANOVA with Tukey’s Multiple Comparisons Test performed for each culture 
condition. Bars represent Mean ± SEM for pooled EOC samples. Different letters denote 
statistically significant differences (p<0.001). 
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Chapter 5  
 
5 Discussion 
 
5.1 Summary of Findings 
 
 The most prevalent subtype of ovarian cancer – high-grade serous carcinoma – is 
also the most lethal, since the majority of cases are characterized by advanced-stage 
(metastatic) presentation1. Given its origins in the distal Fallopian tube, this cancer is 
known to rely on a sequence of cellular exfoliation and re-implantation to achieve 
ovarian tumor formation2. The similarity of this sequence with the process of intra-
peritoneal metastasis is striking, and suggested to us that its underlying molecular 
mechanisms are conserved over the course of disease progression.  
 
 To characterize these mechanisms, we established an in vitro model of metastatic 
dissemination using ascites-derived epithelial ovarian cancer cells (EOCs). When 
cultured under non-adherent conditions, EOCs formed multicellular aggregates 
(spheroids) resembling those seen in patient ascites (Chapter 2). Spheroid cells existed in 
a low-proliferation, quiescent state and also exhibited autonomous down-regulation of 
AKT activity. We suggested that quiescence was maintained by this reduced AKT 
activity via de-stabilization of SKP2, a member of the SCF ubiquitin ligase complex. As 
quiescence is a reversible state by definition, we also demonstrated that spheroid 
attachment to an adherent surface prompted constituent cells to re-enter the cell cycle in 
an AKT-dependent manner.  
 
 In conjunction with quiescence, we discovered that spheroid formation also 
induced autophagy, a conserved cellular self-digestion mechanism (Chapters 3 & 4). 
Likewise, pharmacologic AKT inhibition, which induces cytostasis and quiescence, also 
induced autophagy in both spheroids and adherent cells. By blocking autophagy 
induction using multiple approaches, we demonstrated that this process was important in 
155 
 
sustaining the viability of quiescent cells. Furthermore, combining pharmacologic AKT 
inhibition and autophagy blockade synergistically reduced cell viability, further 
supporting a cytoprotective role for this process in ovarian cancer cells.  
  
 The data presented in this thesis describe quiescence and autophagy separately in 
metastatic ovarian cancer cells. However, they are induced by the same stimuli 
(specifically, non-adherent spheroid formation or AKT inhibition) and occur 
simultaneously. Therefore, when considered together, we propose that coordinate 
induction of quiescence and autophagy constitute a dormant phenotype in metastatic 
ovarian tumor cells (Fig. 5.1). 
 
5.2 Dormancy as a Unifying Concept 
 
5.2.1 Introduction to Cancer Dormancy 
 
 Cancer dormancy is clinically defined as the ‘pause’ in cancer progression where 
residual disease remains undetected, only to emerge later as metastatic lesions 3. Dormant 
disease is traditionally thought to exist as disseminated tumor cells that are found lodged 
at common sites of metastasis in patients (e.g., bone marrow)4,5. These cells are defined 
as dormant based on their lack of proliferative markers such as Ki676,7. Mouse models 
developed to study the phenomenon of dormancy have also demonstrated that a low- or 
non-proliferative cellular state is adopted by disseminated tumor cells 8,9. Therefore, a 
low-proliferation or quiescent state has been established as one of the defining features of 
dormant tumor cells. 
 
 Given the low abundance of these cells, characterizing the molecular mechanisms 
regulating dormancy has been a challenge. However, Aguirre-Ghiso’s group has 
discovered that arrival in a foreign microenvironment activates stress-signaling pathways, 
ushering these cells into dormancy. More specifically, the failure of cells to engage 
foreign    extracellular    matrix   components   reduced   integrin-mediated   intra-cellular  
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Figure 5.1: Proposed Model of Dormancy Regulation in Metastatic Ovarian Cancer.  
Both quiescence and autophagy are controlled by AKT kinases via regulators such as mTORC1, 
p130, and p27. The LKB1/AMPK pathway is positioned to control both quiescence and 
autophagy downstream of AKT by inhibiting mTORC1 and phosphorylating p27 (Thr198). 
PERK may be an upstream activator of LKB1/AMPK signaling in dormant cells. DYRK1B 
regulates quiescence by phosphorylating p27 and the DREAM complex member LIN52. 
Together, quiescence and autophagy constitute two major features of dormancy in metastatic 
ovarian cancer cells; they can promote metastasis, resistance, and recurrence – all of which 
contribute to poor patient outcome. Autophagy box: Autophagy can be divided into “basal” and 
“induced” branches. While basal autophagy depends upon Beclin1, we propose that autophagy 
induction can proceed in a Beclin1-independent manner.  
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signaling while activating stress-associated p38α/β signaling. This pushed cells into a 
quiescent state characterized by upregulation of cyclin-dependent kinase inhibitors (CKI), 
particularly the quiescence-assiciated CKI p27Kip1 3,10-12. Dormancy is also associated 
with activation of all three arms of the unfolded protein response (UPR), of which the 
PERK (pancreatic endoplasmic reticulum kinase) pathway was found to be particularly 
important13,14. PERK activation attenuated translation initiation, thereby suppressing the 
expression of Cyclin D1/D3 and CDK4 genes13. Therefore, dormancy in disseminated 
tumor cells is mediated by mechanisms involving the loss of integrin-mediated signaling 
and the simultaneous upregulation of p38 and PERK signaling. 
 
 While quiescence ensures minimal proliferation of dormant cells, emerging 
evidence suggests that autophagy is a key mechanism promoting their continued survival. 
Autophagy was initially associated with dormancy in studies of C. elegans larvae during 
dauer diapause (a protective whole-organism dormancy induced by environmental 
stress)15. Autophagy disruption in this model compromised survival, supporting its 
conserved role in maintaining viability. Analogous findings have been reported in human 
cancer cells. In gastrointestinal stromal tumors (GISTs), for example, autophagy was 
required for sustained viability during therapy-induced dormancy16. This phenomenon 
has been described in numerous other cancer cell types as well (reviewed by White17). 
Most relevant to this thesis, a seminal study from the Bast lab demonstrated the necessity 
of autophagy for dormancy in ovarian tumor xenografts. The authors showed that re-
expressing the imprinted tumor suppressor DIRAS3/ARHI induced autophagy and tumor 
dormancy. When ARHI expression was down-regulated in these dormant tumors, growth 
was rapidly re-initiated. Strikingly, re-growth was abolished if autophagy was blocked by 
CQ administration during the dormant phase, thus elegantly demonstrating its importance 
for the survival of dormant ovarian cancer cells in vivo18. Taken together, these reports 
indicate that in addition to quiescence, autophagy is emerging as another essential feature 
defining a dormant phenotype.   
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5.2.2 Dormancy and its Mechanisms in Metastatic Ovarian Cancer 
Cells 
 
 Based on the current molecular understanding of dormancy presented above, we 
propose that quiescence and autophagy are in fact two key elements of an overarching 
dormancy phenotype. Although traditionally associated with solitary disseminated tumor 
cells with extremely long latency periods, our findings indicate that clustered ovarian 
tumor cells also employ quiescence and autophagy to achieve a dormant state. More than 
just their conceptual unification as features of dormancy, however, we propose that the 
coordinate induction of quiescence and autophagy in metastatic ovarian cancer is inter-
linked at the molecular level by common regulatory mechanisms. 
 
 One obvious example of such a mechanism is the PI3K/AKT/mTOR pathway, 
since throughout this thesis, we have directly demonstrated that this pathway impinges 
upon both quiescence and autophagy (Fig. 5.1). Aside from the AKT kinases, however, 
another important molecular link is the LKB1/AMPK pathway. As previously discussed, 
AMPK activation can promote autophagy by de-activating mTORC1 via phosphorylation 
of TSC1/219 and Raptor20, as well as activating the autophagy-inducing kinase ULK121. 
Furthermore, work by Liang et al. demonstrated that the LKB1/AMPK pathway could 
induce autophagy by phosphorylating and stabilizing p27, although the precise 
mechanism linking this protein to the autophagic machinery remains unclear22,23. In 
keeping with its role as a cyclin-dependent kinase inhibitor, p27 stabilization by the 
LKB1/AMPK pathway also contributes to the induction of cell cycle arrest and 
quiescence that occurs in conjunction with autophagy upregulation23. Furthermore, 
LKB1/AMPK inhibition of mTORC1 also prevents the translation of important cell 
cycle-dependent genes, thus preventing proliferation19,24. Taken together, these findings 
suggest that LKB1/AMPK signaling – in cooperation with p27 – can simultaneously 
induce both autophagy and quiescence to impart a dormant state.   
 
 The ER-stress kinase PERK is another potential regulator of both quiescence and 
autophagy. As previously mentioned, integrin disengagement stimulates p38-mediated 
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PERK activation in dormant cells, promoting quiescence by blocking the translation of 
cell cycle-dependent genes10,13. Interestingly, PERK also protected dormant cells from 
insults such as glucose-deprivation and chemotherapy treatment, though the mechanism 
mediating this protection was not described13,14. As a possible explanation, recent work 
has demonstrated that PERK signaling is capable of inducing a cytoprotective autophagy 
response in mouse embryonic fibroblasts and mammary epithelial cells25,26. Interestingly, 
the stimulus for this PERK-mediated autophagy was extracellular matrix detachment, 
which is analogous to our own model of non-adherent culture25,26. Moreover, PERK 
activation promoted autophagy by a mechanism dependent upon LKB1/AMPK-mediated 
inhibition of mTORC125. Although mechanistic details have yet to be delineated, this 
emerging data ties the ER-stress kinase PERK into the induction of dormancy, upstream 
of the LKB1/AMPK pathway.  
  
 Based on these reports, and the findings presented in this thesis, we propose that a 
PERK/LKB1/AMPK regulatory mechanism (also involving p27 as an effector) could 
promote a dormant phenotype by coordinately regulating quiescence and autophagy (Fig. 
5.1). In support of this mechanism, our lab has described the immediate and sustained 
activating phosphorylation of both LKB1 and AMPK during spheroid formation (Peart, 
DiMattia and Shepherd, unpublished). We are currently engaged in knockdown studies of 
these proteins to determine their contribution to the dormancy phenotype. Additionally, 
we assessed the expression of BiP, a PERK activator, and found that it was increased 48h 
following seeding to non-adherent culture (Fazio, Shepherd and DiMattia, unpublished). 
Although we predicted this elevation in BiP, its timing was unexpectedly late given that 
autophagy is induced immediately following seeding. It is possible that we are seeing a 
delayed transcriptional response resulting in BiP upregulation following its initial 
dissociation and activation of PERK. It will be important to clarify the status of UPR 
signaling downstream of BiP by more directly assessing PERK phosphorylation and 
activity. If activated during spheroid formation, its contribution to the dormancy 
phenotype can also be tested using RNAi-mediated PERK knockdown experiments. 
Finally, it will be important to also assess phosphorylation of p27 at Thr198, given that 
this residue is uniquely linked to regulating dormancy.  
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 In summary, the regulation of dormancy is likely multi-faceted. Our work thus far 
has identified that AKT signaling is able to coordinately regulate its key features 
quiescence and autophagy by modulating its regulators mTORC1, p130, p27. 
Downstream of AKT, we postulate than an intervening PERK/LKB1/AMPK pathway 
can also coordinately control autophagy and quiescence through many of the same 
targets. AKT signaling and this hypothetical PERK/LKB1/AMPK axis may function 
simultaneously or distinctly in a temporally-regulated or context-dependent manner. By 
assessing and modulating the activity of key members of these pathways, we hope to 
elucidate the importance of each for coordinating dormancy in metastatic ovarian cancer 
cells.  
 
5.3 Remaining Questions Regarding the Role of Beclin1 in 
Ovarian Cancer 
 
 In Chapters 3 and 4, we characterized robust upregulation of cyto-protective 
autophagy in ovarian cancer cells. This finding is seemingly at odds with the accepted 
notion that autophagy is a tumor-suppressive mechanism, which is based largely upon 
evidence that the 17q21 locus (encompassing BECN1, the gene encoding the autophagy-
promoting protein Beclin1) exhibits heterozygous loss in a large proportion of ovarian 
tumors27-31. Losses of 17q21 were taken to mean that BECN1 gene dosage is critically 
important for autophagy. Thus, we questioned how autophagy could still be induced in 
ovarian tumor cells. As a first step, we assessed protein expression of Beclin1 using 
datasets from The Cancer Genome Atlas (TCGA) project, and were intrigued to find that 
instead of being reduced in tumors with mono-allelic BECN1 loss, it was retained at near-
diploid levels. Suspecting that this maintenance of protein level may be facilitating 
autophagy upregulation, we next knocked down Beclin1 expression using siRNAs. 
Surprisingly, this had no effect on autophagy induction in ovarian cancer cells, leading us 
to conclude that while a diploid level of Beclin1 is retained in the majority of ovarian 
cancer cells, this protein appears dispensable for their induction of autophagy.  
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5.3.1 Autophagy-independence 
 
 Our findings raise significant questions about the relationship between Beclin1 
and autophagy in ovarian cancer. For instance, what function is Beclin1 serving in 
ovarian tumors if not mediating autophagy upregulation?  Evidence of autophagy-
independent functions for Beclin1 and the PI3K C3 complex have been emerging in 
recent years (discussed in Chapters 1 & 3). Extra-autophagy functions are also evident 
upon closer examination of the mouse models of autophagy disruption (see Chapter 1, 
Table 1.2). Specifically, the knockout phenotype of core PI3K C3 complex members 
(Ambra1, Becn1, Pik3c3) is embryonic lethality32-35, whereas embryos harboring 
knockout of other Atg genes (Atg3, Atg5, Atg7) are viable at birth (though they die at 
post-natal day 1) 36-39. Additionally, while Becn1 heterozygotes develop malignant 
carcinomas and lymphomas32,33, complete knockout (tissue-specific) of Atg5 or Atg7 is 
required for tumor formation40 – however, tumors that do develop upon Atg5/7 knockout 
are only benign adenomas and never the spectrum of malignancies seen with 
heterozygous Becn1 disruption32,33,40. Interpreting these comparisons, one could conclude 
that the more severe phenotypes observed with abrogation of PI3K C3 complex members 
(most notably of Becn1), indicates important extra-autophagy functions.  
 
 We have begun to explore possible autophagy-independent functions of Beclin1 
by performing viability assays on ovarian cancer cells subjected to Beclin1 knockdown. 
Although autophagy remained unaffected (as demonstrated in Chapter 3), we nonetheless 
observed a significant reduction in cell viability (Appendix A, Fig. 1). Therefore, Beclin1 
appears to be serving a pro-survival function, though we currently do not have data 
clarifying the specific autophagy-independent mechanism by which this occurs. It will be 
important to first investigate how Beclin1 depletion reduces viability by performing cell 
cycle analysis as well as cell death (apoptotic and non-apoptotic) assays. These and other 
experiments can be used to direct further mechanistic studies into Beclin1’s autophagy-
independent function(s).  
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5.3.2 BECN1 and BRCA1 
 
 Our work also raises a fundamental question about the reason for BECN1 
heterozygous loss in ovarian cancer: if Beclin1 is in fact dispensable for autophagy 
upregulation, does its mono-allelic loss actually promote ovarian tumorigenesis? 
Interestingly, upon closer examination of TCGA copy-number data from serous ovarian 
tumors, we have noted that BECN1 mono-allelic deletion results from large deletion 
events encompassing chromosomal region 17q21 (Appendix A, Fig. 2A), rather than 
focal loss of the BECN1 locus. It is therefore conceivable that loss of other tumor-
suppressive genes in this region, and not BECN1, are ‘driving’ these mono-allelic 
deletion events. In other words, BECN1 may simply be a ‘passenger’ gene that is 
inextricably linked to copy-number deletions on chromosome 17q.  
 
 One possible candidate ‘driver’ gene is the breast and ovarian cancer 
susceptibility gene BRCA1. Although not mentioned in the Beclin1 and autophagy 
literature, BRCA1 is actually located only 218,000 bp telomeric to BECN1 (Appendix A, 
Fig. 2A). Moreover, there is a nearly perfect correlation between BECN1 and BRCA1 
heterozygous loss (Appendix A, Fig. 2B).  
 
 BRCA1 is of obvious importance to ovarian tumorigenesis. Germline mutations of 
this gene are found in ~10% of ovarian cancer patients41 and are associated with the 
majority of hereditary tumors42. Sporadic ovarian cancers also harbour somatic BRCA1 
mutation in ~4% of cases (Ref.41 and Appendix A, Fig. A2B), as well as epigenetic 
silencing via hypermethylation of the BRCA1 promoter in 11% of cases41. Importantly, 
all of these BRCA1 alterations are often accompanied by loss of the single remaining 
wild-type allele (i.e., loss-of-heterozygosity, or LOH), resulting in decreased mRNA and 
protein expression43,44. Furthermore, nearly all cases of hypermethylation occur in 
conjunction with single-allele loss45. Therefore, BRCA1 single-allele loss is a prevalent 
feature of both hereditary and sporadic ovarian tumors. It is tempting to speculate that 
instead of BECN1, loss of a BRCA1 allele may be an important driver of chromosome 
17q deletions. 
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5.3.3 A Proposed Model of Beclin1 and Autophagy Regulation in 
Ovarian Cancer 
 
 It is presently unclear what BECN1 loss contributes to ovarian tumorigenesis, or if 
it is simply lost as a ‘passenger’ as discussed above. Therefore, in the absence of 
experimental evidence clearly delineating the role of BECN1 and autophagy in ovarian 
cancer, we propose a model that attempts to satisfy seemingly contradictory viewpoints 
on this subject while integrating our own findings of Beclin1-independent autophagy. 
This model separates basal autophagy from autophagy induction, and by considering each 
as a distinct process, attempts to accommodate both Beclin1-dependent and –independent 
mechanisms of regulation (Fig. 5.1).  
 
 Specifically, we envision that Beclin1-dependent basal autophagy runs at 
unstimulated, homeostatic levels – by definition, it is not dynamically modulated and 
therefore is not intertwined with complex regulatory mechanisms. In contrast, autophagy 
induction is stimulated by a diverse array of cellular stresses and thus may have evolved 
greater versatility and redundancy in its regulation. According to this model, BECN1 
could undergo heterozygous loss in precursor lesions, partially ablating basal autophagy 
to promote ovarian tumorigenesis. Once a tumor has become established, however, 
microenvironmental factors (e.g., spheroid formation) or anti-cancer therapeutics (e.g., 
AKT inhibition) may stimulate cyto-protective autophagy induction by mechanisms that 
circumvent both Beclin1 and basal autophagy altogether.  
 
 Importantly, this model does not preclude autophagy-independent functions of 
Beclin1. In fact, we further speculate that such functions could be responsible for 
Beclin1’s sustained protein expression in advanced tumors. Given that its autophagy-
independent function(s) appear important in promoting metastatic tumor cell viability 
(Appendix A, Fig. 1), this could drive its protein expression back to near-diploid levels. 
Thus, we speculate that following initial down-regulation to promote tumorigenesis, 
Beclin1’s autophagy-independent functions prompt its advantageous re-expression in 
established tumors. 
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 It is clear that many questions remain regarding the role of Beclin1’s autophagy-
dependent and –independent functions in ovarian cancer. These would be best addressed 
using a mouse model of HGS-OvCa pathogenesis in combination with Becn1 disruption. 
For example, Kim et al. recently characterized such model based on conditional deletion 
of Dicer and Pten in the oviduct46. By crossing these mice with Becn1+/- mice, we could 
study the effects of heterozygous Becn1 loss on various paramaters of HGS-OvCa 
pathogenesis (e.g., tumorigenesis, time to ascites formation, survival, etc.). Such a model 
would also allow in vivo assessment of autophagy (e.g., LC3 immunoblot or 
immunofluorescence) as well as Beclin1 protein levels over the course of disease 
progression. Therefore, the combination of Becn1 disruption with models of HGS-OvCa 
could help clarify the contribution of Beclin1 and autophagy to the pathogenesis of this 
disease.     
 
5.4 Remaining Questions Regarding the Regulation of 
Quiescence 
 
 In Chapter 2, it was suggested that reduced AKT activity during spheroid 
formation promotes quiescence by destabilizing the essential SCF ubiquitin-ligase 
complex member SKP2, thus preventing SCF-mediated ubiquitination and degradation of 
p130 and p27. This mechanism was proposed based on clear evidence in the literature 
demonstrating that p130 and p27 are targets of the SCF complex47-49 and that AKT 
exerted control over the SCF complex through its phosphorylation and stabilization of 
SKP250,51 (Fig. 5.1). To actually test this mechanism in our model, we have obtained 
adenoviral expression constructs of AKT1 and AKT2, each containing an N-terminal 
myristoylation sequence (a site of attachment of a myristoyl group, a covalent post-
translational modification that ensures constitutive membrane localization and kinase 
activation). The establishment of constitutively-activate AKT using these constructs has 
been confirmed (Ramos-Valdes, Shepherd and DiMattia, unpublished). We would expect 
that this enforced AKT activity would suppress cell cycle exit to G0. If this occurs via 
SKP2, RNAi-mediated depletion of this protein should serve to rescue the quiescent state. 
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Through these experiments, we hope to delineate the contribution of AKT and SKP2 to 
mediating quiescence in our model.  
 
 We are also interested in assessing the contribution of the DYRK kinases to 
spheroid-mediated quiescence. As described in Chapter 1, DYRK1A/B directly 
phosphorylates and promotes the assembly of DREAM complex members at the 
promoters of E2F target genes, thereby facilitating exit from the cell cycle52. DYRK1B 
also phosphorylates Cyclin D1 and p27 to decrease and increase their abundance, 
respectively, promoting quiescence as a consequence53,54. Although it exhibits low 
expression in most normal tissues, early studies revealed that the DYRK1B gene locus is 
amplified in 30% of ovarian cancers55. A more recent multi-platform genomic analysis of 
high-grade serous ovarian tumors also reported focal amplification of 19q13.2, a 
chromosomal region that includes DYRK1B41. Using publicly available copy-number and 
mRNA expression data (including data from Ref.41), we found that DYRK1B copy-
number gain and high-level amplification occurred in 222/559 (39%) of high-grade 
serous carcinomas (Appendix A, Fig. 3A), appeared to be focal in nature (Appendix A, 
Fig. 3B), and correlated with DYRK1B mRNA expression (R2=0.32, r = 0.57, p<0.0001; 
Appendix A, Fig. 3C). Moreover, we found that amplification and/or elevated mRNA 
expression of this kinase significantly correlated with decreased overall survival (p<0.05; 
Appendix A, Fig. 3D).  
 
 Given that DYRK1B is amplified in high-grade serous ovarian tumors and that this 
correlates with survival, it is of great interest to determine whether its protein product 
regulates quiescence in our model. Friedman’s group has previously demonstrated that 
DYRK1B mediates quiescence in ovarian cancer cells subjected to serum starvation56. 
We suspect that it may also drive quiescence during spheroid formation (despite full-
serum conditions), perhaps most significantly in EOCs that exhibit DYRK1B 
amplification. This could be tested by simply depleting DYRK1B protein abundance in 
those samples exhibiting the highest levels of expression and subsequently determining 
how this affects quiescence during spheroid formation. Alternatively, specific DYRK1B 
small-molecule inhibitors can be used to modulate its kinase activity, as these have 
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recently been published57. Such experiments would determine not only the status of 
DYRK1B in ascites-derived ovarian tumor cells, but also its contribution to spheroid-
associated quiescence.  
 
5.5 Remaining Questions Regarding the Effects of 
Autophagy Blockade 
 
 Concluding Chapter 4, we stated that autophagy promotes the survival of 
metastatic ovarian cancer cells undergoing spheroid formation and/or subjected to AKT 
inhibition. This was based on cell viability assays measuring mitochondrial activity 
(alamarBlue), ATP abundance (CellTiter Glo), or the number of cells with intact plasma 
membranes (Trypan Blue exclusion cell counting). However, a detailed investigation of 
autophagy’s function necessitates other assays that move beyond assessing cell viability. 
For one, it will be important to assay for cell death to determine whether blocking 
autophagy actually causes cells to undergo apoptosis or necrosis.  
 
 Additionally, as a functional assay of viability, we could also use an in vivo 
xenotransplantation model to test tumor-forming potential of cells and spheroids. This 
would involve intra-peritoneal (IP) injection of ovarian cancer cells or spheroids to 
establish tumors and/or ascites, as previously described58. If cells or spheroids were pre-
treated in vitro, this model would serve as an in vivo assay of their viability and 
tumorigenic potential, and the effects of autophagy-modulation during the pre-treatment 
phase could be determined. Alternatively, if treatments were conducted in vivo following 
IP injection and tumor formation, this model could also serve as a pre-clinical tool to 
explore autophagy blockade as a potential therapeutic modality for ovarian cancer 
metastasis. 
 
5.6 Therapeutic Targeting of Dormancy in Metastatic 
Ovarian Cancer 
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 Dormancy is associated with therapeutic resistance3,59. This effect has 
traditionally been attributed to quiescence, which renders cells less vulnerable to 
chemotherapeutics by virtue of their non-cycling state. Moreover, upregulation of the 
quiescence-mediator p27 is associated with chemotherapeutic resistance60-62. However, in 
addition to quiescence, other mechanisms are thought to contribute to dormancy-
associated therapeutic resistance, such as p38-mediated inhibition of apoptosis, for 
example14. Autophagy, which is emerging as a critical feature of dormancy, has also been 
implicated as a therapeutic resistance mechanism in various settings63-66, specifically in 
the context dormant cells16. Therefore, since dormancy is closely tied to therapeutic 
resistance, we propose that targeting it in metastatic ovarian tumor cells will result in 
greater therapeutic sensitivity. 
 
5.6.1 Targeting Quiescence in Metastatic Ovarian Cancer 
 
 By targeting quiescence-promoting mechanisms, it may be possible to drive G0 
cells into the cell cycle, and in doing so, re-sensitize them to chemotherapeutics. 
Recently, targeted inhibitors of DYRK1B have been published57. Friedman’s group has 
demonstrated that inhibition of DYRK1B drove ovarian cancer cells (but not normal 
fibroblasts) into the cell cycle prematurely, leading to ROS accumulation and apoptosis67. 
Additionally, citing our work (Chapter 2) as their rationale, this group has recently begun 
testing DYRK1B inhibition in ascites-derived cultures55 (AACR 2013: Abstract #2164). 
It will be interesting to determine the effect of combinatorial DYRK1B inhibition and 
chemotherapy treatment in our in vitro metastasis model. Additionally, use of pre-clinical 
in vivo models of metastasis (e.g., xenotransplantation via IP injection, as proposed 
above) would be expected to recapitulate our in vitro results and provide insight into the 
utility of this therapeutic paradigm in patients.  
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5.6.2 Targeting Autophagy in Metastatic Ovarian Cancer 
 
 In addition to targeting quiescence, autophagy blockade may also hold promise 
for sensitizing dormant ovarian cancer cells to therapeutics. The rationale for targeting 
autophagy upregulation in metastatic ovarian cancer cells has already been discussed in 
Chapter 4 and data from this chapter demonstrate that combining Akti-1/2 (an allosteric 
AKT inhibitor) with autophagy blockade synergistically compromises cell survival. In 
this chapter, we have suggested further experiments to address the mechanism underlying 
these effects, as well as to test the potential of this therapeutic strategy in vivo. These and 
further pre-clinical studies are highly relevant, since the AKT inhibitor MK-2206 (an 
analog of Akti-1/2), is currently undergoing clinical trials in patients with ovarian, 
Fallopian tube, and peritoneal cancers (NCT01283035). If patient tumors treated with this 
drug respond by inducing autophagy, as our in vitro data suggests they would, it will be 
important to test whether combinatorial autophagy blockade can enhance its efficacy. 
Interestingly, an unrelated trial of MK-2206 and autophagy blockade has been initiated 
for advanced solid tumors – some of which might be ovarian tumors (NCT01480154). It 
is hoped that this and other trials of autophagy blockade (summarized in Chapter 1, Table 
1.4) will not only demonstrate improved efficacy, but also encourage more extensive 
investigation into the potential of autophagy inhibition for cancer treatment.  
 
5.7 Synthesis 
 
 This thesis began with the development of an in vitro model of ovarian cancer 
metastasis and led to the discovery that quiescence and autophagy – key features of a 
dormant state – can readily be induced by metastatic ovarian cancer cells. The data 
presented in Chapters 2, 3, and 4 characterize these features and the molecular 
mechanisms governing their regulation. Taken together, this body of work has 
contributed to a deeper understanding of the ovarian cancer metastatic process as well as 
provided a rationale for targeting dormancy mechanisms as a novel therapeutic paradigm 
in ovarian cancer. To fully realize the potential of targeting dormancy, both basic and 
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pre-clinical investigations are currently underway in ours and other laboratories. By 
delineating the molecular underpinnings of dormancy as well as applying this 
understanding to the clinical realm, it may be possible to someday eradicate dormant 
tumor cells that are at the root of metastasis, therapeutic resistance, and disease 
recurrence. 
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Appendix A: Additional Figures 
 
 
 
Figure 1: Depletion of Beclin1 significantly reduces cell viability.  
EOC147-E2 were transfected with Control siRNAs or siRNA pools targeting BECN1. 
Transfection was repeated 72h later, and following overnight incubation, cells were seeded to 
their respective culture condition. (A) Adherent cultures in quadrouplicate wells were treated with 
DMSO vehicle control or Akti-1/2 (3.5µM) and viability assessed by Alamar Blue at 72h post-
treatment (n = 4 repeated experiments). (B) Spheroids were formed in ultra-low attachment 
plates. Triplicate wells were treated with DMSO vehicle control or Akti-1/2 (1µM) and viability 
assessed by CellTiter Glo (n = 2 repeated experiments). Bars: Mean ± SEM relative to Control 
siRNA pool. One-way ANOVA with Tukey’s Test was performed. Different letters denote 
statistically significant differences (p<0.01).  
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Figure 2: Broad deletions of chromosome 17q in high-grade serous ovarian 
carcinoma encompass both the BECN1 and BRCA1 genes.  
 
(A) Log2-transformed copy number data from 569 high-grade serous ovarian 
cysteadenocarcinomas were generated by The Cancer Genome Atlas (TGCA) Research Network 
and are depicted as a heat-map using the Integrative Genomics Viewer (Broad Institute). Samples 
sorted based on BECN1 copy-number (White: diploid copy-number; Red: gain/amplification; 
Blue: loss/deletion) (B) A ~500,000 bp region from chromosome 17q21.31 is expanded to reveal 
the BECN1 and BRCA1 genes (separation: 218,000 bp). Image generated using NextBio Genome 
Viewer (http://www.nextbio.com/) (C) Sequencing and copy-number data for the BECN1 and 
BRCA1 genes from 311 high-grade serous ovarian cysteadenocarcinomas are depicted as an 
OncoPrint (cBio Portal for Cancer Genomics; http://www.cbioportal.org/; Memorial Sloan-
Kettering Cancer Center). Vertical lines represent a single sample (blue = homozygous deletion; 
teal = heterozygous loss; green = mutation).  
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Figure 3: DYRK1B amplification in high-grade serous ovarian carcinoma correlates 
with reduced overall survival.  
 
(A) Low-level gains (pink) or high-level amplification (red) of the DYRK1B gene in 569 high-
grade serous ovarian cysteadenocarcinomas are depicted in an OncoPrint (cBioPortal for Cancer 
Genomics; http://www.cbioportal.org/; Memorial Sloan-Kettering Cancer Center). Tumour 
samples were analyzed by The Cancer Genome Atlas (TCGA) Research Network. (B) The 
Integrative Genomics Viewer (Broad Institute) was used to generate a heat-map representation of 
log2-transformed copy number values (sorted based on DYRK1B amplification; white = diploid 
copy-number, red = gain/amplification, blue = loss/deletion). (C) mRNA expression data from 
538 of these samples were plotted as a function of log2 copy-number, and linear-regression 
analysis performed. (D) Overall survival was compared between patients with low-level gain, 
high-level amplification, and/or expression z-score >1.5 (DYRK1B High) and those without 
(DYRK1B Low) using cBioPortal’s survival analysis tools. Results of log-rank test are indicated. 
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Appendix C: Summary of Clinical Data for EOCs 
 
Sample Age Histological Subtype Grade Stage 
EOC171 65 Serous carcinoma High IIIC 
EOC168 77 Serous (70%) and clear cell (30%) High IIIC 
EOC166 64 Serous carcinoma High IIIC 
EOC161 67 Serous carcinoma High IIIC 
EOC155 66 Serous adenocarcinoma High IIIC 
EOC154 66 Serious carcinoma High IIIC 
EOC148 67 Serous carcinoma High ≥ IC 
EOC147 43 
Serous (70%) and clear cell (30%) 
adenocarcinoma 
2 IIC 
EOC136 42 Serous carcinoma High IV 
EOC129 74 Serous carcinoma High IIIC 
EOC122 56 Serous carcinoma High IIIC 
EOC118 57 Serous adenocarcinoma 3 IIIC 
EOC114 58 Serous borderline Low III 
EOC105 43 
Serous (70%) and clear cell (30%) 
adenocarcinoma 
2 IIC 
EOC104 28 Serous adenocarcinoma 1/3 IIIC 
EOC101 43 Serous adenocarcinoma 3 IIIC 
EOC100 65 
Serous adenocarcinoma (>90%), 
Endometrioid (<10%) 
High IIIA 
EOC98 51 Serous adenocarcinoma 3 IIIC 
EOC96 52 Serous adenocarcinoma 3/3 IIIC 
EOC89  56 Serous and clear cell components 3 IV 
EOC88 67 Serous adenocarcinoma 3/3 IIIC 
EOC87 47 
Adenocarcinoma, mostly serous with 
some clear cell differentiation 
3 IV 
EOC81 69 Ovarian mucinous borderline tumor  IIB 
EOC80 49 Serous borderline/adenocarcinoma 3/3 III 
EOC75 77 Papillary serous carcinoma 3/3 IIIC 
EOC68 67 Papillary serous carcinoma 2 IIIB 
EOC67 51 Serous adenocarcinoma 2 IIIC 
EOC65 67 Serous adenocarcinoma 3 IIIC 
EOC61 78 Serous adenocarcinoma 3 IIIC 
EOC59 47 Serous adenocarcinoma 3 IV 
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EOC52 59 Papillary serous carcinoma 2 IIIC 
EOC50 53 Serous adenocarcinoma High IIIC 
EOC42 50 Serous adenocarcinoma 2/3 IIIC 
EOC39 66 Serous adenocarcinoma 2/3 IIIC 
EOC35 81 Serous adenocarcinoma 3/3 IIIC 
EOC33 79 Serous adenocarcinoma 3/3 IIIC 
EOC32 52 Serous adenocarcinoma 3/3 IIIC 
EOC30 81 Serous adenocarcinoma 2/3 IIIC 
EOC27 77 Serous adenocarcinoma 3/3 III 
EOC10 61 Serous adenocarcinoma 2/3 IIIC 
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Appendix D: Protocol for Processing Solid Tumor Samples 
 
Protocol for generating (A) fixed and (B) frozen specimens, as well as to (C) release 
tumor cells for in vitro culture. 
 
Equipment: 
-scalpel handle (autoclaved, sterile) 
-scalpel blades (sterile) 
-orange-capped (pee-bottle) container filled with 10% formalin 
-tissue cassettes 
-forceps (2 or more pairs; autoclaved, sterile) 
-dry ice/ethanol bath  
-dry ice pellets (small container) 
-sheet of tin foil (approx. 15cm in length) 
 
• Ensure that tumor tissue is submerged in sterile PBS as soon as possible to 
maintain viability and moisture. Ideally the sample is received already submerged 
in saline from the OR.  
• Dissect the tumor tissue as symmetrically as possible (i.e., try to include all the 
different ‘regions’ of the tumor sample if you can grossly distinguish 
morphological differences). This way, all ‘regions’ can be represented in 
specimens that are frozen, fixed, and processed for in vitro culture. 
 
(A) To fix the tissue: 
 
1. Label the cassette (using a pencil) with patient number or some other 
distinguishing number. 
2. Place individual pieces in tissue cassettes, close cassettes by snapping shut. 
3. Drop cassettes into formalin container 
4. Write patient sample number, description of sample (e.g., “omentum nodule”), 
and date on side of container 
5. Store in 4°C fridge (“Rohann” shelf).  
6. These samples should be rinsed in PBS twice the next day and subsequently 
stored in 70% EtOH. 
 
(B) To freeze the tissue: 
 
1. Tear tin foil into ~3cm2 squares (for each piece of tissue) 
2. Completely wrap each piece in its own tin foil square 
3. Immediately bury wrapped pieces in dry ice pellets.  
4. Once frozen, collect all wrapped pieces and place in a 50mL tube. 
5. Write patient sample number, description of sample (e.g., “omentum nodule”), 
and date on side of tube. 
6. Store @ -80°C in “Solid Tumor Samples” box (lowest shelf, stand-up -80°C 
freezer) 
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(C) To harvest tumor cells: 
 
1. Dissect tumor pieces further into smaller (2-5mm2)pieces 
2. Place each piece in its own 15mL tube 
3. Pipet 1mL of Trypsin/EDTA into tubes with tissue 
4. Place tubes in 37°C water bath for 30-45 min., vortexing every 10 min. 
5. Collect 1mL of trypsin and tumor piece from each tube and pipette into individual 
wells of a 6-well plate 
6. Pipette an additional 1mL of trypsin to each well 
7. Using a sterile scalpel, chop and mince tumor pieces as thoroughly as possible 
8. Using a pipette, triturate trypsin (now 2mL) and minced tumor to attempt to break 
up clumps 
9. Collect contents and return to 15mL tubes.  
10. Return tubes to 37°C water bath for another 30-45 min., vortexing every 10 min. 
11. Inactivate trypsin with 3mL of FBS-containing medium 
12. Spin @ 1,500 rpm for 3 min. 
13. Aspirate supernatant and resuspend pellet in 3mL medium (triturate pellet several 
times) 
14. Pass resuspended pellets through 40µm cell strainers (can use a single strainer 
several times) and into a common 50 mL tube (i.e., pool all samples at this point) 
15. Seed 6-well plates with filtered, single cell suspension (3mL/well) 
 
Note: Tissue fragments collected in the cell strainer can be recovered by 
washing out the bottom of the strainer using PBS. Fragments can them be 
pelleted, resuspended in media, and cultured to obtain tumour cells.  
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